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Chapter 1 General introduction
Chronic Obstructive Pulm onary D isease
Definition
Chronic Obstructive Pulmonary Disease (COPD) is a disease state characterized by airflow 
limitation that is not fully reversible. The airflow limitation is usually progressive and associated 
with an abnormal inflammatory response o f the lungs to noxious particles or gases. COPD may 
be due to a mixture o f emphysema and peripheral airway obstruction from chronic bronchitis (1). 
Chronic bronchitis is clinically defined as the presence o f chronic productive cough for 3 months 
in each o f two successive years in a patient in whom other causes o f chronic cough have been 
excluded. Emphysema is pathologically defined as abnormal permanent enlargement o f the 
airspaces distal to the terminal bronchioles, due to destruction o f their walls and without obvious 
fibrosis (2).
E pidem iology
COPD is a major and growing health care problem worldwide, with high prevalence, morbidity, 
mortality rates and medical consumption (1). It is currently the fourth leading cause o f death in 
the adult population. As the major cause o f COPD is cigarette smoking, the epidemiology of 
COPD reflects the demographics o f cigarette smoking. Observed increases in morbidity and 
mortality appear to be related to past trends in cigarette smoking. Men and women have similar 
COPD mortality rates before the age o f 55, but the rate for men rises thereafter (2).
In the Netherlands, the prevalence o f COPD in 1994 was 21/1000 for men and 10/1000 
for women. Changes in size and composition o f the population will cause the prevalence to 
increase to 33/1000 for men in 2015 and for women to 23/1000. Changes in smoking behaviour 
will reduce the projected prevalence to 29/1000 for men, but increase it to 25/1000 for women
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Causes
Cigarette smoking is by far the commonest cause o f COPD worldwide, accounting for over 85% 
of cases. Smokers have higher rates for chronic bronchitis and emphysema and have higher 
prevalence o f lung function abnormalities and respiratory symptoms. Differences between 
cigarette smokers and non-smokers increase in direct proportion to quantity o f smoking. Age of 
starting, total pack-years, and current smoking status are predictive o f COPD mortality (2). 
Usually there is a smoking history o f > 20 pack years. Active smoking causes both mucus 
hypersecretion and chronic airflow obstruction. Cessation reduces the rate o f decline in lung 
function. Passive smoking is weakly associated with COPD (1,2). However, not all smokers 
develop clinically significant COPD, which suggests that genetic factors must modify each 
individual’s risk (1).
Air pollution is associated with chronic simple bronchitis and COPD. There may be 
interactions between cigarette smoking and air pollution. Occupational exposure to fumes, dusts 
and solvents may be important and interacts with cigarette smoking (1,2). Chest infections in the 
first year o f life are associated with COPD in later life, but there is little evidence that subsequent 
infections are important (1). Early nutrition may be important and small-for-date babies have an 
increased risk o f development o f COPD in later life. In adults low dietary intake o f antioxidant 
vitamins is also associated with increased risk o f COPD. There is some evidence that a diet rich 
in fish oil is associated with a lower prevalence o f COPD (4).
There has been considerable debate about the influence o f atopy and airway 
hyperresponsiveness on the development o f COPD, but how they influence the development of 
COPD is unknown. Genetic factors are likely to be important and there are several inherited 
forms o f antiproteases deficiency which may predispose to the development o f emphysema. 
Alpha^antitrypsine (AAT) is a well known genetic abnormality that leads to COPD. The serum 
protease inhibitor phenotype is determined by the independent expression o f the two alleles. At 
present about 75 different alleles are known (1,2,4).
Pathology
Chronic bronchitis is due to hyperplasia o f submucosal glands and increased numbers o f goblet 
cells in the epithelium. These changes underlie the mucus hypersecretion.
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Chronic obstructive bronchitis is associated with structural narrowing o f the small airways as a 
result o f chronic inflammatory changes, represented by activated T lymphocytes and 
macrophages (4,5). Fibrotic changes are also present. There is evidence o f neutrophil 
inflammation, as judged by increased numbers o f neutrophils in bronchoalveolar lavage and 
induced sputum. However, bronchial biopsies show infiltration with mononuclear cells, CD4 and 
CD8 T lymphocytes, rather than neutrophils, suggesting that the neutrophils may transit rapidly 
from the circulation into the airway lumen (5). Macrophages and T lymphocytes are prominent at 
sites o f destruction. There is also an imbalance between proteases and antiproteases. Cigarette 
smoking induces increased release o f proteases that are counteracted by antiproteases in amounts 
that are insufficient to prevent parenchymal damage (1,2,4,5). Emphysema is due to enzymatic 
destruction o f the alveolar walls.
Considerable evidence has been gathered that oxidative stress is increased in patients with 
COPD and that reactive oxygen species contribute to its pathophysiology (4,6). Oxidants are 
present in cigarette smoke and are produced endogenously by activated inflammatory cells, 
including macrophages and neutrophils. Oxidants damage serum protease inhibitors, potentiate 
elastase activity, increase mucus production and activate the transcription o f factor nuclear factor- 
kB (figure 1.1). The airspace epithelial surface o f the lung is particularly vulnerable to oxidant 
damage. Alveolar epithelial cells are important in maintaining the integrity and fluid balance of 
the lungs. Increased epithelial permeability is one o f the earliest effects o f cigarette smoking and 
may enhance the inflammatory process.
Antioxidants
Cigarette smoke
(ROS)
Proteases Elastases Nuclear Factor-kB Mucus production
F igure  1.1. O xidan ts  a re  p ro d u ce d  by c ig a re tte  sm oke  and  in fla m m a to ry  cells and  s tim u la te  p ro te a se s , e las tases , n u c le a r Facto r-kB  and  m ucus 
p ro d u c tio n . O xidan ts  a re  in h ib ite d  by a n tio x id a n ts .
Exhaled hydrogen peroxide in COPD 12
Chapter 1 General introduction
There is an increase o f the sequestration o f neutrophils within the pulmonary microcirculation. 
The neutrophils also have increased ability to release oxygen radicals in COPD patients. 
Increased markers o f oxidative stress have been demonstrated in epithelial lining fluid, in exhaled 
breath, in urine and in blood o f COPD patients (4,6). Oxidative stress is the result o f an 
imbalance between oxidants and antioxidants. Pulmonary antioxidant defences are widely 
distributed and include both enzymatic and non-enzymatic systems. The major enzymatic 
antioxidants are superoxide dismutase (SOD) and glutathione. Vitamin E, ß-carotene, vitamin C, 
uric acid and bilirubine are some o f the non-enzymatic antioxidants (6,8).
Sym ptom s and lung function
Extensive pulmonary damage occurs before the patient is aware o f any symptoms, such as 
dyspnoea during exercise, due to the slowly progressive nature o f the airflow obstruction and 
various coping mechanisms. The symptoms o f COPD are slowly progressive over many years, in 
contrast to the episodic and variable symptoms o f asthma. Patients usually have lost a 
considerable amount o f their lung volume by the time they present to a doctor. Main symptoms 
are cough and sputum expectoration, and breathlessness. Sputum production is insidious, initially 
occurring in the morning. Sputum is usually mucoid but becomes purulent with an exacerbation 
(1,2). With disease progression, the intervals between acute exacerbations grow shorter. Late in 
the course o f the disease, an exacerbation may lead to hypoxemia with cyanosis. Hypercapnia is 
often present in end-stage disease (1,2).
Early on, examination o f the chest may reveal only slowed expiration and wheezing on 
forced expiration. As obstruction progresses, hyperinflation becomes evident, and the 
anteroposterior diameter o f the chest increases. Breath sounds are decreased, expiration is 
prolonged (1,7). For educational reasons, a simplified classification o f disease severity into four 
stages is recommended (GOLD) (1).
Stage 0\ at risk. Characterized by chronic cough and sputum production, lung function is still 
normal.
Stage I: mild COPD. Characterized by mild airflow limitation (FEVj/FVC < 70%, FEVj  ^ > 80%) 
and usually chronic cough and sputum production.
Stage II: moderate COPD. Characterized by worsening airflow limitation (30% < FEVj  ^ < 80%) 
and usually progression o f symptoms, with shortness o f breath on exertion.
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Stage III: severe COPD. Characterized by severe airflow limitation (FEVj < 30%) or the presence 
o f respiratory failure or right heart failure.
Pulmonary function parameters are necessary for diagnosis and assessment o f the severity 
o f disease and are helpful in following its progress. Airflow obstruction is an important indicator 
o f impairment o f the whole person and o f the likelihood o f blood gas abnormalities (2). A 
postbronchodilator forced expiratory volume in 1 second (FEVj) < 80% predicted and a 
FEVj/FVC ratio < 70% confirms the presence o f airflow limitation that is not reversible (1).
Static lung volume measurements may show an increase in total lung capacity, functional 
residual capacity and residual volume. The vital capacity may be decreased. The single-breath 
carbon monoxide diffusing capacity is decreased in proportion to the severity o f emphysema 
(2,4,7).
Treatm ent
COPD is usually a progressive disease. Symptoms and objective measures o f airflow limitation 
should be monitored for development o f complications and effect o f therapy. Frequency and 
severity o f exacerbations should be evaluated (1). The treatment o f COPD begins with reducing 
risk factors. The most effective therapy is smoking cessation. The clinician should always express 
strong and continued interest in smoking cessation for the patient with COPD. A strong social 
support system is associated with cessation and long-term abstinence. Group smoking cessation 
clinics are offered by many hospitals (1,2).
The pharmacotherapeutical goals are to induce bronchodilation, decrease the 
inflammatory reaction and facilitate expectoration. Bronchodilators cause only a small increase in 
FEVj, but they may improve symptoms by reducing hyperinflation and thus dyspnea. Beta2- 
agonists produce less bronchodilation in COPD than in asthma. There is no evidence to suggest 
that regular use o f beta-agonists significantly curtails survival o f patients with COPD. Topic 
administration o f an anticholinergic aerosol may be more effective than a beta-agonist in COPD, 
and the side effects tend to be less. The drug has a slower onset and longer action than beta- 
agonists. They do not appear to influence the long-term decline o f FEVj  ^ (1,2,4).
Theophylline is o f particular use for less compliant or less capable patients who cannot 
use aerosol therapy optimally.
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The ability o f theophylline to improve respiratory muscle function, stimulate the respiratory 
centre, and enhance activities o f daily living can be important to patients who are severely limited 
by COPD.
In contrast to their value in asthma management, the role o f anti-inflammatory drugs in 
the management o f COPD is less clear. Most studies suggest that only 20-30% of patients with 
COPD improve if given chronic oral steroid therapy. The evidence o f effect o f inhaled 
corticosteroids is insufficient. There may be an effect on exacerbation frequency and symptoms, 
but there is no or little influence on the decline o f lung function (1,2,4).
Non-pharmacotherapeutical goals are also important. Since exacerbations o f COPD have 
an important effect on morbidity and quality o f life, it is important to diagnose and treat 
exacerbations early. Acute exacerbations o f COPD are commonly assumed to be due to bacterial 
infection, since they may be associated with increased volume and purulence o f the sputum. 
However, it is increasingly recognized that exacerbations may be due to viral infections, so that 
antibiotic treatment is not always necessary. In acute exacerbations oral o f parenteral steroids are 
the main treatment, besides bronchodilator therapy (1,2,4).
COPD is commonly associated with progressive hypoxemia. Long-term oxygen therapy 
will reverse secondary polycythemia, increase body weight, alleviate right heart failure, strengthen 
cardiac function, enhance neuropsychological function, and improve exercise performance and 
activities o f daily living. Two studies have shown that long-term oxygen therapy improves 
survival in hypoxic patients with COPD (1,2,4,7).
The principal goals o f pulmonary rehabilitation are to reduce symptoms, improve quality 
o f life and increase physical activities. Patients with COPD at all stages o f the disease can benefit 
from exercise programs. These programs should be multidisciplinal, with attention for social 
isolation, mood states, muscle wasting and weight loss (1).
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A ssessm ent of airway inflam m ation and oxidative stress
As mentioned before, COPD has a major morbidity and mortality. The presence and severity of 
airflow limitation are associated with the prognosis o f the disease with respect to survival. It is 
therefore important to identify risk factors for the development o f COPD and factors that 
influence the prognosis o f COPD.
In epidemiological studies bronchial hyperresponsiveness, high number o f pack-years, low FEV! 
and low reversibility are known risk factors. However, lung function parameters give information 
about the degree o f airflow limitation and not about the underlying pathological process. Direct 
markers o f the pathological process in COPD need to be identified. They should be 
reproducible and easy to obtain, reflecting changes in airway inflammation and pulmonary 
oxidative stress (8).
Pulm onary function m easurem ents
These measurements are necessary for diagnosis and assessment o f the severity o f the disease and 
are helpful in following its progress. The FEV! is easy measurable, has less variability than other 
measurements o f airway dynamics, and is more accurately predictable from age, sex and height. 
Lung function measurements show an increase in total lung capacity, functional residual capacity 
and residual volume. The vital capacity may be decreased. The single breath carbon monoxide 
diffusing capacity is decreased in proportion to the severity o f emphysema because o f loss of 
alveolar capillary bed (1,2).
However, lung function measurements do not always correlate with the degree of 
symptoms. Some patients show a reasonably good lung function and suffer from significant 
dyspnea, while others show much worse lung function tests and have less complaints. Also, in 
COPD patients the FEV! shows quite a large variation over time. Pulmonary function tests are 
difficult to perform in young children, in very severe patients or during severe exacerbations.
There are only a few studies on the relationship between hyperresponsiveness and airway 
inflammation in COPD. Bronchial hyperresponsiveness is defined as an abnormal sensitivity and 
exaggerated response o f the airway to pharmacological, chemical, physical or physiological 
stimuli.
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Bronchial hyperresponsiveness can be measured by means o f provocation with histamine, 
metacholine (direct) or AMP (indirect). In one study there was a negative correlation between 
PC20histamine and membranous bronchial inflammation in cigarette smokers (9). Another study 
compared smokers with COPD and ex-smokers with COPD and showed that the smokers were 
more hyper-responsive to AMP, while the hyperresponsiveness to metacholine was similar in 
smokers and ex-smokers (10). A disadvantage o f provocation tests is that they are rather invasive. 
Patients can react strongly to the provocation, which makes it less suitable for repeated 
measurements.
Bronchoscopy
Bronchoscopy provides direct information about the pathological changes in the lungs o f COPD 
patients. Bronchoscopy can be used to perform bronchial biopsies or bronchoalveolar lavage 
(BAL). By taking biopsies o f bronchial tissue, inflammatory changes can be directly observed 
using electron microscopy. This allows assessment o f the mucosal structure, including the 
epithelium, basal membrane, lamina propia and vasculature. Electron microscopy also allows 
study o f inflammatory cells. Another technique to process and analyse biopsy samples is 
immunohistochemistry. This is the staining o f tissue with conjugated monoclonal or polyclonal 
antibodies, so that the inflammatory cells can be classified according to the cell surface antigens. 
Bronchoscopy is known to carry a medical risk and the invasiveness o f the procedure may 
discourage patients from participating in biopsy studies (11).
In bronchial biopsy specimens the inflammatory changes in the mucosal o f COPD 
patients constitute o f increased numbers o f macrophages and activated, predominantly CD8 cells. 
Eosinophilic numbers are increased during exacerbations and possibly also during stable disease 
in a subgroup o f patients (11).
In bronchoalveolar lavage (BAL) fluid macrophages are mainly found, followed by 
increased neutrophil and eosinophil numbers. BAL is frequently performed at the same time as 
bronchial biopsy, and gives information about the presence o f inflammatory cells in the alveolar 
lining fluid. The disadvantage o f BAL is that it is usually a dilute sample, largely derived from the 
alveolar compartment. The proportion o f the sample that derives from the airways can be 
increased by reducing the lavage volume (11,12)
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Sputum
Spontaneously produced sputum can be used to study airway inflammation. However, the 
volume o f the sputum produced must be sufficient. One o f the problems o f this technique is that 
there is also often contamination with saliva. Bhowmik and colleagues showed that in COPD 
patients spontaneous sputum was less viable than induced sputum, though total and differential 
cell counts were similar (13).
Sputum production can be induced by inhaling saline. Induced sputum has become the 
most widely used research tool in study o f airway inflammation in asthma and more recently in 
COPD (14). The reason for the dramatic increase in the use o f induced sputum has been its 
safety and relative ease o f use by comparison with bronchoscopy, the other tool that enables 
directs sampling o f the airways. It is viewed by volunteers to be less invasive and therefore more 
acceptable than bronchoscopy. Differential cell counts are different in BAL fluid and sputum. 
Induced sputum probably provides a more representative sample o f several proximal airways.
Unprocessed sputum contains abundant and often thick mucus. Researchers had to 
develop and validate methods that break up the mucus and allow assays to be performed. In 
most laboratories the mucolytic agents that are used are dithioerythritol (DTE) or dithiothritol 
(DTT). Recovery o f mediators is currently assessed by “spiking” the fluid phase o f sputum with 
known amounts o f mediators and calculating the percent recovery by comparing the spiked with 
non-spiked samples. The recovery differs for different mediators (15). Vlachos-Mayer and 
colleagues showed that sputum induction performed carefully by trained staff was successful in 
93% of patients with asthma or chronic airflow limitation (16). Excessive bronchoconstriction 
only occurred in 8% of patients with asthma .
In smokers with a chronic cough consistent with the definition o f chronic bronchitis, but 
who do not have chronic airflow limitation, induced sputum shows inclusions in the 
macrophages and a mild neutrophilia. When COPD develops, sputum neutrophilia becomes 
more pronounced. The sputum shows an increase in neutrophil proteins such as 
myeloperoxydase, elastase and IL-8. There is also an elevation o f eosinophil proteins. The 
occurrence o f eosinophilia during exacerbations in patients with COPD has been attributed to 
the inflammatory effects o f cigarette smoking (17,18,19,20).
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M arkers in exhaled air
The main task o f the respiratory system is the exchange o f oxygen and carbon dioxide, but 
exhaled air also contains a large number o f other volatile substances and the analysis o f these 
compounds has a long tradition in medicine. In the past few years research has mainly focused on 
volatile compounds, particularly nitric oxide (NO), but recently other (non-volatile) compounds 
o f exhaled air have been studied, e.g. hydrogen peroxide (H20 2), ethane, isoprostanes, 
thiobarbituric acid-reactive substances (TBARs) (21).
Analysis o f these non-volatile substances requires cooling o f the expired breath, which 
results in condensation. Cooling o f the exhaled air can be achieved by using wet or dry ice or 
liquid nitrogen. The patient is instructed to breathe tidally directly into the tubing or through a 
mouthpiece connected to the tubing. It takes about 5-10 minutes to collect 1-5 ml in adults. As 
most substances are present not only in the lower airways but throughout the respiratory tract 
including nasal passages, it is important to prevent contamination o f the exhaled breath. 
Contamination with saliva should also be prevented. Although measuring markers in exhaled 
breath condensate (EBC) is promising because o f the simple, non-invasive technique, it has 
limitations. The most important problem is lack o f standardization o f the method o f collection. 
Secondly, the exact location where the compounds originate is not yet determined (22). A more 
detailed overview o f exhaled markers is presented in chapter 2.
Exhaled hydrogen peroxide
Hydrogen peroxide (H20 2) is an oxidant that passes the alveolar membrane and can be measured 
in exhaled air. H 20 2 is marker o f pulmonary oxidative stress. Oxidative stress is thought to play 
an important role in the pathophysiology o f COPD. Oxidative stress can be defined as increased 
exposure to oxidants and /o r decreased antioxidant capacities (6).
Oxidants are formed from oxygen. First superoxide anion ( 0 2~)is formed. Reaction o f 0 2 
with H 20 2 in the presence o f transition metal produces hydroxyl radical (OH). When catalized by 
neutrophil myeloperoxydase (MPO) H 20 2 and a chloride form hypochlorous acid (HOC1). H 20 2 
is a central precursor (6).
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Pulmonary antioxidant defences are widely distributed and include both enzymatic and non- 
enzymatic systems. The major enzymatic antioxidants are superoxide dismutase (SOD) and 
glutathione (GSH). Vitamin E, ß-carotene, vitamin C, uric acid and bilirubine are some o f the 
non-enzymatic antioxidants (6).
Cigarette smoke is a rich source o f oxidants. The tar component contains an estimated 
1018 radicals per gram. Oxidants are also produced by inflammatory cells, mainly neutrophils, 
macrophages and eosinophils. This means that the degree o f oxidative stress may indirectly 
reflect the degree o f airway inflammation. The level o f H 20 2 in EBC could provide information 
on the oxidative and inflammatory status o f COPD patients in a simple, non-invasive manner.
Several investigators have used exhaled H 20 2 to study healthy volunteers and patients 
with different pulmonary diseases e.g. asthma, COPD, bronchiectasis, cystic fibrosis and ARDS. 
Dekhuijzen and colleagues showed that exhaled H 20 2 is increased in stable COPD patients 
compared with young healthy volunteers and even more increased during exacerbation (23). 
However, it is difficult to compare these studies because o f lack o f standardization. There is a 
large variety in EBC collection methods, methods o f analysis and storage. Data on reproducibility 
and variability are scarce or absent.
Outline of the thesis
COPD is a major health care problem and will be contributing increasingly to medical 
consumption and costs. It is important to identify risk factors for the development o f COPD and 
to prevent worsening o f the disease in an early stage, in order to alter its natural history. An 
individual estimation o f the risk for presence or absence o f a rapid decline o f lung function is 
difficult to make. Sensitive clinical tools to establish the diagnosis at an early stage and to monitor 
the activity o f the disease, are not yet available. Exhaled biomarkers may be helpful in the 
identification o f the individual risk factors. An important advantage is that exhaled biomarkers 
can be measured non-invasively and repeatedly.
Several exhaled biomarkers have been investigated in COPD patients. However, reliable 
data on reproducibility, sensitivity and accuracy o f these markers are scarce. Exhaled biomarkers 
can not be used in clinical practice unless these characteristics are known.
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In this thesis we have focussed our investigations on exhaled H 20 2. H 20 2 is one o f the central 
oxidants and can be measured relatively easy. The aim o f this thesis was therefore to evaluate the 
accuracy o f the measurement o f exhaled H 20 2 and to establish its clinical significance for the 
diagnosis and treatment o f COPD.
In Chapter 2 a review o f exhaled biomarkers is presented, discussing their role in the diagnosis, 
management and prognosis o f COPD.
Chapter 3 describes the evaluation o f an automated flow injection method for measuring H 20 2 
in EBC in order to increase sensitivity.
In Chapter 4 the development o f a reliable, reproducible method o f collection o f EBC and 
method o f analysis o f the EBC is shown.
In Chapter 5 the variability over time o f exhaled H 20 2 in stable COPD patients and healthy 
matched controls is investigated.
In Chapter 6 the superoxide release o f polymorphonuclear leukocytes is measured in COPD 
patients and healthy persons, before and after stimulation with PMA, DEP, UF and ufCB.
In Chapter 7 the changes o f exhaled H 20 2, lung function parameters and serum inflammatory 
markers during COPD exacerbation and subsequent treatment are shown.
Chapter 8 presents a randomised single-blind crossover study investigating the effect o f inhaled 
corticosteroids with different lung deposition on exhaled H 20 2 levels in stable COPD patients.
In Chapter 9 the summary and conclusions o f this thesis and directions for further research are 
presented.
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A bstract
Several diagnostic tools have been developed for diagnosing, monitoring and evaluating Chronic 
Obstructive Pulmonary Disease (COPD). There is an increasing interest in the use of non- or less invasive 
biological markers (biomarkers) which reflect the character and intensity of the pathological processes in 
the lungs of COPD patients. The main goal of this review was to discuss the origin and current role of 
exhaled biomarkers in the diagnosis, evaluation of treatment and prognosis of COPD.
Data of cross-sectional, cohort and intervention studies on exhaled biomarkers were studied. 
These studies were identified by a Medline search on papers in the English language published from 1990 
to November 2001. The following markers were discussed: exhaled nitric oxide (NO ), exhaled carbon 
monoxide (CO), exhaled alkanes, exhaled hydrogen peroxide (H2O2), exhaled isoprostanes, exhaled NO  
metabolites and exhaled thiobarbituric acid-reactive substances (TBARs).
Data on these markers were summarized. The origin of each marker, the technique of analysis, the 
values in healthy controls and COPD patients, the effect of treatment and the correlation with other 
parameters were presented. Most studies however were cross-sectional studies with small populations. It 
was also difficult to compare studies because of differences in technique and study population.
This review shows that exhaled biomarkers need to be studied further before using them in clinical 
practice. There is a need for standardization of the measurements, for comparison of COPD patients with 
healthy persons matched for age and smoking-status, for data on reproducibility and variability of all 
markers, for correlation of exhaled markers with other parameters and for intervention studies.
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is responsible for a considerable part o f the 
annual morbidity and mortality o f the world population. Several diagnostic tools have been 
developed for diagnosing, monitoring and evaluating COPD.
Lung function tests are essential tools to provide insight into the physiological 
derangements in static and dynamic lung volumes and gas exchange. Radiologic techniques, 
especially HR-CT scanning, provide insight into the loss o f lung tissue.
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Invasive measurements (bronchoscopy, induced sputum) to assess the intensity o f inflammation 
and oxidative stress, processes which are assumed to play a key role in the onset and progression 
o f the disease, are only applied in research settings.
There is an increasing interest in the use o f non- or less invasive biological markers 
(biomarkers) which reflect the character and intensity o f the pathological processes in the lungs 
o f COPD patients. The inflammatory process in COPD is characterized by chronic inflammation 
throughout the airways, parenchyma and pulmonary vasculature. Macrophages, T lymphocytes 
(predominantly CD8+) and neutrophils are increased in various parts o f the lung. There is also a 
small number o f tissue eosinophils, which in contrast to asthma are not degranulated (1,2).
In this review we provided an overview o f exhaled biomarkers which have been studied 
thus far in patients with COPD. The main goal was to discuss their origin and their current role 
in the diagnosis, evaluation o f treatment and prognosis o f COPD.
Data o f cross-sectional, cohort and intervention studies were studied. These studies were 
identified by a Medline search on papers in the English language published from 1990 to 
November 2001. The terms we used for this search were the combination o f ‘CO PD ’ and one of 
the following terms: oxidative stress, biomarkers, exhaled breath condensate (EBC), exhaled 
nitric oxide (NO), exhaled carbon monoxide (CO), exhaled ethane, exhaled isoprostanes, exhaled 
N O  metabolites, exhaled thiobarbituric acid-reactive substances (TBARs) and exhaled hydrogen 
peroxide (H20 2). The references o f the identified articles were also screened for relevant papers.
Biomarkers in exhaled air
The measurement o f markers in exhaled air is totally noninvasive and can be performed even in 
infants and patients with severe disease, in contrast to bronchoscopy and induced sputum. Like 
sputum, exhaled air originates directly from the lungs and represents the physiology in the 
pulmonary system. There are several biomarkers that can be measured in exhaled air, o f which 
exhaled N O  is the most used and studied. So far it is the only measurement in exhaled air that 
has been standardized in official guidelines (3). O ther markers are under investigation, e.g. 
exhaled CO and exhaled ethane.
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Firstly, the origin and technique o f analysis o f each biomarker will be described. Secondly, the 
results o f cross-sectional, cohort and intervention studies will be summarized, presenting 
(available) information about reference values in healthy persons, values in COPD patients, 
comparisons with other respiratory diseases, the effect o f therapy, correlations with other 
inflammatory parameters and lung function and prognosis o f the disease.
Exhaled N itric O xide
Nitric oxide (NO) is a molecular gas, it regulates vascular and bronchial tone within the 
respiratory system, it helps to facilitate the coordinated beating o f ciliated epithelial cells and it is 
an important neurotransmitter between non-adrenergic, non-cholinergic neurons which run in 
the bronchial wall. N O  is formed from L-arginine by the action o f one o f the isoforms o f the 
enzyme nitric oxide synthase (neuronal (n)NOS, inducible (i)NOS, endothelial (e)NOS) (figure 
2.1). There is considerable evidence that alveolar macrophages synthesize N O  after stimulation 
by endotoxin and cytokines and that this elaboration o f N O  is integral to host defense. N O  is 
easily converted in biological systems to peroxynitrite (OONO-), which is a potent epithelial 
toxin and finally N O  may promote the preferential proliferation o f T helper 2 (Th2) lymphocytes 
and thus foster overproduction o f interleukin 4 (IL-4) and interleukin 5 (IL-5), a condition which 
is associated with asthma (4,5,6).
The precise anatomic source o f expired N O  is not known. N O  is produced along the 
entire length o f human airways. The conducting airways secrete N O  into the lumen, which mixes 
with alveoli derived N O  during exhalation. In the lungs N O  is thought to be mainly excreted in 
the large central airways, which is supported by the flow-dependency o f exhaled N O  (7). The 
nasal sinuses contain very high levels o f N O, other sources o f N O  are oropharyngeal and 
ambient NO.
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F igure  2 .1 . S ynthesis  of n itr ic  ox ide  (N O ) fro m  L -a rg in in e  by n itr ic  ox ide  syn thases (n e u ro n a l (n)N O S , endo the lia l (e)N O S , in d u c ib le  (i)N O S ). From NO, 
n itr ite  (N O ;) and  p e ro x yn itr ite  (ONOO ) can be fo rm ed .
Measurements o f exhaled N O  are usually made by chemiluminescence analyzers and are based 
on the photochemical reaction between N O  and ozone generated in the analyzer. The majority of 
methods used for collection o f expired air for measuring the N O  concentration can be divided 
into one o f two types: online and offline. The term offline is used to describe methods in which 
the subject exhales either single or multiple breaths into a N O  impermeable reservoir. This 
reservoir is sealed and brought to the N O  analyzer. Online measurement involves sampling gas 
expired directly into the N O  analyzer. In most systems a small resistance to the exhalation flow is 
introduced automatically to avoid contamination with nasal N O  by closing the soft palate (8).
Recently, recommendations for standardized procedures for the online and offline 
measurement o f exhaled N O  in adults and children have been published (3). It is important that 
exhaled N O  is measured in a standardized manner. Contamination with nasal N O  and flow- 
dependence must be taken into account (7). Conditions that may affect N O  concentrations in 
exhaled air should be avoided, for example allergen exposure, nitrite-enriched food, smoking, 
exercise etc (8).
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Several investigators have measured exhaled N O  levels in healthy subjects. Most studies showed 
exhaled N O  levels o f 3 to 7 ppb (9,10,11). Exhaled N O  levels were lower in current smokers 
(10,11). The variation o f exhaled N O  in healthy subjects has only been studied by Ekroos and co­
workers (9); they found an intra-individual coefficient o f variation o f 15.8% within an interval of 
7 days and 16.8% within an interval o f 23 days (N=26).
The findings in COPD patients are not uniform. Several investigators found no 
difference in exhaled N O  levels between stable COPD patients and healthy subjects (10,12), but 
they measured lower N O  levels in current smokers (12). However, in unstable COPD patients 
(N=12) Maziak and coworkers showed increased exhaled N O  levels (12) compared with stable 
patients, which can be explained by increased neutrophilic inflammation and oxidant/antioxidant 
imbalance in unstable disease.
In contrast, other investigators showed higher levels o f exhaled N O  in stable COPD 
patients compared with healthy subjects (11,13,14), and also lower levels o f exhaled N O  in 
current smokers. The fact that some investigators found increased levels o f exhaled N O  in stable 
COPD patients, while others did not, could indicate that there is a subgroup o f (stable) COPD 
patients that have increased exhaled N O  levels, possibly due to asthmatic features. It seems clear 
that tobacco smoking reduces exhaled N O, which could be caused by stimulation o f antioxidant 
mechanisms by cigarette smoke thereby reducing exhaled NO.
Studies with asthmatic patients showed that exhaled N O  was increased compared with 
healthy subjects. The levels were also higher in asthmatics than in (stable) COPD patients 
(14,15,16). During exacerbation exhaled N O  was further elevated. Ho and colleagues and 
Kharitonov and coworkers showed that exhaled NO  was also elevated in allergic/atopic adults 
and children without asthma (17,18).
The effect o f treatment on exhaled N O  levels in COPD patients, especially the effect of 
oral and inhaled corticosteroids (ICS), has been studied by several investigators. An observational 
study by Maziak and coworkers in stable COPD patients (N=33) showed higher levels o f exhaled 
N O  in patients treated with ICS compared with steroid-naive patients, but the first group 
included more severe patients as assessed by lung function (12). Agusti and colleagues 
investigated the course o f exhaled N O  in 17 COPD patients who were hospitalized because o f an 
exacerbation o f the disease (19). On admission exhaled N O  levels were higher than in stable 
condition (41.0 ppb versus 13.3 ppb), and exhaled N O  remained elevated despite treatment with 
intravenous steroids throughout recovery. When the patients were again clinically stable, exhaled 
N O  was significantly reduced and comparable to healthy subjects.
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Recently, Ferreira and coworkers performed the first randomized placebo controlled study 
evaluating the effect o f ICS on exhaled N O  levels in COPD patients (N= 20). They found that 
exhaled N O  decreased significantly after 2 week treatment with beclomethasone (500 ^g bid) in 
contrast to treatment with placebo (20). The authors explained this by the hypothesis that some 
eosinophilic inflammation is probably present also in COPD patients which is responsive to ICS. 
Studies with other medication like leukotriene antagonists or beta-agonists have not been 
performed yet.
In asthma, several studies have shown that exhaled N O  is a very sensitive and rapid 
marker o f the effect o f ICS treatment. In asthma patients using steroids, exhaled N O  was 
reduced to levels comparable with healthy subjects (16, 21, 22).
Several investigators have studied the relation between exhaled N O  and other 
inflammatory parameters. They found a relation between exhaled N O  and sputum eosinophilia in 
stable COPD patients (23,24). In asthma patients exhaled N O  levels were also correlated with 
sputum eosinophils (25,26). Levels o f exhaled N O  were inversely correlated with FEV! in stable 
COPD patients (12,13,27,28).
In summary, it is not yet clear if exhaled N O  can be used as a marker o f the severity of 
the underlying processes in COPD. Some investigators found a significant difference between 
stable COPD patients and healthy persons, while others did not (mean N O  concentration in 
healthy persons around 6.0 ppb). This may indicate that in a subgroup o f COPD patients (i.e. 
those with asthmatic features) exhaled N O  is increased. In current smokers N O  levels are lower 
than in ex- or nonsmokers, possibly due to more stimulation o f the antioxidant mechanisms. It is 
clear that in asthma exhaled N O  levels are higher (approximately 20-25 ppb) than in COPD and 
that the N O  levels are significantly reduced by treatment with steroids. N O  levels are probably 
increased during an exacerbation o f COPD compared with stable disease. Exhaled N O  levels 
seem to be inversely correlated with the lung function (FEVj). ICS seem to have an effect on 
exhaled N O  levels in at least a subgroup o f COPD patients.
Exhaled Carbon M onoxide
Several inflammatory mediators including cytokines, reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) are able to induce heme oxygenase-1 (HO-1), which catalyses the 
degradation o f heme into biliverdin, carbon monoxide (CO)and free iron (29) (figure 2.2).
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The predominant endogenous source o f CO is from the degradation o f hemoglobin, but about 
15% arises from degradation o f myoglobin, catalase, N O  synthases etc. Bilirubine is an 
antioxidant and CO has several biological activities including stimulation o f gauntlet cells (29).
Cytokines ROS RNS
CO
heme -----------► heme oxygenase
(hemoglobin) (HO-1)
Fe
F igure  2 .2 . Fieme is con ve rte d  by hem e oxygenases (H O -1 , H O -2, H O -3) in to  ca rbo n  m o no x id e  (CO), b ilive rd in  and  iro n  (Fe ).
-► biliverdin
The predominant site where exhaled CO is produced are the alveoli (29). CO is not only 
produced in the lungs, but also in the nose and paranasal sinuses (30). Exhaled CO levels are also 
affected by environmental CO, which may fluctuate considerably during the course o f the day 
especially in cities. Active and passive smoking have the greatest effect on exhaled CO levels.
CO can be quantified by a number o f different techniques. Most o f the measurements in 
humans have been made using electrochemical sensors. The sensor is selective, gives 
reproducible results and is inexpensive. Exhaled CO can also be measured by adjustable laser 
spectrophotometer or by a near-infrared CO analyzer (29).
In healthy subjects investigators have measured levels o f exhaled CO from 1 to 8 ppm 
(31,32,33). Montuschi and colleagues found significant higher levels o f exhaled CO in healthy 
smokers than in nonsmokers (7.9 ± 1 . 4  ppm versus 3.0 ± 0.3 ppm) (11). Exhaled CO was also 
increased in healthy subjects during upper respiratory tract infections (33).
Two investigators compared exhaled CO levels between stable COPD patients and 
healthy controls (11,34). They both showed that exhaled CO levels were higher in stable COPD 
patients.
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Montuschi and colleagues also found that exhaled CO levels were higher in current smokers with 
COPD than in ex-smokers with COPD. The elevation o f exhaled CO could indicate a higher 
degree o f oxidative stress. The difference between smokers and ex-smokers might partly be due 
to cigarette smoking which causes a marked elevation in exhaled CO (11).
More information is present about exhaled CO levels in asthma patients. Yamaya and 
coworkers found no difference in exhaled CO between mild and moderate asthma patients and 
healthy subjects, while in severe asthma patients exhaled CO levels were significantly higher 
compared with nonsmoking control subjects (N=71) (31). Exhaled CO concentrations were also 
higher in unstable severe asthmatics than in stable severe asthmatics (35). To our knowledge 
there are no randomized studies investigating the effect o f ICS or other interventions on exhaled 
CO levels in COPD patients. Paredi and coworkers measured exhaled CO levels in 22 stable 
COPD patients in a cross-sectional study, 12 were treated with ICS and 10 not. They found that 
exhaled CO levels were similar in treated and untreated patients and higher than in normal 
subjects (34).
In asthma CO has been shown to be increased in patients not treated with ICS, and in 
patients who are on steroid treatment but not stable. The rise in exhaled CO levels during 
exacerbation was reversed after treatment with oral glucocorticoids (35). Exhaled CO levels were 
correlated with the eosinophil count in the sputum.
Few investigators have studied the relationship between exhaled CO levels, lung function 
and other inflammatory markers in asthma patients. Yamara and coworkers found a significant 
relationship between exhaled CO concentrations and FEVj  ^ (35), in addition exhaled CO was 
correlated with the eosinophil count in the sputum. On the other hand, Montuschi and 
colleagues found no correlation o f exhaled CO with lung function (11). There are no data 
correlating exhaled CO levels with prognosis o f COPD.
In summary, exhaled CO levels are increased in COPD and most in current smokers. 
However, exhaled CO is also elevated in asthma patients. The application o f CO as a diagnostic 
marker is also limited because exhaled CO levels are markedly affected by environmental CO, 
which may fluctuate considerably over the day, and secondly by active and passive smoking. 
There are no data from intervention studies on the effect o f ICS on exhaled CO in COPD.
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Exhaled ethane
One mechanism by which oxidants can cause lung injury is through lipid peroxidation. ROS such
as oxygen radical ( 0 2") and hydrogen peroxide (H20 2) released by activated inflammatory cells 
may induce peroxidation o f polyunsaturated membrane fatty acids, in this way impairing 
membrane function and inactivating membrane-bound receptors and enzymes, increasing tissue 
permeability and thus contributing to airflow limitation. The main source o f exhaled 
hydrocarbons is the liver, with contribution from red blood cells and other organs. Several 
hydrocarbons can be measured in exhaled air, for example alkanes like ethane and pentane (figure
2.3) (36).
ROS RNS
fatty acids 
arachidonic acid
hydroperoxides (TBARs) bicycloendoperoxide
/  \  intermediates
prostaglan dines, 
leukotriens
I
isoprostanes
hydrocarbons : aldehydes (TBARs)
alkenes alkanes
(ethane, pentane)
F igure  2 .3 . The syn the s is  o f e thane  fro m  a ra ch id o n ic  acid v ia  severa l lip id  rad ica ls .
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Ethane has received particular attention because o f its easier and faster chromatographic 
measurement compared with other hydrocarbons. Exhaled pentane has not yet been studied in 
COPD patients, this is why we focused on exhaled ethane. Exhaled air is collected during a flow 
and pressure-controlled exhalation into a reservoir discarding dead space air contaminated with 
ambient air. A sample o f the collected expired air is analyzed for ethane using gas 
chromatography. The measurement is expensive and time consuming and avoidance of 
contamination with environmental ethane is important. The level o f exhaled ethane is correlated 
with airway obstruction. Age does not influence the levels o f ethane in exhaled air (36).
Few investigators have studied exhaled ethane levels thus far. Paredi and coworkers 
measured exhaled ethane levels in healthy subjects and found a mean concentration o f 0.88 ±
0.09 ppb (34). Habib and colleagues investigated the effect o f cigarette smoking on ethane levels 
and found that smoking caused a direct increase in exhaled ethane. Exhaled ethane was higher in 
smokers than in ex-smokers and nonsmokers (37).
Ethane was found to be increased in COPD patients that smoke. There was a correlation 
between ethane levels and the degree o f airway obstruction in COPD, and current and lifelong 
tobacco consumption. In a cross-sectional study (N=22), Paredi and coworkers showed that 
exhaled ethane levels were elevated in steroid-naive COPD patients compared with healthy 
subjects (34). They found no difference between ICS treated patients and normal persons.
In asthmatic patients, exhaled ethane levels were higher in patients with steroid-naive 
asthma compared with steroid—treated and healthy subjects (38).
Information about the relationship o f exhaled ethane with other inflammatory parameters 
is not yet available.
In summary, levels o f exhaled ethane are increased in stable COPD patients compared 
with healthy controls and are reduced during treatment with steroids. Exhaled ethane is also 
increased in patients with asthma. Smoking has a direct effect on exhaled ethane levels. The 
measurement is still expensive and time consuming, and the available data are scarce.
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Biomarkers in exhaled breath condensate
Some biomarkers cannot be measured directly in exhaled air, but have to be measured in exhaled 
breath condensate (EBC), because they are not gases. There is no standard method for 
condensation o f exhaled air, but the principle exists o f cooling the exhaled air to a temperature 
around 0 °C, so that the warm air condensates. The most common approach is to ask the subject 
to breathe tidally via a mouthpiece through a non rebreathing valve in which inspiratory and 
expiratory air is separated. During expiration the exhaled air flows trough a condenser, which is 
cooled to 0 °C by for example melting ice, and breath condensate is then collected into a 
collection vessel. There are several markers that can be measured in exhaled breath condensate: 
H 20 2, isoprostanes, N O  metabolites and TBARs. Salivary contamination may influence the levels 
o f these markers.
Exhaled hydrogen peroxide
In both asthma and COPD airway inflammation is the most prominent characteristic. Activated 
inflammatory cells respond with a “respiratory burst”, which results in the production o f ROS. 
Naturally occurring free radicals have an oxygen- or nitrogen-based unpaired electron. Classical 
examples are superoxide anion ( 0 2"), hydroxyl radical (OH") and NO. 0 2 is formed from oxygen. 
Reaction o f 0 2 and hydrogen peroxide (H20 2) in the presence o f transition metal produces OH. 
When catalyzed by neutrophil myeloperoxydase (MPO), H 20 2 and a chloride form hypochlorous 
acid (HOC1) (figure 2.4) (39). H 20 2 acts as a central precursor. H 20 2 levels reflect the underlying 
state o f oxidative stress in the lungs. A study by Schleiss and coworkers showed that the level of 
exhaled H 20 2 significantly depends on expiratory flow rate, indicating that the exhaled H 20 2 is at 
least partially produced within the airways (40).
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Figure 2.4. Oxygen radicals (0--) are converted by supoxide (SOD) into hydrogen peroxide (H;0;) which can form hydroxy radical ( OH ) or can be 
converted into water and oxygen by catalase (CAT) and gluthatione peroxidase reductase system (GPX).
Methods o f H 20 2 measurement in breath condensate are based on the ability o f H 20 2 to react 
with suitable substrates leading to the release o f colour, light or fluorescence. Two methods of 
analysis have been used most: the spectrophotometrical method according to Gallati and Pracht 
and the fluorimetrical method according to Hyslop and Sklar or to Ruch (36).
Some problems with the H 20 2 procedure still exist. The concentration in normal 
individuals is almost undetectable and in many diseases the levels found are at the lower limit of 
detection o f the assays employed (41-44). The collection and storage o f the samples is also a 
source o f errors. Samples (after adding the reagentia) should be rapidly frozen. Furthermore the 
H 20 2 concentration is not only determined by the airway inflammation, but other factors also 
appear to influence the concentration. Exercise for example appears to increase the production 
o f oxidants and could thus influence the H20 2 concentration in the breath condensate. Food and 
beverage intake might also influence the H 20 2 concentration, possibly due to oxidants and /or 
antioxidants in some products (41, 42). Schleiss observed a rather high variation coefficient 
within repeated measurements (60-80%) (40).
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Several groups have explored the value o f H 20 2 measurement in different groups o f subjects 
such as smokers, patients with asthma or COPD. In general it is difficult to compare different 
studies, because o f differences in procedure and techniques o f analysis. In healthy young 
nonsmoking subjects exhaled H 20 2 levels diverge from 0.01 to 0.09 ^mol/1. (43 - 46). In a 
previous study van Beurden and colleagues measured elderly persons, all smokers or ex-smokers 
and found a higher H 20 2 concentration (0.21 ^mol/1) (47). Nowak and colleagues showed a 
circadian rhythm of exhaled H 20 2 with highest levels at 12.00 and 24.00 hours, they also found 
higher levels o f exhaled H 20 2 in healthy smokers compared with nonsmokers (48). In addition, 
van Beurden and colleagues showed that in COPD patients the exhaled H 20 2 showed the same 
circadian rhythm (47). Van Beurden and colleagues also found a significant variability (43%) over 
a period o f one day and several weeks in healthy persons (47).
Few investigators studied exhaled H 20 2 levels in COPD patients. Two cross-sectional 
studies showed an increased concentration o f exhaled H 20 2 in stable COPD patients compared 
with healthy subjects (N=31). Exhaled H 20 2 levels appeared to be lower in current smokers in 
the study by Dekhuijzen and coworkers (46), while Nowak and colleagues found no difference 
between current and ex-smokers (45). The concentration was further increased in COPD patients 
with an exacerbation (46). In contrast, van Beurden and colleagues did not find a difference in 
levels o f exhaled H 20 2 between stable COPD patients and elderly smoking healthy persons (47), 
which could be explained by a possible effect o f age and smoking history on exhaled H 20 2. The 
exhaled H 20 2 concentration appeared to be the same in current smokers and ex-smokers, though 
the subgroups were small.
Most studies measuring exhaled H 20 2 have been performed in asthma patients. Exhaled 
H 20 2 levels were increased in asthmatic children and adults (44,49,50,55). There was an inverse 
correlation between H 20 2 concentration and FEVj  ^ % o f predicted, and exhaled H 20 2 
concentration was related to the number o f sputum eosinophils and airway hyperresponsiveness 
in asthma o f different severity (44).
Few interventions studies have been performed investigating the effect o f treatment on 
the H 20 2 concentration. Recently, Ferreira and coworkers treated 20 stable COPD patients ( 
mean FEVt 55% predicted) for 2 weeks with beclomethasone (500 ^g bid or placebo). The 
baseline H 20 2 concentration did not change after treatment (20).
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Another group performed a crossover study in which COPD patients were treated for 4 weeks 
with beclomethasone-HFA (800 bid) or fluticasone (750 ^g bid) and found a reduction (0.1 
^m ol/, 0.2 ^mol/1, respectively) in exhaled H 20 2 level in both treatment groups (51). The 
difference in effect could be explained by the longer treatment period in this study. Kasielski and 
coworkers performed an intervention study with N-acetylcysteine (600 mg daily), which is an 
antioxidant, and placebo in 44 stable COPD patients for a period o f a year (52). The exhaled 
H 20 2 concentration was significantly lower in patients treated with NAC compared with placebo 
after 9 months and after 12 months.
In asthma patients (N = 17) one intervention study has been performed comparing the 
effect o f a 4 week treatment with ICS on the H 20 2 concentration (53) and placebo. The baseline 
concentration was significantly higher in asthmatic patients than in normal subjects. The H 20 2 
concentration decreased significantly after treatment and was significantly lower than that in the 
placebo group.
Only a few studies investigated correlations between exhaled H 20 2 levels and 
inflammatory markers or lung function. Nowak and colleagues found a positive correlation 
between exhaled H 20 2 and age, they did not find significant correlations between levels o f H 20 2 
and FEVj, which may be due to the low number o f patients included.
In summary, levels o f exhaled H 20 2 are higher in stable COPD patients compared with 
young healthy nonsmoking controls. When H 20 2 levels o f stable COPD patients are compared 
with controls o f the same age and smoking status, there seems to be no difference. In healthy 
persons exhaled H 20 2 levels are higher in current smokers, while in COPD patients levels seem 
to be the same in current smokers and ex-smokers. One study has shown that exhaled H 20 2 is 
further increased during exacerbation. ICS could have an effect on the exhaled H 20 2 
concentration after a longer treatment period. One study has suggested that antioxidant therapy 
reduces exhaled H 20 2 levels. In asthma patients the exhaled H 20 2 concentration is higher than in 
COPD patients and is reduced after treatment with ICS. Measuring exhaled H 20 2 is not yet 
standardized and there seems to be quite a large intra-individual variability.
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Isoprostanes
Oxygen radicals such as 0 2 and 0 2 react with unsaturated bonds o f arachidonic acid, leading to 
the formation o f bicycloendoperoxide intermediates. The reduction o f these intermediates lead to 
the formation o f isoprostanes. Reactive nitrogen species and polyunsaturated fatty acids other 
than arachidonic acid may also participate in the production o f isoprostanes (figure 2.3) (54).
Isoprostanes can be measured with analytic techniques such as high pressure liquid 
chromatography (HPLC), gas chromatography-mass spectrometry or radio-immunoassay. They 
are stable in isolated samples o f body fluids and their measured values do not exhibit diurnal 
variations (54).
There are few investigators that have measured exhaled isoprostanes. Montuschi and 
coworkers measured concentrations o f exhaled 8-isoprostane in 10 healthy nonsmokers and 12 
healthy smokers. The concentration was significantly higher in smokers (55).
Montuschi and coworkers also investigated 8-isoprostane levels in patients with COPD 
(55). They measured significantly higher 8-isoprostane levels in COPD patients compared with 
healthy subjects and found no difference between current smokers and ex-smokers, indicating 
that in COPD exhaled 8-isoprostane is largely derived from oxidative stress from airway 
inflammation rather than from cigarette smoking. There was no relation between 8-isoprostane 
and age, sex, FEV1 and history o f smoking.
Exhaled 8-isoprostane levels are also elevated in asthma patients (56) in relation to the 
severity o f the disease.
The effect o f steroids on exhaled 8-isoprostane levels in COPD is not known. In asthma 
ICS had little effect on exhaled isoprostanes levels.
In summary, 8-isoprostane levels are significantly higher in COPD patients compared 
with healthy persons and thus may be used to differentiate these groups, but 8-isoprostane levels 
are also increased in healthy smokers, asthma patients and patients with interstitial lung diseases. 
More studies have to be performed to confirm these findings and to clarify the role o f this 
marker in diagnosing and monitoring COPD.
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N itric oxide m etabolites
Nitric oxide is a highly reactive molecule with a relatively short half life in vivo. It can be oxidized 
or complexed with other biomolecules. The stable oxidation end products o f N O  metabolism are 
nitrite (N 0 2") and nitrate (N 0 3"). N O  can undergo a reaction with superoxide anion ( 0 2") to form 
peroxynitrite (ONOO"). Peroxynitrite reacts with tyrosine residues in proteins to form the stable 
product nitrotyrosine. N O  and N O  metabolites can also react with thiols (the major enzymatic 
antioxidants) to produce S-nitrosothiols (RS-Nos) (figure 2.1) (57).
All the mentioned N O  metabolites can be measured in EBC. The concentration o f nitrite 
can be assessed by a fluorimetrie assay (58). Incubation o f samples with nitrate reductase allows 
the nitrate to be converted to nitrite, which can be measured subsequently. Nitrosothiols are also 
measured by the same assay. Nitrotyrosine is measured using a specific enzyme immunoassay
Only a few investigators have measured N O  metabolites in EBC of healthy controls and 
patients with pulmonary disease. Balint and colleagues (59) measured the short and long term 
effect o f cigarette smoking on N O  metabolism in healthy subjects (N = 29). They found a 
significant increase in levels o f nitrite and nitrate 30 minutes after smoking a cigarette in the 
current smokers, no change in nitrosothiols or nitrotyrosine. There was no significant difference 
in the baseline levels o f nitrite, nitrate, S-nitrosothiols or nitrotyrosine between current smokers 
and non-smokers. This may suggest that exogenous oxidative stress by cigarette smoking may not 
exert a long term effect on N O  oxidation. They found no correlation between exhaled N O  and 
exhaled N O  metabolites.
Recently, Corradi and coworkers compared nitrosothiols levels in EBC of healthy 
subjects (smoker and nonsmokers) asthma patients (mild and severe), COPD patients and 
patients with cystic fibrosis (57). Levels o f nitrosothiols were elevated in COPD patients 
compared with nonsmoking controls. They were also increased in healthy smokers, severe 
asthma patients and CF patients. Another group measured nitrotyrosine levels in asthma patients 
(N = 39) and found that levels were increased in patients with mild asthma, but lower in patients 
with moderate or severe asthma, who were treated with steroids (60).
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No intervention studies using N O  metabolites in EBC have been performed in COPD or asthma 
patients. In asthma patients Hanazawa and colleagues showed that the level o f exhaled 
nitrosothiols was reduced in severe asthma patients using systemic corticosteroids (60).
In summary, exhaled N O  metabolites are increased directly after cigarette smoking. Most 
N O  metabolites are higher in COPD patients compared with nonsmoking healthy subjects (the 
data on nitrosothiols are controversial). However, NO metabolites are also increased in moderate 
to severe asthma patients. The effects o f steroids in COPD patients are unknown, whereas in 
asthma patients they appear to have some effect.
Thiobarbituric acid-reactive substances (TBARs)
Thiobarbituric acid-active substances (TBARs) are also a product o f lipid peroxidation, they are 
volatile and may be present in expired breath. They are low molecular weight compounds formed 
by the decomposition o f certain primary and secondary lipid peroxidation products (figure 2.3) 
(29). At a low pH  and elevated temperature the lipid peroxidation products participate in a 
nucleophilic addition reaction with thiobarbituric acid, generating a red fluorescent complex. 
They can by measured colometrically or fluorimetrically (29).
In healthy smokers (N = 18) Nowak and colleagues found a concentration o f 0.04 ± 0.14 
^M, in nonsmokers (N = 40) it was not detectable. They found no relation o f TBARS with other 
inflammatory parameters (48).
Few studies have been performed using exhaled TBARs levels to measure different 
patient groups. A cross-sectional study by Nowak and colleagues showed a higher concentration 
o f TBARs (0.48 ± 0.86 ^M) in stable COPD patients than in healthy subjects. There was no 
difference between current smokers and ex-smokers. (43).
They also measured levels o f TBARs and H 20 2 concentration in asthma patients and 
found levels that were significantly higher than in healthy control subjects and also higher than in 
COPD patients. A significant positive correlation was found between H 20 2 concentration and 
TBAR concentration (44).
No intervention studies have been performed yet studying the effect o f treatment on 
exhaled TBARs levels.
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In summary, the concentration o f TBARs could differentiate between healthy persons and stable 
COPD patients and between COPD patients and asthma patients. Smoking does not seem to 
influence exhaled TBARs levels in COPD patients. Further studies have to be done. Up till now 
there are no data about the effect o f steroids on the TBARs levels.
Conclusions and future directions
In summary, the literature presents the following information. In stable COPD patients exhaled 
CO and exhaled ethane levels are higher than in healthy controls, with the highest levels in 
currently smoking COPD patients. Isoprostanes, nitrosothiols and TBARs levels are also 
increased in stable COPD patients but there is no difference between current and ex-smokers. 
Exhaled H 20 2 levels are increased in stable COPD patients compared with young healthy non­
smokers. However, there is no difference between stable COPD patients and healthy, age- 
matched current and ex-smokers. Exhaled N O  levels are not elevated in COPD patients and, in 
contrast to the other markers, lower in currently smoking COPD patients. Treatment with ICS 
decreases exhaled N O  and ethane, but they do not affect exhaled CO. Studied on the effect of 
ICS on exhaled H 20 2 show either no effect or a reduction. The effects o f ICS on isoprostanes, 
N O  metabolites and TBARs are not known.
What is the clinical relevance o f this information? Most studies are cross-sectional, few 
randomized studies have been performed. Certainly, exhaled biomarkers have a great potential as 
noninvasive techniques to monitor airway inflammation and oxidative stress in the lungs since 
the technique o f collecting exhaled air or EBC is simple for patients to perform and can even be 
performed in children and patients with severe airway obstruction. The main problem, however, 
is the lack o f standardization for the collection and analysis o f most markers. This complicates 
the comparison o f the results o f different studies and centers.
This review clearly shows that most exhaled biomarkers need to be studied further before 
using them in clinical practice. First o f all, the technique o f collection o f the exhaled air or EBC 
and the techniques o f analysis for the several markers should be recorded in official guidelines. 
This is important in order to compare the results o f studies performed in different centers. 
Secondly, reference data on values o f all these markers in healthy persons need to be available.
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There is a need for large studies comparing COPD patients with healthy persons o f comparable 
age and smoking status. Only then will become clear which marker (if any) can be applied in 
diagnosing and monitoring COPD. Thirdly, data on reproducibility and variability o f different 
markers are scarce. This information is important in order to determine if repeated measurements 
can help in the clinical management, for example in measuring the effect o f treatment. Also, the 
relation between exhaled biomarkers and other parameters used to study COPD should be 
investigated, e.g. (inflammatory) cell count in blood and sputum and lung function, to gain 
information about the relevance o f exhaled markers. Finally, the effect o f treatment with 
different medications has to be investigated in randomized, placebo-controlled studies. Only then 
will it become clear whether exhaled markers can be used to evaluate the effect o f treatment.
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A bstract
In the pathophysiology of Chronic Obstructive Pulmonary Disease (COPD) oxidative stress plays an 
important role, which can be determined by measuring hydrogen peroxide (H 2O2). H 2O2 can be measured 
fluorimetrically in exhaled breath condensate (EBC), however, not standardized. The objective of this 
study was to investigate the sensitivity and reproducibility of the fluorimetrical method using an automated 
flow injection device with varying flow rates and measurements.
10 jul p-hydroxyphenylacetic acid (1.0 mmol/1) and 10 ul horseradish peroxidase (15 mU/1) were 
manually added to several hydrogen peroxide containing solutions and EBC of patients suffering from 
COPD. The fluorescence of the reaction product was measured with an automated sampler, flow injection 
and scanning fluorescence detector, excitation wave 295 nm, emission wave 405 nm at different flow rates. 
The degree of fluorescence was expressed as either area under the curve (AUC) or peak value.
A flow rate of 1 m l/m in gave the best results. There were no significant differences in calibration 
curves or detection limits using AUC or peak value (respectively 0.007 and 0.005 p,mol/l) (flow rate 1.0 
m l/m in). The mean volume of EBC was 2.8 ml, the mean H 2O2 concentration in the patient group was 0.2 
^mol/1 and the standard deviation of duplication 0.009 p,mol/l.
The low detection limit may be explained by using flow injection, because it measures the 
fluorescence over a period of time. It is important to chose an appropriate flow rate. There is no difference 
in detection limit between measuring the fluorescence as AUC or as peak value.
Introduction
There is an increasing interest in non-invasive methods for studying the pathogenesis o f several 
pulmonary diseases. Chronic Obstructive Pulmonary Disease (COPD) is a disease with increasing 
worldwide morbidity and mortality. COPD may be due to a mixture o f emphysema and 
peripheral airway obstruction from chronic bronchitis (1). Chronic obstructive bronchitis is 
associated with structural narrowing o f the small airways as a result o f chronic inflammatory 
changes, represented by activated T lymphocytes and macrophages. Emphysema is due to 
enzymatic destruction o f the alveolar walls. Macrophages and T lymphocytes are prominent at 
sites o f destruction. There is an imbalance between proteases and anti-pro teases (1-4). There is 
also considerable evidence that oxidative stress is increased in patients with COPD and that 
reactive oxygen species contribute to its pathophysiology.
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Oxidants are present in cigarette smoke and are produced endogenously by activated 
inflammatory cells, including macrophages and neutrophils (5).
Information about the degree o f airway inflammation and oxidative stress is important in 
relation to diagnosis, treatment and prognosis o f COPD. There are several methods to collect 
this information. The main task o f the respiratory system is the exchange o f oxygen and carbon 
dioxide, but exhaled air also contains a large number o f other volatile substances and the analysis 
o f these substances has a long tradition in medicine. In the past few years research has mainly 
focused on volatile compounds, particularly nitric oxide (NO), but recently other (non-volatile) 
compounds o f exhaled air have been studied, e.g. hydrogen peroxide (H20 2)(6). H 20 2 can be 
measured in exhaled breath condensate (EBC).
In general, two analyzing techniques have been described in literature for measuring H 20 2 
in EBC: the spectrophotometrical and the fluorimetrical method. The fluorimetrical method 
appears to be more sensitive, i.e. having a lower detection limit. The beginning o f this technique 
was described by Guilbault et al. in 1968 (7). They presented a survey o f 25 indicator substrates 
for fluorimetrical measurements and concluded that p-hydroxyphenylacetic acid was the best 
substrate. Hyslop et al. developed a method for measuring H 20 2 in 1984 (8). The method was 
based on the reaction o f H 20 2 and horseradish peroxidase (HRP) to form a compound which 
oxidized p-hydroxyphenylacetic acid to form a dimer that was fluorescent. This method has been 
adapted by others to analyse H 20 2 in EBC (9-11).
The main problem of measuring H 20 2 in EBC is the very low concentration o f H 20 2 in 
this substrate. Healthy young persons have a H 20 2 concentration in EBC of less than 0.1 ^mol/1, 
while the concentration in patients with stable Chronic Obstructive Pulmonary Disease (COPD) 
is around 0.2 ^mol/1 and in asthma patients can rise above 2.0 ^mol/1. Therefore it is important 
to have a very low detection limit in order to establish a reliable tool. There are different ways to 
measure the detection limit o f a measurement. IUPAC (International Union o f Pure and Applied 
Chemistry) defines the detection limit as the smallest concentration o f a sample that can be 
detected with reasonable certainty for a given analytic procedure. Consequently, the detection 
limit depends on the amplitude o f the blank readings (concentration zero) and is also related to 
the precision o f these measurements. The detection limit for H 20 2 in EBC described in literature 
varies from 0.01 to 1.0 ^mol/1 (9-19).
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There are more difficulties in the measurement o f H20 2 in EBC. H 20 2 in EBC is very unstable, it 
returns readily to its volatile form. In order to store EBC, it is necessary to add the reagentia to 
the EBC so that the reaction product can be stored (20).
Nowak et al. and Van Beurden at al. showed that the H 20 2 concentration varies 
considerably over the day and with repeated measurements (21, 22). It is therefore important to 
perform repeated measurements on the same time o f day under similar conditions. Schleiss and 
colleagues also found that H 20 2 concentrations depend on the expiratory flow rate (23).
The objective o f this study was to increase the sensitivity o f fluorimetrical analysis of 
H 20 2 (in EBC) by using an automated flow injection fluorimeter. Several problems and 
possibilities o f the automated flow injection fluorimeter were evaluated in this study. Firstly, the 
reaction product has to be injected with a certain flow rate. What is the influence o f flow rate on 
degree o f fluorescence and detection limit? Secondly, the fluorimeter produces a curve and the 
degree o f fluorescence can be determined by measuring the area under the curve (AUC) or by 
measuring the peak value. Does this influence the degree o f fluorescence or detection limit? 
Finally, is this method reproducible when used to measure H 20 2 concentration in EBC of 
patients?
M aterials and m ethods
M aterials
P-Hydroxyphenylacetic acid 1.0 mmol/1 was purchased from Fluka AG (Bormen, Belgium) and 
horseradish peroxidase 15 U /l from Sigma-Aldrich Chemie BV (Zwijndrecht, the Netherlands). 
Distilled water TKF 7114 was obtained from Baxter (USA) and hydrogen peroxide 107209.1000 
from Merck KgaA (Darmstadt, Germany).
Study population
Twenty patients with stable COPD (FEVj < 60% predicted) were recruited.
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Inclusion criteria were: age between 45 and 85 years, a diagnosis o f COPD according to the ERS 
criteria (24), current smokers or ex-smokers with at least ten pack-years (Table 3.1).
Patients were excluded if they had signs o f upper respiratory tract infections, another pulmonary 
disease at present or in the past possibly contributing to chronic airflow obstruction, or any other 
significant medical disease that could influence the study results. They were not allowed to use 
vitamin C, E, acetylcystein, inhaled or oral corticosteroids and theophyllin at least one month 
before the study.
Age (years, mean ± SD) 65 ± 6.8
Sex (male/female) 19/1
Smoking status (smoker/exsmoker) 8/12
± ±  
± ±  
FEVj/FVC (%, mean ± SD) 49 ± 8
Table 3.1. Characteristics of study population (N =  20). N =  number of patients, SD =  standard deviation, FEVi =  forced expiratory volume in 1 
second, FVC =  forced volume capacity.
Collection and processing o f EBC
Current smokers were told to refrain from smoking during visit days, starting at midnight before 
each visit day. All measurements were performed in the morning, after taking bronchodilating 
medication. Before each measurement the subjects rinsed their mouth with water. During the 
collection o f EBC, patients wore a noseclip.
The patients breathed tidally during ten minutes into a mouthpiece connected to a valve 
system, the expiratory flow rate was not standardized. The expiration valve was connected to a 
bulbcooler, which was constantly cooled by flowing ice water. At the end o f the bulbcooler, the 
condensate was collected in a glass container, with an air volume meter attached to a side opening 
at the bottom of the cooler (Fig 3.1).
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The valve system was heated to > 37°C with a stream of hot air to avoid condensation on the 
valves and to make sure that all o f the condensate formed could be collected (the influence o f the 
heating o f the system on the stability o f H 20 2 was not tested). The device was cleaned with 
distilled water each time before and after the measurement (without drying the collecting system). 
The reproducibility o f the collecting device was investigated earlier (14).
Ambient air-
“ f 11 Valve system
Mouth piece
Air Volume 
Meter
Glass Container
Figure 3.1. Collecting device: a mouthpiece is connected to a valve system and the expiration valve is connected to the top of a 0.4 m high glass 
bulbcooler, which is constantly cooled by a reverse stream of ice water (0 °C).
The condensate was immediately transported to the laboratory in a sealed glass container. First of 
all the volume o f the condensate was measured (2.5 to 3.5 ml) and subsequently the reagentia 
were added (within 30 minutes). To 250 (jl o f H 20 2 containing solution, 10 (jl p- 
hydroxyphenylacetic acid (1.0 mmol/1) and 10 (jl horseradish peroxidase (HRP)(15 U/l) were 
added manually (modified after Hyslop and Sklar (8).
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After completion o f the reaction (one hour), the fluorescence o f the reaction products was 
measured with an automated sampler, 717 plus, flow injection 600 controller and scanning 
fluorescence detector 474 from Waters, Millipore Corporation (Milford, USA). The fluorescence 
was measured with an excitation wave length o f 295 nm and an emission wave length o f 405 nm, 
at different flow rates. For the flow injection 25 ^1 o f the reaction product was needed. All 
condensates were measured in duplicate and the standard deviation o f duplication was 
determined. The results were expressed as mean [SEM],
D egree o f  fluorescence and detection lim it
The influence o f the flow rate used to put the reaction product through the fluorimeter, on the 
degree o f fluorescence and on the detection limit was determined by measuring the fluorescence 
using different flow rates. The following flow rates were used: 0.10, 0.25, 0.50, 1.00, 2.50, and 
5.00 ml/min. Also several H 20 2 concentrations were used in this experiment: 0.01, 0.025, 0.05, 
0.10, 0.20 and 0.50 ^mol/1.
The degree o f fluorescence was both determined by measuring the AUC and the peak 
value and calibration curves were formed. The influence o f expressing the degree o f fluorescence 
on the detection limit, either by AUC or by peak value, was determined.
For determining the detection limit the following equation was used: Xlimit = Xbknk + 
k.SDblank. (Xblank is the mean o f the blank measurements, SD is the standard deviation o f these 
measurements, k was assigned a factor o f 3 to obtain a detection limit that has a probability of 
99%). We used 20 samples o f distilled water to determine the detection limit for a blank 
measurement.
Results
D egree o f  fluorescence and detection lim it
Measuring several H 20 2 solutions, the degree o f fluorescence, measured both as AUC or as peak 
value, increased with lower flow rates (Fig 3.1a, 3.1b).
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flow rate ml/min
Figure 3.1a. The degree of fluorescence, expressed as area-under-the-curve, is plotted against the flow rate measured with H;0; concentrations, o 
H2O2 concentration 0.02 |amol/l, □ H2O2 concentration 0.05 |amol/l, A  H2O2 concentration 0.1 |amol/l, 0  H2O2 concentration 0.2 |amol/l, □ H2O2 
concentration 0.5 |amol/l.
flow rate ml/min
Figure 3.1 b. The degree of fluorescence, expressed as peak value, is plotted against the flow rate measured with H2O2 concentrations, o H2O2 
concentration 0.02 |amol/l, □ H2O2 concentration 0.05 |amol/l, A  H2O2 concentration 0.1 |amol/l, 0  H2O2 concentration 0.2 |amol/l, □ H2O2 
concentration 0.5 p.mol/1.
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However, at low flow rates the variation in fluorescence increased. A flow rate o f 1.0 m l/m in 
gave the lowest detection limit (Table 3.2).
Flow rate (m l/m in) 0.10 0.25 0.50 1.0 2.0
(^mol/1)
AUC 0.012 0.010 0.012 0.007 0.009
Peak value 0.013 0.009 0.011 0.005 0.007
Table 3.2. The detection limits that were measured using different flow rates, expressed as AUC (area under the curve) or as peak value.
Measured at a flow rate o f 1.0 m l/m in and expressed as AUC, the detection limit was determined 
to be 0.007 ^mol/1. The detection limit was 0.005 ^mol/1 measured at a flow rate o f 1.0 m l/m in 
and expressed as peak value. There were no significant differences in the detection limit 
expressing the fluorescence as AUC of expressing it as peak value (mV). Calibration curves wer 
formed measuring the degree o f fluorescence as AUC or as peak value. The course o f the 
calibration curves were linear in both cases until 2.0 ^mol/1 (not shown).
h 2o 2 concentration in EBC
The mean condensate volume was 2.8 [0.14] ml. The mean H 20 2 concentration o f the 
condensates was 0.22 [0.03] ^mol/1. The standard deviation o f duplication was 0.009 ^mol/1.
D iscussion
We showed that the degree o f fluorescence is influenced by the flow rate, the fluorescence being 
higher with decreasing flow rates. Furthermore, the detection limits and calibration curves were 
not significantly influenced when expressing the degree o f fluorescence as either AUC or as peak 
value.
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The detection limit we found in this study is lower than the detection limits described in 
literature. Jöbsis et al. found a detection limit o f 0.1 ^mol/1 using the p-hydroxyphenylacetic 
acid/horshradish peroxidase method with a fluorimeter (10). However, it is not described how 
they obtained this detection limit. Worlitzsch et al. obtained a detection limit o f 0.01 ^mol/1 
using the same method and fluorimeter as Jöbsis (11). They measured the reaction in a cuvet 
during 40 seconds immediately after adding the reagentia to the condensate. By measuring 
kinetically the increase o f fluorescence over a period o f time, their analyzing method may be 
more sensitive then other measuring methods. By using flow injection the measurement is 
continuously because it measures the fluorescence over a period o f time instead o f at one time 
point, while software provides a calculated area under the curve. This may explain the low 
detection limit we obtained in our study.
As shown in Figure 3.2 the degree o f fluorescence was higher when measuring the 
samples at a lower flow rate. The H 20 2 concentration is calculated from the degree of 
fluorescence and can be determined more accurately when the fluorescence is greater, because 
the calibration curve can be read more accurately. When using higher flow rates the degree of 
fluorescence is low and the determination o f the H20 2 concentration less accurate. On the other 
hand, at a low flow rate small changes in flow rate produce great differences in fluorescence. It 
can be difficult to establish exactly the same flow rate in repeated measurements. This was 
confirmed by the fact that the detection limit was the lowest at a flow rate o f 1.0 m l/min.
The detection limit was comparable expressing the fluorescence as AUC or as peak value. 
The AUC represents the surface o f the curve produced by the fluorimeter. The peak value is 
calculated from several points on this curve, so it also represents the calculated shape o f the 
curve. This means that both measurements represent (almost) the same. However, in contrast to 
the peak value the fluorimeter calculates the AUC automatically. Because o f the very small 
differences in detection limits obtained by measuring with peak values or AUC, it might be 
recommended, from a practical point o f view, to use AUC measurements to measure the degree 
o f fluorescence instead o f peak values.
The mean H 20 2 concentration in the EBC we found in our o f the COPD patients was
0.22 ^mol/1. This is comparable to other studies (12,13).
Automated flow injection for measuring H 20 2 in EBC has several advantages. Firstly, 
only 25 ^1 condensate is needed for the flow injection, which is less than for the cuvet technique. 
Secondly the machine is automated, so that measurements can be made constantly, also during 
the night.
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In summary, automated flow injection is a reliable and efficient method for measuring H 20 2 in
EBC. Low detection limits can be obtained when using a flow injection rate o f 1.0 ml/min. From
a practical point o f view we advise to use AUC measurements to express the degree of
fluorescence.
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Chapter 4
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IN EXHALED BREATH CONDENSATE
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A bstract
We investigated the sensitivity and reproducibility of a test procedure for measuring hydrogen peroxide 
(H 2O2) in exhaled breath condensate and the effect of storage of the condensate on the H 2O2 concentration 
and compared the results to previous studies.
Twenty stable COPD patients breathed into our collecting device twice for a period of ten minutes. 
The total exhaled air volume (EAV) and condensate volume were measured both times and the H 2O2 
concentration of the condensate was determined fluorimetrically. The concentration was measured again 
after freezing the reaction product at -70°C for a period of 10,20 and 40 days.
We collected 2-5 ml condensate in 10 minutes. The EAV and condensate volumes were strongly 
correlated. There was no significant difference between the mean H 2O2 concentration of the first and 
second test. We obtained a detection limit for the H 2O2 concentration of 0.02 p,mol/L. The H 2O2 
concentration appeared to remain stable for a period up to 40 days of freezing.
Compared to previous studies we developed a more efficient breath condensate collecting device 
and obtained a lower H 2O2 detection limit. The measurement of exhaled H 2O2 was reproducible. In 
addition, storage of the samples up to 40 days showed no changes in H 2O2 concentration.
Introduction
Oxidative stress plays an important role in the development o f Chronic Obstructive Pulmonary 
Disease (COPD). Oxidants may damage different cells and enzyme systems in the lungs (1,2). 
Oxidative stress is increased in COPD patients compared to healthy subjects, due to (increased) 
exposure to exogenous oxidants such as inhaled cigarette smoke and air pollution, or enhanced 
endogenous production o f hydrogen peroxide (H20 2) due to neutrophilic inflammation and due 
to a relatively impaired antioxidant system (3,4).
The degree o f oxidative stress can be determined by measuring the hydrogen peroxide 
(H2O2) concentration in exhaled breath condensate. This is a relatively easy and noninvasive 
method and reflects the oxidative status in the lungs of these patients. However, there are 
several methodological issues at present, which limits its application in large and prospective 
trials.
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Firstly, there is no standardized method for collecting breath condensate. The various collecting 
devices described in literature collect variable amounts o f breath condensate, ranging from 1 to 5 
ml in 15 to 20 minutes (3-13). For the analysis at least 1 ml is needed. If  a more efficient 
collecting device could be found, the collecting time could be considerably reduced, which is less 
inconvenient for the patient. As such an efficient collecting device is a prerequisite.
Secondly, the H 20 2 detection limit varies from study to study; most investigators achieved 
a detection limit around 0.1 ^mol/1. It is important to obtain a low detection limit because the 
H 20 2 concentrations measured in previous studies were low (< 1.0 ^mol/1) in selected patient 
groups as well as in healthy control groups. In a number o f cases this was even below the 
detection limit (3-13). We have tried to lower the detection limit.
Thirdly, there are limited findings on the stability o f H 20 2 concentration during storage of 
the breath condensate before analysis. The period o f storage by freezing the breath condensate 
varies from 6 hours up to one month (3-6). Detailed data on the actual stability o f H 20 2 
concentrations are not provided in most studies. The advantage o f storage o f the breath 
condensates is that the condensates need not be analyzed immediately, which is a time­
consuming procedure. Furthermore all measurements can be performed using one calibration 
curve, which is more reliable.
In view o f the above mentioned problems, we conducted this study with the following 
research questions. Firstly, can we adapt the breath condensate collecting devices described in 
literature in order to develop a more efficient device? Secondly, are we able to improve the 
existing analytical methods to establish a lower detection limit? Thirdly, is the procedure 
reproducible in a group o f COPD patients? Finally, is the H 20 2 concentration influenced by 
freezing the condensate-reagent mixture at —70°C?
M aterials and m ethods
Patients
We performed this study in a population o f COPD patients, because in most healthy persons the 
H 20 2 concentration is below the H 20 2 detection limit. The H 20 2 concentration is significantly 
higher in COPD patients (3,13).
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Stable COPD patients were recruited from the outpatient-clinic o f a large non-academic teaching 
hospital. Inclusion criteria were: 1. a diagnosis o f COPD according to the ERS criteria (14), 2. 
smokers or ex-smokers with at least ten pack years, 3. age between 40 and 85 years, 4. a EEV^ < 
60% of predicted and FEV1/VC ratio < 60%, with a reversibility o f less than 12% of predicted 
after taking a bronchodilator. Patients used their own bronchodilators, but any inhaled 
corticosteroids and /o r acetylcystein were discontinued for at least four weeks prior to the study. 
The study was approved by the local ethics committee. All patients gave informed consent. 
Twenty stable COPD patients (19 male, mean age 65 years, mean FEV1 48 % predicted) from 
the outpatient-clinic were included in the study. Eight patients were current smokers and 12 were 
ex-smokers. Patient characteristics are shown in table 4.1.
Age (years) 65 (6.8)
Table 4.1. Characteristics of study population (N =  20) Mean (SD), PY =  packyears, FEVi =  forced expiratory volume in 1 second, FVC =  forced vital 
capacity, pred. =  predicted.
C ollecting device
The collecting device consisted o f a mouthpiece connected to a valve system. The expiration 
valve was connected to the top o f a 0.4 m high glass bulbcooler with an inside air volume o f 155 
ml, which was constantly cooled by a reversed stream of ice water (0 °C). At the bottom  of the 
bulbcooler the condensate was collected in a glass container. An air volume meter (Ohmeda type 
5410) was attached to the side opening o f a T-glass tube at the bottom of the bulbcooler.
Sex (male/female)
Smoking status (smoker/exsmoker)
19/1
8/12
Pack years (PY) 
FEV! % of pred 
FEVi/FVC (%)
39 (12.5)
48 (7.25)
49 (8)
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To avoid condensation in the valve system, the system was heated by a fan. The fan produced a 
diverging stream of hot air with a minimum temperature o f 42° C, it was placed approximately 
0.5 m from the valve system. The bulbcooler was flushed with distilled water (not containing 
H 20 2) before and after each test to remove any H 20 2 residue from the previous test (figure 4.1).
Ambient air-
“ f 11 Valve system
Mouth piece
Air Volume 
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Glass Container
Figure 4.1. Collecting device: a mouthpiece is connected to a valve system and the expiration valve is connected to the top of a 0.4 m high glass 
bulbcooler, which is constantly cooled by a reverse stream of ice water (0 °C).
At the base o f the bulbcooler the condensate is collected in a glass container. To the side opening 
o f the T-glass tube at the base o f the bulbcooler, an air volume meter (Ohmeda type 5410) is 
attached. To avoid condensation in the valve system, the system is heated to a fan producing a 
diverging stream of hot air with a minimum temperature o f 42° C.
Because we suspected that flushing the bulbcooler with distilled water before each test 
might dilute the obtained breath condensate and change the measured H 20 2 concentration, we 
also investigated this effect by performing the following tests.
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The bulbcooler was flushed with physiologic saline (0.9%) before performing a breath test. The 
condensate was obtained in fractions o f 0.3 ml and the sodium concentration o f these fractions 
was measured by means o f a selective sodium electrode. Using this method we could determine 
how much condensate had to be collected in order to wash out all traces o f the saline left behind 
on the glass wall after flushing the bulbcooler with saline. By comparing the subsequent sodium 
concentrations, it was affirmed that the waterfilm on the inside wall o f the glass bulbcooler was 
replaced for 95% after the formation o f 1.8 ml o f condensate during the breath test. The actual 
collected condensate volumes varied in our patients from 1.85 to 4.75 ml. This meant that the 
waterfilm formed after flushing the cooler, was almost completely replaced by breath condensate 
at the end o f each test and that the H 20 2 concentration o f the condensate had to be corrected for 
the dilution with the volume o f the waterfilm, which was formed by flushing the cooler before 
each test.
To determine the degree o f dilution, the volume of the waterfilm (a ml) formed in the 
cooler after flushing had to be measured. We determined this by flushing the cooler again with a 
NaCl containing solution (1500 mmol/1), followed by flushing the cooler with a fixed amount of 
distilled water (5 ml). Subsequently, the sodium concentration o f the solution collected at the 
base o f the bulbcooler was measured (b mmol/1) and compared to the initial concentration of 
the NaCl. The volume o f the film in the bulbcooler could be calculated by: a = b x 5/1500. With 
this method the volume o f the waterfilm on the inside o f the bulbcooler was determined to be 
0.35 ml. This was used for correcting the H 20 2 concentration o f the breath condensates 
(condensate volume c + 0.35/c x measured H 20 2 concentration).
The condensate o f three random patients was checked for amylase in order to exclude 
contamination o f the breath condensate by saliva. An enzymatic colorimetric assay for the 
quantitative determination o f a-amylase in human serum, plasma and urine, according to the 
recommendations o f the IFCC, was used.
Analysis o fH 20 2 in the condensate
P-hydroxyphenylacetic acid 1.0 m m ol/L  from Fluka AG (Bormen, Belgium) was used for the 
analysis, together with horshe radish peroxidase 15 U /m L  and catalase 160 U /m L  from Sigma 
Chemical Co (St Louis, USA). Distilled water TKF 7114 was obtained from Baxter (USA) and 
the hydrogen peroxide 107209.1000 from Merck KgaA (Darmstadt, Germany).
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After collection o f the condensate, its volume was measured. Subsequently, to 250 |.lL o f breath 
condensate, 10 |.lL p-hydroxyphenylacetic acid and 10 |.lL 15 U /L  horshe radish peroxidase were 
added within thirty minutes after collection. (15)
The fluorescence o f the reaction product (dimer 2,2’-dihydroxybiphenyl-5,5’-diacetate) 
was measured with an automated sampler, flow injection and scanning fluorescence detector 
from Waters, Millipore Corporation (Milford, USA), with an excitation wave length o f 295 nm 
and an emission wave length o f 405 nm. The reaction product was injected into the fluorimeter 
which produced a curve and the fluorescence was presented by the area under the curve. Besides 
a blank measurement, several standard concentrations o f H 20 2 were measured, using 
concentrations o f up to 3.0 (jmol/L. Additionally the detection limit was determined by 
measuring several times the standard H 20 2 concentration o f 0.0 ^m ol/L  and calculating the 
mean and standard deviation o f the samples, with the detection limit being 3 x SD. Each 
collected condensate was analyzed in duplicate and mean values were used for further analysis.
To determine the specificity o f the assay, in a pilot study o f 17 condensate samples, 
catalase was added to convert H20 2 to water, and the H 20 2 concentration was measured again.
Procedure o fth e  breath test
All patients performed the breath tests in the morning, after they had taken their medication. 
They refrained from smoking after midnight o f the preceding day, since cigarette smoke contains 
oxidants. Before the test, patients rinsed their mouth with tap water to avoid contamination of 
the breath condensate. They breathed in the collecting device twice for a period o f ten minutes, 
while wearing a nose-clip. After both tests the condensate volumes and total exhaled volume 
(EAV) were measured. To test the reproducibility o f the whole procedure, the H 20 2 
concentration measured during the first test was compared to the concentration measured during 
the second test.
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Stability o fth e  reaction product
Several condensate-reagent mixtures were frozen at —70 °C. In a pilot study o f 34 condensates, 
the stability o f the condensate-reagent mixture was tested (the condensates were also collected in 
stable COPD patients not included in the study population). The fluorescence o f the reaction
°
Statistical m ethods
Results are expressed as mean ± SEM. The paired student t-test was used to compare the results
a
the first and second test and the difference between the two tests was presented in a Bland- 
Altman plot. The relation between the EAV and condensate volume was expressed as correlation 
coefficient. The mean H20 2 concentration o f the samples measured at day o was compared with 
the concentration at day 10, day 20 and day 40 using the paired student t-test (a < 0.05).
Results
Collecting device
±
±
0.01). Three condensates were checked for the presence o f amylase; no amylase was found.
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Validation o fth e  analysis o fH 20 2 in the condensate:
A calibration curve was constructed, with a range up to 3.0 (jmol/1 (fig 4.2). The detection limit 
was determined to be 0.02 ^mol/1. After adding catalase to seventeen separate condensates, the 
mean H 20 2 concentration decreased from 0.25 (jmol/1 to below the detection limit.
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Figure 4.2. Calibration curve obtained with standard amounts of H;0;. H;0; concentration is plotted against area-under-the-curve measured by the 
fluorimeter
R eproducibility ofthe  breath test
The H 20 2 concentration measured during the first breath test was 0.22 ±0.03 ^mol/1 and during 
the second test 0.21 ± 0 .0 3  ^mol/1. There was no significant difference between both 
measurements (p = 0.7). The reproducibility is also shown in a Bland Altman plot (figure 4.3). 
There was no significant difference in H 20 2 concentration between current smokers and ex-
± ±
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The difference was significant (p = 0,04). The correlation (r) between the EAV and the volume 
o f the collected condensate was 0.90 (p < 0.01) during the first test and 0.95 (p < 0.01) during 
the second test (fig 4.4).
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Figure 4.3. Biand-Altman plot: the H;0; concentration measured during the first and second test, the plots represent difference against mean. Lines 
represent mean difference - - - and 2 x S D difference - - - - -
Condensate volume (ml)
Figure 4.4. The correlation between the total exhaled air volume and condensate volume of the first and second breath test. The correlations from the 
first test are represented by □ (r =  0.90), and from the second test by ■ (r =  0.95).
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Storage ofthe  reaction product
The H20 2 concentration in 15 frozen reaction products was measured immediately and after a 
period o f 10 days (fig 4.5a). Twelve reaction products were measured directly and 20 days later 
(fig 4.5b) and 7 were repeated after 40 days (fig 4.5c). The H 20 2 concentration appeared to 
remain stable over all these time periods.
There was no significant difference in mean H 20 2 concentration between day 0 (0.44 ±0.19 
^mol/1) and day 10 (0.43 ± 0.18 ^mol/1: p = 0.56), or day 0 (0.48 ± 0.13 ^mol/1) and day 20 
(0.47 ± 0.14 ^mol/1) or day 0 (0.39 ± 0.16 ^mol/1) and day 40 (0.38 ± 0.17 ^mol/1).
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Figure 4.5a. The H;0; concentration measured immediately and after freezing the reaction product for 10 days.
1.0
0.8
tí_o
IS
otío
C.
af
0.6
0.4
0.2
20 Days
Figure 4.5b. The H;0; concentration measured immediately and after freezing the reaction product for 20 days.
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Figure 4.5c. The H;0; concentration measured immediately and after freezing the reaction product for a period of or 40 days.
D iscussion
The present study shows that the collecting device used in this procedure was able to collect a 
sufficient amount o f condensate within a smaller time period. A lower detection limit for 
measuring H 20 2 concentration in breath condensate was obtained compared to other studies. 
The reproducibility o f the whole procedure was acceptable; there was no significant difference in 
H 20 2 concentration between test 1 and 2. Finally, the H 20 2 concentration did not appear to be 
influenced by storage o f the reaction product at —70° C for a period up to 40 days.
Initially we used other constructions for collecting breath condensate that were described 
in literature (3,4,7). A condense chamber and subsequently a sphere were cooled with solid 
carbon dioxide, but the volume o f the obtained condensate was very variable. This was probably 
caused by the inability to establish sufficient contact time between the exhaled air and the cooling 
system. Therefore the amount o f condensate collected was never more than 1 ml after 15 
minutes o f breathing. Antczak (9) and Nowak (4) used a glass tube cooled by a package o f ice 
and were able to collect 2-5 ml condensate in twenty minutes.
Exhaled hydrogen peroxide in COPD 76
Chapter 4 A h efficient method for measuring exhaled hydrogen peroxide
With our current device we collected 2-5 ml condensate in only ten minutes by means o f a glass 
bulbcooler cooled by a reverse stream of ice water, which leads to better condensation.
In accordance with other investigators the patients were instructed to rinse their mouth 
before each breath test to avoid contamination o f the breath condensate by saliva. Unlike others, 
we did not use a separate saliva trap, because the device was constructed in such a way that the 
exhaled air went up through the valve system before entering the cooled bulbcooler. Indeed, no 
amylase was found.
Recently, Schleiss et al. showed that exhaled H 20 2 depends on expiratory flow rates (18). 
In our study we did not control expiratory flow rates. There was a significant, but small 
difference in EAV between the first (108.6 1) and second test (103.4 1). The mean flow rate during 
the first test was 181 m l/sec and during the second test 171 ml/sec. However, H 20 2 
concentrations were similar in the two tests (0.21 and 0.22 ^mol/1, respectively).
To ensure that no H 20 2 was left behind from the previous patients, the bulbcooler was 
cleaned before and after each breath test. We cleaned the cooler with distilled water.
No tapwater was used in order to avoid contamination with particles that could influence the 
fluorescence. Flushing the cooler with distilled water before each test caused dilution o f the 
obtained condensate by distilled water from the waterfilm, so we corrected the H 20 2 
concentration for this dilution. The correcting factor could have been avoided by heating the 
collecting device to make all H 20 2 disappear. However, the heating and cooling down o f the 
collecting device would be time consuming and thus unpractical, since we wanted to measure 
several patients on the same day with an interval o f only 30 minutes.
Looking at the method o f analysis described in literature to determine the H 20 2 
concentration in the breath condensate, two methods have been used in general; the 
spectrophotometrical method according to Gallati and Pracht (16) and the fluorimetrical method 
according to Hyslop and Sklar (15) or Ruch (17). Sznajder (5), Loukides (7) and Dekhuijzen (3) 
used the spectrophotometrical method and obtained a detection limit o f 0.1 (jmol/L. Others, 
using a fluorimetrical method, found detection limits o f 0.083 to 0.1 (jmol/1 (4,6,8,9). We 
performed the analysis o f the breath condensate according to Hyslop and Sklar, and were able to 
establish a detection limit o f 0.02 (jmol/1. This is lower than the detection limits described by 
others using the same method. This could be explained by the fact that the fluorimeter reads the 
degree o f fluorescence o f the condensate-reagens mixture and this is converted into a 
concentration.
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Usually a cuvet containing the condensate-reagens mixture is placed into the fluorimeter. We 
chose to use flow injection o f the mixture with fluorimetrical detection instead, which may be 
more sensitive (although comparative data are lacking).
Our test procedure for measuring exhaled H 20 2 concentration proved to be reproducible. 
There was no significant difference between the H 20 2 concentration in the first and second test. 
W ien  we consider the Bland-Altman plot o f these tests, all but one patient showed a difference 
between the two tests o f less than 2 SD from the mean difference. In this patient the relatively 
great difference might be explained by a delay between the collection o f the condensate and its 
analysis.
In this study we found a mean H 20 2 concentration o f 0.21 ^mol/1 in stable COPD 
patients. Dekhuijzen et al. found a similar mean H 20 2 concentration in stable COPD patients (3). 
The concentration measured by Nowak et al. was somewhat higher; 0.48 ^mol/1 (4). O ther 
investigators measured the H20 2 concentration in asthma patients, in these patients the H20 2 
concentration varied from 0.6-0.8 ^m ol/L  (6,9,12).
There was a difference in EAV and condensate volume during the first and second test, 
which can be explained by variation within the patients themselves. It proved to be difficult to 
perform several breath tests with exactly the same tidal volume and frequency. The mean EAV 
was lower after the second test, while the condensate volume was higher. A possible explanation 
is that different breathing patterns cause different VD/V T ratios (dead space volum e/ tidal 
volume). The humidity o f the VD is lower than that o f the VT, which could lead to a difference in 
humidity o f the exhaled air. However, EAV and condensate volume were strongly correlated 
both times.
Finally, storage o f the reaction product for at least 10 days at —70°C was possible without 
any changes in H 20 2 concentration and appeared to have virtually no influence on the measured 
H 20 2 concentration up to 40 days (fig 4). Others have studied the possibilities o f storage o f the 
breath condensate and found that the H20 2 concentration in the condensate remained stable for 
only a few hours to several days. This could be explained by the fact that they froze the breath 
condensate instead o f the reaction product, as we did in the present study.
In conclusion, we were able to develop a more efficient breath condensate collecting 
device, by adapting collecting devices described in literature. By adapting the fluorimetrical 
method o f analysis we could lower the detection limit. The test procedure proved to be 
reproducible and easy to perform.
Exhaled hydrogen peroxide in COPD 78
Chapter 4 A h efficient method for measuring exhaled hydrogen peroxide
In addition, the H 20 2 concentration after storage of the breath condensate appeared to remain 
stable for a period up to 40 days. These findings may facilitate the application o f this method in 
future prospective and multicentre studies.
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A bstract
Because inflammation induces oxidative stress, exhaled hydrogen peroxide (H 2O2), which is a marker of 
oxidative stress, may be used as a non-invasive marker of airway inflammation in COPD. There are no data 
on the circadian variability of exhaled H 2O2 in COPD patients. The aim of this study was to investigate the 
variability of the H 2O2 concentration in breath condensate of stable COPD patients and of matched healthy 
control subjects.
We included twenty patients with stable mild COPD (FEV1 ~ 70% of predicted) and twenty 
healthy subjects, matched for age, sex and pack-years, all smokers or ex-smokers. Breath condensate was 
collected and its H 2O2 concentration determined fluorimetrically three times on day 0 (9 am, 12 am, 3 pm) 
and once on days 1 ,2 ,3 , 8 and 21.
The mean H 2O2 concentration increased significantly during the day in both the patient and 
control group (respectively p=0.02, p<0.01). Over a longer period up to 21 days, the mean concentration did 
not change in both groups. There was no significant difference between patients and controls. The mean 
coefficient of variation (CV) over 21 days was 45% in the patient group and 43% in the control group 
(p=0.8).
We concluded that the exhaled H 2O2 concentration increased significantly during the day in both 
stable COPD patients and controls. Over a period of weeks the mean H 2O2 concentration did not change 
and the variability within the subjects was similar in both groups.
Introduction
Airway inflammation and oxidative stress have been implicated in the pathogenesis o f Chronic 
Obstructive Pulmonary Disease (COPD) (1,2,3). The presence o f inflammation in the 
(peripheral) airways o f COPD patients has been demonstrated by analyses o f sputum induction, 
transbronchial biopsies and bronchoalveolar lavage. Biopsies from the lungs o f COPD patients 
and smokers contained an increased number o f neutrophils (4,5). These investigations provide 
direct information about the level o f airway inflammation, but are invasive for patients and thus 
not very suitable for determining the severity o f COPD or for evaluating the effect o f therapy in 
clinical practice.
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Besides airway inflammation, oxidative stress plays an important role in the pathogenesis of 
COPD. Oxidative stress is caused by an imbalance between the production o f oxidants and the 
presence o f antioxidants. Oxidants are produced in the lungs by inflammatory cells, especially 
neutrophils and macrophages (6). An important exogenous source o f oxidants in COPD patients 
is cigarette smoke. Oxidants deactivate antiproteases that protect the lungs against proteases like 
elastase. Elastase can damage alveoli, stimulate inflammation, impair healing and produce 
surfactant abnormalities. Oxidants also increase mucus production by epithelial cells and impair 
cilia function (2).
The level o f pulmonary oxidative stress may be used as an indirect marker o f airway 
inflammation. It can be determined by measuring the hydrogen peroxide (H20 2) concentration in 
exhaled breath condensate (7-12). This is a rather simple and non-invasive procedure. Several 
investigators found that the H20 2 concentration was significantly elevated in patients with mild 
stable COPD compared to healthy non-smoking control persons and that it was further increased 
in COPD patients with acute exacerbation (7, 12, 13).
Although H 20 2 exhalation has been studied by several investigators, there are few data on 
variability within one day and over a longer period o f time. To investigate if the H 20 2 
concentration may be a suitable measurement for the follow-up o f COPD patients, it is necessary 
to get insight into the variability o f the H 20 2 concentration in exhaled breath condensate over 
time. This study was therefore performed to determine the variability o f the H 20 2 concentration 
in exhaled air in stable COPD patients and in matched healthy controls.
Patients and m ethods
Patients
We recruited stable COPD patients from the out-clinic with no increase o f symptoms over the 
last three months. Inclusion criteria were: age between 45 and 85 years, a diagnosis o f COPD 
according to the ERS criteria (14), current smokers or ex-smokers with at least ten pack-years.
Patients were excluded if they had signs o f upper respiratory tract infections, another 
pulmonary disease at present or in the past possibly contributing to chronic airflow obstruction, 
or any other significant medical disease that could influence the study results.
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They were not allowed to use vitamin C, E, acetylcystein, inhaled or systemic corticosteroids and 
theophyllin at least one month before the study.
The study was approved by the local Ethic Committee o f the hospital and all subjects 
gave informed consent.
Control group
The inclusion criteria for the control group were: healthy males and females between 45 and 85 
years o f age, normal lung function tests (FEVj and FEVj/V C within 1.64x standard deviation) 
current smokers or ex-smokers with at least ten pack-years. The control persons were not 
allowed to have any pulmonary or non-pulmonary disease that could influence the study, or 
complaints o f chronic cough and /or dyspnoea, or atopic complaints.
Each patient was matched with a healthy control person regarding sex, age (+ /-  five 
years), sex and pack-years (+ /-  five pack-years).
Study design
The H20 2 concentration in breath condensate was measured several times in all patients and 
control persons. The concentration was measured three times on day 0 with an interval o f three 
hours (9 am, 12 am and 3 pm). In addition, the H 20 2 concentration was measured once on day 1,
2, 3, 8 and 21 at the same time each day for each subject (some in the morning, some in the 
afternoon). Patients were withdrawn from the study if they developed an exacerbation.
To confirm the current smoking status, cotinine concentration in the urine was measured. 
In both groups flow-volume curves were measured. In the patient group we also measured 
postbronchodilator FEVj (after inhalation o f 400 ^g  salbutamol by pMDI). The measurements 
o f exhaled H 20 2 were performed 30 minutes after the lung function tests.
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M easurem ent o f  exhaled H20 2
All subjects were asked not to drink coffee or tea during visit days, since these beverages have 
shown to contain oxidants. Otherwise they were allowed to drink and eat normally before and 
during visit days. The current smokers were told to refrain from smoking during visit days, 
starting at midnight before each visit day. Before each measurement the subjects rinsed their 
mouth with water.
The patients and control persons breathed tidally during ten minutes into a mouthpiece 
connected to a valve system. The expiration valve was connected to a bulbcooler, which was 
constantly cooled by flowing ice water. At the end o f the bulbcooler, the condensate was 
collected in a glass container, with an air volume meter attached to a side opening at the bottom 
of the cooler. The valve system was heated to > 37° C with a stream of hot air to avoid 
condensation on the valves and to make sure that all o f the condensate formed could be collected 
(the influence o f heating o f the system on the stability o f exhaled H 20 2 was not tested). The 
device was cleaned with distilled water each time before and after the measurement (without 
drying the collecting system).
The condensate was immediately transported to the laboratory in a sealed glass container. 
First o f all the volume o f the condensate was measured and subsequently the reagentia were 
added (within 30 minutes). To 250 (jl condensate, 10 (jl p-hydroxyphenylacetic acid and 10 (j,l 
horseradish peroxidase (15 U/l) were added (modified after Hyslop and Sklar [15]). The reaction 
product (dimer 2,2’-dihydroxybiphenyl-5, 5’diacetate) was frozen at —70°C.
Every two weeks the reaction products were measured fluorimetrically. The fluorescence 
o f the reaction product was measured with an automated sampler, flow injection and scanning 
fluorescence detector from Waters, Millipore Corporation (Milford, USA), with an excitation 
wave length o f 295 nm and an emission wave length o f 405 nm. The reaction product was 
injected into the fluorimeter which produced a curve and the fluorescence was presented by the 
area under the curve. The detection limit was 0.02 ^mol/1 H 20 2.
In a previous study we showed that this procedure was reproducible, that the sensitivity 
o f the method o f analysis was good and that there was no effect o f storage on the H 20 2 
concentration up to 40 days (16).
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In addition we compared total exhaled air volume and number o f breaths with the exhaled H 20 2 
concentration and found no correlation. Therefore we did not control the expiratory flow in the 
present study.
Cotinine m easurem ent
To establish the actual smoking status o f all patients and control persons, we measured the 
cotinine concentration in morning urine. The concentration in nonsmokers is below lmg/1; in 
current smokers it is > 3mg/l. The cotinine concentration was measured colometrically according 
to Hedley et al (17, 18). In short, 1 ml centrifuged urine was mixed with acetate buffer, potassium 
cyanide, chlooramine T and diethylthiobarbituric acid (DETB). The extinction o f the specimen 
was measured at 532 nm. The subjects were categorized as current or ex-smokers according to 
their cotinine concentration, because this is an objective measurement (the results from the 
cotinine measurements were only known at the end o f the study).
Statistical analysis
Data are expressed as mean ± SEM. To investigate the variability o f the H 20 2 concentration in 
exhaled breath condensate during the day, we compared the mean H 20 2 concentration at 9 am 
with the mean concentration at 12 am and 3 pm using the paired student t-test. To investigate the 
variability over a longer time period, we compared the mean H 20 2 concentration measured at day
1 with that o f day 2, 3, 8 and 21 using the paired student t-test, for both groups. We determined 
the intra-individual variability by calculating the coefficient o f variation over the study period: 
SD/m ean x 100. We used the unpaired student t-test to compare the mean H 20 2 concentrations 
and mean differences between the patient group and the control group. A p-value o f 0.05 was 
considered to be statistically significant.
We performed these tests for the whole patient, respectively control group, and for subgroups 
according to the smoking status.
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Results
Study population
Twenty patients and twenty healthy controls were studied. Characteristics o f the study population 
are shown in table 5.1. One patient was withdrawn from the study after day 0 because o f an 
exacerbation. The matching control person was also left out o f the analysis after day 0.
Patients (N—20) Controls (N—20)
Gender (Male/Female) 17/3 17/3
Age (yr) 63 (9.7) 60 (8.3)
Current/Ex smokers 4/16 6/14
Pack years (yr) 36 (24.0) 29 (21.0)
FEVi © 1.49 (0.37) 3.42 (0.67)
FEVi % of pred. 49 (12.2) 105 (15.4)
FVC © 2.87 (0.59) 4.43 (0.87)
FVC % of pred. 74 (16.6) 108 (14.8)
FEVi/FVC (%) 52 (9.8) 77 (4.0)
Reversibility FEVi (% pred.) 6 (2.4)
Table 5.1. Characteristics of study population. Mean (SD), N =  number of subjects, pred. =  predicted, FEVi =  Forced Expiratory Volume in 1 second, 
FVC =  Forced Vital Capacity, Reversibility of FEVi was tested after the inhalation of 400 |ag salbutamol
Cotinine m easurem ent
All patients and control persons were asked if they were current smokers or ex-smokers. We 
checked this by determining the cotinine concentration in the urine. All but two outcomes were 
compatible, these were left out o f the sub-analysis according to smoking status.
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Variability o fth e  H20 2 exhalation
Patient group: The mean H20 2 concentrations were 0.22 ± 0 .0 2  ^mol/1 at 9 am, 0.30 ± 0.03 
^mol/1 at 12 am and 0.36 ± 0 .06  ^mol/1 at 3 pm. The changes compared to the value o f 9 am 
were significant, respectively p= 0.02 and p= 0.02 (figure 5.1). The SEM appeared to be smallest 
at 9 am. The mean H 20 2 concentration increased during the day in both the current smoking 
group and the ex-smoking group, though not significantly.
The mean H 20 2 concentrations at day 1, 2, 3, 8 and 21 were 0.28 ± 0 .0 4  ^mol/1, 0.30 ± 0.03 
^mol/1, 0.30 ± 0 .03  ^mol/1, 0.30 ± 0 .05  ^mol/1 and 0.26 ± 0 .0 4  ^mol/1, respectively. These 
concentrations were not significantly different (p = 0.69, 0.63, 0.75, 0.67, respectively). (Figure
5.2). The mean CV over the study period was 45%.
Control group: The mean H 20 2 concentrations were 0.23 ± 0 .02  ^mol/1 at 9 am, 0.30 ± 0.04 
^mol/1 at 12 am and 0.35 ±0.04 ^mol/1 at 3 pm.
The changes in concentration compared to 9 am were significant (p= 0.04, p< 0.01, respectively) 
(figure 5.1).
The SEM appeared to be smallest at 9 am. The mean H 20 2 concentration increased during the 
day in both the current and the ex-smoking group, though not significantly.
The H 20 2 concentrations at day 1, 2 ,3, 8 and 21 were respectively 0.28 ± 0 .04  ^mol/1,
0.23 ±0 . 03  ^mol/1, 0.27 ± 0 . 04  ^mol/1, 0.28 ±0 . 05  ^mol/1 and 0.27 ±0 . 03  ^mol/1. These 
concentrations were not significantly different (p= 0.10, 0.79, 0.97, 0.82, respectively). (Figure
5.2). The mean CV over the study period was 43%.
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Time
Patients Controls
N=20 N=20
Figure 5.1. The H;0; concentration in the group of stable COPD patients and in the group of matched 
Healthy controls at three time points of a day. The error bar represents the mean H;0; concentration ± SEM. 
N =  number of subjects, *: difference significant (p <  .05).
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Figure 5.2. The H Æ  concentration in the group of stable COPD patients and in the group of matched healthy controls measured on day 1-21 
(differences not significant). The error bar represents the mean H Æ  concentration ± SEM. N =  number of subjects.
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Differences between pa tien ts and controls
The mean H 20 2 concentration o f day 0 (mean o f measurements at 9 am, 12 am, and 3 pm) in the 
patient group (0.28 (jmol/1) did not differ significantly from the mean H 20 2 concentration o f day 
0 in the control group (0.29 (jmol/1: p = 0.8). When we compared the mean H 20 2 concentrations 
only measured at 9 am, there was also no significant difference between the patient and control 
group. This was also the case for all other days.
D iscussion
The H 20 2 concentration in exhaled breath condensate increased significantly over the day in 
both patients and healthy persons (in both current smokers and ex-smokers). The variability 
within both groups appeared to be the smallest at 9 am. Over a period o f several days and weeks 
the mean H 20 2 concentration did not change significantly, but the intra-individual variability was 
high (>40%). There was no significant difference in H 20 2 concentration between the stable 
COPD patients and matched healthy controls.
The method applied to measure the exhaled H 20 2 concentration was valid and 
reproducible (16). Therefore the variability in H 20 2 concentration we observed in this study had 
to originate from biological mechanisms. There are several factors that could play a role. First, 
there is some evidence that the H 20 2 concentration in breath condensate is influenced by the 
intake o f food and drinks or by exercise. Substantial amounts o f H 20 2 can be present in several 
beverages like instant coffee (19). Also exercise may play a role. An increased production of 
oxidants in serum of COPD patients has been demonstrated during exercise (20). Exhaled Nitric 
Oxide (NO), which is another marker o f inflammation, is increased during exercise in patients 
with stable COPD as well as in healthy persons (21).
Another explanation for the high daily variability may be the presence o f a circadian 
rhythm in the activity o f the inflammatory cells. Recently Nowak and colleagues showed a 
circadian rhythm of exhaled H 20 2 in healthy subjects (22).
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These authors postulated that several mechanisms might be involved in this circadian rhythm, 
including possible fluctuations in the number and activity o f phagocytes and epithelial cells to 
produce H 20 2, diurnal changes o f leukocyte receptors (23), o f circulating levels o f adhesion 
molecules (24) and circadian rhythms in antioxidant capacities (25).
Some indirect information that may point into this direction is a study performed by 
Wojnarowski et al. They found a relatively high intra-individual variability o f ECP concentrations 
in nasal lavages, but not a clear circadian rhythm (26).
In this study we found a mean coefficient o f variation (CV) o f respectively 45 and 43% 
for the patient and control group, representing the intra-individual variability. Few studies have 
investigated the variability o f exhaled biomarkers. One study investigating the variability of 
exhaled N O  showed a CV of 16.8% over a period o f 23 days in healthy non-smoking subjects 
(27).In another study the intra-individual variability o f exhaled H 20 2 was tested at three 
expiratory flow rates over a period ranging from 1 to 40 days. The CV was 68, 62 and 82% (28). 
The variability appears to be higher for exhaled H 20 2 than for exhaled NO. Our data show that 
the variability may be smaller when samples are obtained early in the morning.
Although not the aim o f the present study, we found in contrast to other investigators no 
significant difference in H 20 2 concentration between stable COPD patients and healthy controls. 
Previous investigators showed that the exhaled H 20 2 concentration in stable COPD patients was 
significantly higher than the concentration in healthy controls (7,12,13).
The difference between those studies and the present study is that in previous studies the 
control persons were (young) healthy never-smokers, while we compared stable COPD patients 
with current or ex-smokers o f the same age. This may indicate that the H 20 2 concentration is 
influenced not only by chronic airway inflammation, but also by age and /or smoking history. 
Indeed, Nowak and colleagues found a positive correlation between age and exhaled H 20 2 in 
healthy persons (22). If  we want to use exhaled H 20 2 as a diagnostic tool for COPD in clinical 
practice, we will need comparisons between COPD patients and healthy persons o f comparable 
age and smoking habits.
In conclusion, the H 20 2 concentration increased significantly during the day in stable 
COPD patients as well as in healthy persons. The high variation indicates that the H 20 2 
concentration is not only determined by pulmonary oxidative status, but also by other factors, 
which are still unclear. The present data suggest that the influence o f these factors may be smaller 
early in the morning, which is o f importance when using H 20 2 as an effect parameter in 
intervention studies.
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Abstract
Polymorphonuclear leukocytes (PMN) have been implicated in the pathogenesis of COPD, partly because 
of the release of oxidants, like superoxide anion (SA). The goal of this study was to measure the 
spontaneous and stimulated release of SA by peripheral PM N in stable COPD compared with healthy 
controls.
Seventeen patients with stable moderate COPD and 17 healthy age-matched controls were 
included. SA release from peripheral PM N was measured spectrophotometrically as the superoxide 
dismutase (SOD) inhibitable reduction of cytochrome c. PM N were stimulated with phorbol myristate 
acetate (PMA, 1 and 10 n g /m l), diesel exhaust particles (DEP), carbon black (CB) and ultrafine CB (ufCB, 
125,250 and 500 ng/m l).
The spontaneous SA release (PMA-0) between patients and control subjects was not significantly 
different. After stimulation with PMA, SA release increased in both patients and controls. The SA release 
did not increase after stimulation with DEP and CB in patients nor in controls. There was only an increase 
after stimulation with ufCB in the patient group.
The increased SA release in COPD patients after stimulation with ufCB may suggest that PM N of 
COPD patients are more prone to stimulation and that the smaller particle size of ufCB might be a crucial 
factor.
Introduction
Polymorphonuclear leukocytes (PMN) have been implicated in the pathogenesis o f COPD. They 
are involved in the inflammatory process, reflected by an increased number of neutrophils in 
sputum, bronchoalveolar lavage fluid (BAL fluid) and bronchial biopsies in smokers and COPD 
patients (1-5). In addition, a large pool o f PMN is present within the micro vessels o f the lung (6).
Following a stimulus (e.g. infection, injury, inhalation o f smoke and particulate matter), 
PMN migrate from the peripheral blood into the extravascular space. Some migrate to the lungs 
and through the endothelium into the airway lumen, where they perform their ‘task’ of 
phagocytosis and destruction o f an intruding organism or particle (7,8).
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Bosken et al. showed that the number o f submucosal PMN is related to the amount smoked (4).
A possible mechanism is that alveolar macrophages o f smokers release a chemotactic factor for 
neutrophils (5).
Eventually, the accumulation and activation o f PMN may result in an adverse effect of 
destruction o f parenchymal tissue (i.e. development o f emphysema), both through proteolysis by 
the elastase released from the lysosomal granules and the release o f reactive oxygen-derived 
species (ROS), like superoxide anion (SA) and hydrogen peroxide (H20 2). In vivo evidence for an 
increased oxidative burden has been provided by Dekhuijzen et al., who showed that patients with 
stable COPD had higher concentrations of H20 2 in exhaled breath condensate than healthy control 
subjects (9). The production of H20 2 was further increased during exacerbations.
The increased oxidative burden is not only determined by an increase in the number of 
inflammatory cells like PMN, but also by an increased production o f oxidants per cell (10). In 
healthy smokers PMN showed increased production o f oxidants (11). In COPD patients 
Teramoto et al. showed that spontaneous production o f oxidants (superoxide anion, SA) by 
PMN was similar to normal subjects.
In contrast, Noguera et al. showed an increased production o f oxidants by PMN in 
COPD patients compared with smokers with normal lung function (12,13). Two studies showed 
that the production o f oxidants by PMN was increased after stimulation with phorbol myristate 
acetate (PMA) in COPD patients compared with healthy smokers (12,13). The production was 
also higher in smokers compared with non-smokers (11).
Elevated concentrations o f respirable particulate (i.e. fine particles with a diameter less 
than 10 (jm in diameter (PM10)) have been implicated in adverse health effects, including COPD 
(14,15). Respirable particulates contain a variety o f toxic substances on their surface and arise 
amongst others from motor vehicle exhausts, especially those emitted from diesel engines (16). 
These diesel exhaust particles (DEP) contain both dust (elemental carbon), traces o f heavy metals 
and organic components, which both enhance production o f ROS by alveolar macrophages in 
vitro (17,18). In animal studies, intratracheal instillation o f DEP, carbon black (CB) and ultrafine 
particulate (ufCB), caused an acute inflammatory response with an influx o f PMN in alveolar air 
spaces and interstitium (17,18,19). Respirable particulate can also be used to stimulate PMN 
directly.
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The effects o f stimulation with respirable particulate on SA generation by PMN of COPD 
patients in vitro, are not known. Therefore the aim o f the present study was to compare the 
release o f SA by peripheral PMN, both spontaneously and after stimulation with PMA, DEP, CB 
and ufCB between stable COPD patients and healthy controls.
M ethods
Subjects
Seventeen patients diagnosed with (stable) COPD according to the criteria o f the ERS (20) 
participated in this study. Inclusion criteria were: age < 7 5  years, current or ex-smoker, EEV^ 
between < 70 % of predicted or FEVj/FVC < 60 % of predicted and reversibility less than 15 % 
of predicted after inhalation o f 400 salbutamol or 80 ^g ipratropium bromide. Further, 17 
healthy age-matched control subjects were recruited. Exclusion criteria for both healthy controls 
and patients were a history o f asthma, allergy, atopic constitution, known □ ^proteinase inhibitor 
deficiency or other pulmonary diseases, an exacerbation or cold within the previous eight weeks 
and use o f supplemental dietary anti-oxidants, vitamins or N-acetylcystein. Both control subjects 
and patients were considered to be ex-smokers if they had discontinued smoking for at least one 
year prior to the study. This study was approved by the local Ethical Committee and informed 
consent was obtained from all subjects.
Sam ple collection and preparation
From each participant 30 ml o f venous lithium-heparinized blood was collected at 16.00 hours. 
Samples were kept overnight at room temperature in the dark and prepared according to 
Schalkwijk et al. (21) at the next day at 08.00 hours. After centrifugation, plasma was removed and 
the buffy coat diluted 1:1 with physiological saline. Subsequently, 8 ml o f the plasma expander 
Plasmasteril was added for sedimentation o f the red cells.
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The dextran plasma layer, containing plasma, lymphocytes and monocytes was collected and 7 ml 
o f Ficoll-Hipaque solution (Pharmacia Biotech) with a density o f 1.070 g/m l was gently brought 
under the supernatant. After centrifugation at room temperature during 20 minutes at 2000 rpm, 
the plasma, lymphocytes, monocytes and Ficoll Hipaque were removed. The remaining PMN 
(density 1.080 g/ml) and erythrocytes (density 1.085 g/ml) in the cell pellet were suspended in 0.5 
ml Hanks’ balanced salt solution (HBSS), and 13 ml o f aqua pure was added to lysate the 
erythrocytes. After centrifugation at 4 °C during 5 minutes at 1000 rpm, the cell pellet was 
washed with HBSS and finally resuspended in 2.5 ml HBSS + 0.1 % glucose.
The total and differential cell counts were performed with a standard hemocytometer. 
Viability was assessed with the trypane blue exclusion test. The yield o f PMN was 30-40 % of the 
first sample with a high percentage o f neutrophils (mean (SEM) 92.4 % (0.37)) and a viability of 
98 % or more.
Superoxide assay
Superoxide anion (SA) release was measured spectrophotometrically as the superoxide dismutase 
(SOD) inhibitable reduction o f cytochrome c, adapted for 96-well assay. Briefly, 25 (jl o f HBSS 
was added to 50 (jl o f cytochrome c (640 |_iM, Sigma Chemicals), 25 (jl o f SOD (2400 U/ml, 
Sigma Chemicals), 25 (jl o f PMN suspension (4xl06/ml) and 50 (jl o f stimulus.
For measurement o f spontaneous release no stimulus was added (PMA-0). For measurement of 
release with (25 (j,l) and without SOD and with (50 (jl) and without cells, respectively, the final 
volume o f 200 (jl was adjusted by adding HBSS.
Stim uli
PMA (Phorbol 12-Myristate 13-Acetate, Sigma Chemicals) was used as a stimulus in a 
concentration o f 1 and 10 ng/m l. Samples were incubated during 30 minutes at 37 °C. The 
extinction was measured every 2 minutes at 540 nm and 550 nm using a Softmax 96-wells 
microplate reader.
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Since there was a linear increase up to 30 minutes for both patients and healthy control subjects, 
the extinction after 30 minutes was used to calculate the concentration o f reduced cytochrome 
with a extinction coefficient o f 14964 mol-1 x L x cm4.
D EP were collected from a 4 kW diesel engine (Yanmar, L90E, single cylinder). DEP, CB 
(acetylene carbon black, Strem, Newsburyport, MA, USA) and ufCB (Printex-90, diameter 20 
nm, surface area 33.7 m2/g) were suspended in a final concentration o f 2 m g/m l phosphate 
buffered saline with 0.05 % Tween-80 after sonification (MSE 100 Watt, Ultrasonic Disintegrator 
7100). Concentrations o f 125, 250 and 500 (Jg/ml were prepared. After stimulation, reaction 
mixtures were incubated at 37 °C during 30 minutes in a 24-wells plate.
Since addition o f these stimuli caused a black mixture, measurement o f extinction in time 
was not possible. Therefore, samples were filtered (0.2 (j) after 30 minutes and extinction o f the 
supernatant was measured in the 96-wells microplate reader. The addition o f 500 (jg/ml ufCB to 
PMN probably caused a toxic reaction, since cells coagulated and SA release was diminished. 
Therefore, the results o f stimulation with 500 (jg/ml ufCB were disregarded.
All samples were prepared in duplicate and the average value o f the extinction was used 
for calculation. Finally, the SOD inhibitable reduction o f cytochrome c was calculated as the 
differences in extinction between the wells with and without SOD. The results were expressed as 
the concentration o f reduced cytochrome c (nmol/ml) per 1 x 106 PMN per 30 minutes.
Statistical analysis
Data are expressed as mean and standard error o f the mean (SEM). Differences between patients 
with COPD and healthy controls were analysed with the Student’s /-test for independent 
samples. Influence o f smoking and use o f medication was analysed by analysis o f covariance. The 
slope o f SA release with increasing concentration o f the stimuli was calculated with the linear 
regression equation. Differences in the slope between groups were tested with the Mann W iitney 
U-test using the individual slopes. Differences in the slopes within groups between similar stimuli 
were tested with the Friedman’s analysis o f variance for related samples. For all analyses, a p- 
value less than 0.05 was considered significant.
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Results
Subjects
Seventeen COPD patients (mean FEVj  ^ 56.6 (4.9) % o f predicted) and 17 healthy controls were 
included (table 6.1).
Healthy controls 
(N = 17)
Patients 
(N = 17)
Age (years) 58(2) 61(2)
FEVj  ^ (% o f predicted value) na 56.6 (4.9)
Reversiblity (%) na 6.8 (1.1)
Smoking history
N on smokers 8 na
Ex-smokers 6 14
Current smokers 3 3
Medication
BD only na 6
BD + ICS na 11
T a b le  6 .1 . C ha rac te ris tics  o f th e  s tudy  popu la tion .
M ean (S E M ), FEVi =  fo rce d  e x p ira to ry  vo lu m e  in 1 second ; na  =  no t app licab le ; BD =  b ro n c h o d ila to r; ICS =  inha led  c o rtico s te ro id s .
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Spontaneous SA release
The spontaneous SA release (PMA-0) between patients and control subjects was not significantly 
different (mean (SEM) 10.4 (1.4) versus 10.3 (0.9) nm ol/m l per 106 cells per 30 minutes, p = 0.9) 
(figure 6.1). Both smoking history and use o f medication did not influence this result (data not 
shown). The concentrations o f DEP-0, CB-0 and ufCB-0 in the patient group were 5.5 (0.9), 4.7 
(0.8), and 4.2 (0.9) nm ol/m l 106 cells per 30 minutes, respectively. In the healthy control group 
the concentrations were 6.1 (0.8), 6.3 (0.7) and 5.1 (0.7) nm ol/m l 106 cells per 30 minutes, 
respectively. There were no significant differences between patients and healthy controls.
SA release after stim ulation with PMA
The concentration o f reduced cytochrome c per 106 cells per 30 minutes after stimulation with 1 
ng/m l PMA (PMA-1) and 10 ng/m l PMA (PMA-10), increased significantly in both patients and 
control subjects (p < 0.01, p < 0.01, respectively) (figure 6.1).
The mean concentration for PMA-1 was 24.84 (2.14) nm ol/m l in patients and 27.9 (2.4) 
nm ol/m l in healthy controls (p = 0.34). For PM A-10, the mean concentration was 45.1 (10.7) 
nm ol/m l in patients and 45.3 (10.5) nm ol/m l in healthy controls (p = 0.95).
No significant differences in SA release nor in the slope o f increase in SA release were observed 
between patients and control subjects. Smoking and the use o f ICS did not influence the results 
(data not shown).
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F igure  6 .1 . R eg ress io n  ana lys is  o f th e  co n ce n tra tio n  o f PMA an d  th e  c o n cen tra tion  o f red uce d  cy to ch ro m e  c (n m o l/m l)  p e r 10 6 cells p e r 3 0  m inu tes . 
Open c irc les ( 0 )  and  e r ro r  ba rs  re p re s e n t m ean (SEM ) va lues  o f hea lthy  co n tro ls , so lid  c irc les ( • )  and  e r ro r  ba rs re p re s e n t m ean (SEM) va lues  of 
p a tien ts .
SA release after stim ulation with DEP, CB and ufCB
The mean concentrations o f reduced cytochrome c per 106 cells per 30 minutes were similar in 
patients and healthy controls, and did not increase after stimulation with D EP (figure 6.2). After 
stimulation with CB a small increase in SA release was observed in patients (figure 6.3). Yet, the 
slope o f increase in patients compared to controls was not significantly different. In contrast, 
after stimulation with ufCB, the slopes o f increases were significantly different (p = 0.02) (figure 
6.4), i.e. an increased SA release in patients compared with healthy controls. Again, smoking 
history and the use o f medication did not influence the results with respect to DEP, CB and 
ufCB (data not shown).
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F igure  6 .2 . R eg ress ion  ana lys is  o f th e  co n ce n tra tio n  o f DEP and  th e  con ce n tra tio n  o f red uced  cy to ch ro m e  c (n m o l/m l)  pe r 10 6 cells p e r 3 0  m inu tes . O pen 
pa tien ts .
F igure  6 .3 . R eg ress io n  ana lys is  o f th e  c o n c e n tra tio n  o f CB and  th e  co n ce n tra tio n  o f red uced  cy to ch ro m e  c (n m o l/m l)  p e r 1 0 6 cells p e r 3 0  m inu tes , 
va lu es  o f pa tie n ts .
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F igure  6 .4 . R eg ress io n  ana lys is  o f th e  co n ce n tra tio n  o f ufCB and  th e  con ce n tra tio n  o f red uced  cy to ch ro m e  c (n m o l/m l)  p e r 10 6 cells p e r 3 0  m inu tes .
D iscussion
The present study shows that the spontaneous release o f SA by peripheral PMN in COPD is not 
increased compared with healthy control subjects. After stimulation with PMA, SA release was 
equally increased in both COPD patients and healthy controls. After stimulation with D EP and 
CB, the SA release was not increased in patients nor in healthy controls. Only after stimulation 
with ufCB the SA release was significantly higher in COPD patients.
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The results o f the present study are in accordance with the study o f Teramoto et al, who 
also found no difference in spontaneous SA release between COPD patients and healthy controls
(12). In contrast with Ludwig et al. we observed no differences between smoking and non­
smoking individuals (11). Postma et al. did not find a difference between smokers and ex-smokers 
with chronic airflow obstruction either (22).
In contrast to the present study, Noguera et al. found that the production o f ROS by 
PMN was increased in patients with COPD compared with healthy smokers and non-smokers
(13). However, they measured the ROS production by the NADPH oxidase method and not by 
SA release, which makes it difficult to compare results.
The use o f ICS did not influence the results in the present study. Verhoeven et al. also 
found no effect o f inhaled fluticasone propionate on superoxide production by pulmonary cells 
retrieved with bronchoalveolar lavage in smoking COPD patients (23).
The failure to demonstrate differences in spontaneous SA release may suggest that the 
rest status o f PMN in stable COPD patients is not different from that in controls. However, SA 
is only one o f the oxidants that is produced by PMN, they also produce H 20 2 and hydroxyl 
radicals. On the other hand, since formation o f SA occurs prior to other members o f ROS, 
differences in production o f other oxidants by PMN at rest between COPD patients and healthy 
controls is very unlikely.
The concentrations o f DEP-0, CB-0 and ufCB-0 were lower than the PMA-0 
concentration. Since addition o f these stimuli caused a black mixture, measurement o f extinction 
in time was not possible. Therefore, samples were analysed as described in the method section, 
which may explain the difference in baseline value.
The data o f the present study show that the release o f SA by PMN after stimulation with 
PMA is equally increased in COPD patients and healthy controls. This is in contrast with the data 
presented by several other investigators (12,13,22).
As mentioned above it is difficult to compare our results with the results o f Noguera et al. 
because o f the difference in technique (13). The difference in result between our study and the 
study by Postma et al. could be due to the time o f reaction (22). They measured the SA release 
after 15 minutes o f reaction while in the present study the SA release was measured after 30 
minutes. Indeed, the SA release was higher in our study using the same PMA concentration. It is 
possible that the difference in SA release between PMN of COPD patients and healthy controls 
present at 15 minutes disappears after a longer reaction time.
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Teramoto et al. measured the SA release in whole blood by chemiluminescence, since in their 
opinion this is more likely to reflect the in vivo situation (12). Unfortunately, comparison with the 
current data is difficult, primarily due to the different methodologies applied.
After stimulation with particles present in environmental air (DEP, CB and ufCB) SA 
release increased only after ufCB stimulation in COPD patients. To our knowledge the effect of 
stimulation with respirable particles on PMN of COPD patients has not been studied. It seems 
that exposure to D EP leads to accumulation o f PMN, possibly through chemotactic agents, but 
not to increased production o f oxidants by PMN (17,19). Only ufCB had an effect on the 
production o f oxidants by PMN in COPD patients in this study. This effect may be explained by 
the smaller particle size o f ufCB. Several studies have shown that ufCB is more inflammogenic 
than other particulates, probably caused by increased surface area (24-27). The increased 
production after stimulation with ufCB was not observed in controls. Consequently, these data 
suggest a different response o f PMN to ultrafine particles in vitro. PMN of COPD patients react 
stronger to stimulation with small respirable particles, which suggests that there is a difference 
between PMN of COPD patients and PMN of healthy persons.
In conclusion, the increased SA release in COPD patients with increasing concentrations 
o f ufCB may suggest that PMN in COPD patients are different from PMN in healthy persons. 
Furthermore, the smaller particle size o f ufCB is a crucial factor in the stimulation o f PMN, since 
similar observations were not made after stimulation with D EP and CB.
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Abstract
Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) frequently occur, and are a major cause 
of morbidity, mortality and health care utilization. The aim of this study was to investigate if non- or less 
invasive markers of inflammation and oxidative stress indicate the course of exacerbations.
Twenty-five patients who were admitted to hospital with a COPD exacerbation were included. 
Within 24 hours after admittance, spirometry (FEVi, FVC, MEF 50), measurement of hydrogen peroxide 
(H 2O2) in exhaled breath condensate (EBC), symptom scores and analyses of ESR, CRP, ECP, and MPO 
in serum were performed. All patients were treated with intravenous dexamethasone, nebulised 
salbutamol/ipratropium and, if needed, antibiotics. The tests were repeated at day 2 ,3 , 7 and 30.
Complete data of the first four visits were collected in 19 patients. The H 2O2 concentration and 
spirometry parameters did not change significantly during the study period. CRP, ESR and MPO levels 
decreased significantly during treatment, while the other serum inflammatory parameters did not change. 
There were no significant correlations between H 2O2 concentration, spirometry and serum inflammatory 
parameters.
In conclusion, this study showed no significant changes in H 2O2 concentration in EBC, or 
spirometry during treatment of a COPD exacerbation. In contrast, several serum inflammatory markers did 
decrease during hospitalization, thus providing a simple tool to monitor exacerbations.
Introduction
In patients with Chronic Obstructive Pulmonary Disease (COPD) exacerbations o f COPD 
frequently occur, and are a major cause o f morbidity, mortality and health care utilization (1). 
Studies have shown that COPD patients experience a mean o f one or two exacerbations per year, 
with a wide range, depending on the definition used (2-4). The effect o f recurrent exacerbations 
on the decline o f lung function is o f considerable importance, acute exacerbations also have a 
profound effect on quality o f life (3,5).
Exacerbations are diagnosed usually on clinical observations represented by an increase of 
specific symptoms and /o r a reduction o f lung function. However, in patients with COPD, 
spirometrical changes associated with exacerbations may be small (3). Although it is presumed 
that exacerbations are associated with increased airway inflammation, there is little information 
available on the nature o f inflammatory markers during exacerbation.
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It is important to find a reliable marker o f early airway inflammation in order to detect and treat 
exacerbations in an early stage, so that the negative effects o f exacerbations remain limited.
Sputum induction has gained interest as a tool for studying airway inflammation in 
COPD. Several investigators have studied inflammatory parameters in induced sputum during 
COPD exacerbations (6-8). However, because o f the risk o f aggravating the exacerbation when 
performing induced sputum during exacerbation, we decided not to use this method.
Another method o f establishing the degree o f airway inflammation is measuring 
pulmonary oxidative stress. Oxidants are a prerequisite in the antimicrobial and antitumor 
defense mechanisms o f the lung. However, excessive production o f oxidants by alveolar 
macrophages and neutrophils may lead to oxidative damage to the tissue, and involvement of 
oxidants has been associated with a number o f pulmonary diseases, including COPD (10,11).
One method o f determining the degree o f oxidative stress is measuring the hydrogen 
peroxide (H20 2) concentration in exhaled breath condensate (EBC). It is a relatively simple and 
noninvasive method which can also be performed during exacerbation. Van Beurden et al. 
described a reliable and reproducible procedure for measuring H 20 2 in EBC (12). Dekhuijzen et 
al. found that the H 20 2 concentration was higher during exacerbation than during stable disease 
in COPD patients, but they did not investigate the course o f the H 20 2 concentration during 
exacerbation (13).
There is also evidence that COPD leads to or is accompanied by a systemic inflammatory 
response, which may have an important negative influence on the quality o f life. There is 
evidence o f systemic oxidative stress in COPD (10). Some patients have profound weight loss, 
which has been associated with increased levels o f T N F -a  and leptin (14). Several parameters of 
(systemic) inflammation can be measured in serum: erythrocyte sedimentation rate (ESR), 
cationic reactive protein (CRP), leukocyte count, myeloperoxidase (MPO) and eosinophil cationic 
protein (ECP).
The goal o f this study was to obtain more information about the course o f H 20 2 levels in 
EBC, lung function and inflammatory parameters during exacerbation o f COPD and its recovery 
phase and their mutual correlation. Specifically, the following questions were addressed:
1) How is the course o f H 20 2 concentration, serum inflammatory parameters, symptom score 
and lung function during exacerbation and treatment?
2) Is there a correlation between H20 2 concentration, serum parameters, symptom score and 
lung function during exacerbation and treatment?
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In order to answer these questions, EBC, spirometry, blood analyses and symptoms scores were 
collected in COPD patients who were admitted to hospital with an exacerbation.
Materials and m ethods
Patients
We selected patients who were admitted to hospital because o f an exacerbation o f COPD. An 
exacerbation was defined by the presence o f at least two o f the following symptoms: 1) increase 
o f dyspnoea 2) increase o f production o f sputum 3) increase o f purulence o f sputum.
Inclusion criteria were: a diagnosis o f COPD according to ATS guidelines (15), age between 45 
and 85 years, current smokers or ex-smokers with at least 10 pack-years, a post-bronchodilator 
FEVI below 70% of predicted FEVI and /o r a FEV1/FVC ratio below 69% during stable 
disease. Patients were excluded when they had a history o f asthma or other pulmonary disease, an 
improvement o f the FEVI o f more than 10% after bronchodilation and if there were clinical 
and /o r radiological evidence o f sinusitis. Chest x-rays were performed to see if there were any 
infiltrates present. All patients gave signed informed consent.
Study design
This study was approved by the local Ethics Committee. Patients who were admitted to hospital 
because o f a COPD exacerbation and gave informed consent were included in this study. As 
soon as clinically safe, but always within 24 hours after admittance, spirometry, collection of 
EBC, symptom score and blood analyses were performed. From the moment o f admission, all 
patients were treated according to a standard protocol: with intravenous dexamethasone 
according to a standard protocol, with or without antibiotics (depending on the result o f the 
sputum culture). Data about previous most recent lung function (up to six months prior to 
admission) were collected from the patient’s records.
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The protocol existed o f three days treatment with dexamethasone 8 m g /24 hours, after which the 
dexamethasone was reduced each following day (6 m g/24 hours, 4 m g /24 hours, 2 m g/24 
hours). Subsequently, dexamethasone was discontinued and the patients received oral prednisone, 
which was reduced every two days by with 5 mg (25 mg, 20 mg, 15 mg, 10 mg, 5 mg, 0 mg). 
During admission all patients received ipatropium and salbutamol by nebuliser six times a day. 
After discharge, patients were treated with their own bronchodilators and /or inhaled 
corticosteroids. When the sputum culture showed bacteria, patients were also treated with 
antibiotics. During the study no patients used theophylline nor acetylcysteine.
The tests (EBC, spirometry and blood analysis) were taken at day 1, 2, 3, 7 and day 30 
after admission. All tests were performed between 9.00 and 10.00 am, patients had to be sober 
and were not allowed to smoke 12 hours before the tests. In a previous study Van Beurden et al 
showed that the H 20 2 concentration varies significantly over the day and that it is important to 
measure H 20 2 concentration early in the morning when patients are sober (16) T he  patients were 
allowed to take their bronchodilators before the tests.
Collection o f  EBC
Patients were not allowed to have smoked since 24.00 hours the previous day. The collection of 
EBC was performed after taking their bronchodilator, early in the morning, before the other 
tests. The patients had to rinse their mouth just before the test was conducted. The collection of 
EBC was performed according to a validated protocol (12). In short, the patients had to breathe 
during ten minutes into the mouth piece o f the condensate collecting device, while wearing a 
noseclip. Before and after each measurement the collecting device was cleaned with distilled 
water.
In the laboratory 10 ^1 p-OH-phenylacetic acid (1.0 mmol) and 10 ^1 horse radish 
peroxidase (15 mU/1) were added to the condensate. The product was frozen at —70 °C. 
Measurements o f H 20 2 concentration were performed every two weeks. The reaction product 
was measured fluorimetrically; the fluorescence corresponded with the H 20 2 concentration. The 
detection limit was 0.03 (jmol/L.
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Spirom etry
All lung function tests were performed with the patient in sitting position, at least half an hour 
after taking their bronchodilator. Patients were instructed to give a maximal forced expiration 
according to ATS criteria. FEVI, FVC and FEF50 were measured using a spirometer (Master 
Screen Pneumotachograph, Jaeger, Germany) which recorded flow-volume or time-volume 
curves according to ATS criteria (15). At least three measurements were made, the highest 
recording from these measurements was used.
B lood analysis
In serum the percentage leukocytes was measured with differential cell counts. Also measured 
were the ESR, CRP, ECP, and MPO concentrations.
ESR (normal values < 20 mm) was measured in citrate blood. CRP (normal values < 1 0  mg/1) 
was measured in heparine blood using Hoffmann la Roche reagens on a Hitachi 911 clinical 
chemical analyzer.
MPO concentration (normal values < 523 M-g/1) was measured by means o f radioimmunoassay 
using reagens manufactured by Pharmacia (Sweden). ECP concentration (normal values < 11.5 
M-g/1) was measured according to the CAP method with reagens from Pharmacia (Sweden).
Sym ptom  score
To establish the severity o f the symptoms, patients were asked to presents their complaints using 
the Borg Scale. The Borg scale is a validated scale from 0 to 10, corresponding with different 
degrees o f dyspnoea. The patient reported a point from the scale, representing his/her 
complaints.
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D ata analysis
The data are expressed as mean [SEM], The mean values o f the different visits were compared 
using a non-parametric test (Wilcoxon).
A p value o f < 0.05 was considered to be statistically significant. Possible correlation between 
these parameters were determined by performing regression analysis (ANOVA). We did not 
compare the results o f patients with infiltrates on the chest x-ray to the results o f those with 
normal x-rays, because o f the small groups.
Results
Patients
Twenty-five patients were included in this study (Table 1). Fourteen patients completed the study 
(all five visits). Most patients (N = 7) did not appear at the last outpatient visit and four patients 
were withdrawn because o f a new or persistent exacerbation. Therefore, in the analysis we have 
included only the results from the first four visits. Nineteen patients (fifteen men, mean age 71) 
completed the first four visits and were used in the data analysis. The mean FEVj  ^was 0.99 (0.07)
1. Fifteen patients were treated with inhaled corticosteroids before the start o f the study and 8 
with maintenance oral corticosteroids. Twelve patients were also treated with oral acetylcysteine. 
Four patients already received antibiotic treatment before hospital admission and four patients 
received a course o f oral steroids. During the study 12 patients were treated with antibiotics and 5 
o f them showed infiltrates on the chest x-ray (table 7.1).
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Age (years) 71.47 (1.55)
Sex (male/female) 15/4
Smoking status (smokers / ex-smokers) 8/11
Pack years (years) 56.1 (7.8)
FEVi G) 0.99 (0.07)
FEVj  ^ % o f pred. (%) 39.8 (3.0)
FVC (1) 2.54 (0.17)
FVC % of pred. (%) 78.0 (5.0)
FEVi/FVC ratio (%) 35.63 (2.14)
MEF50 (1) 0.37 (0.04)
TCO (1) 4.36 (0.54)
TCO % of pred. (%) 61.4 (5.9)
RV(1) 4.25 (0.25)
RV % of pred. (%) 180.3 (9.5)
TLC (1) 7.26 (0.34)
TLC % of pred. (%) 119.5 (3.8)
Antibiotics (yes/no) (before study) 4/15
Inhaled corticosteroids (yes/no) 15/4
Acetylcysteine (yes/no) 12/7
Oral corticosteroids (yes/no) (before study) 12/7
Antibiotics (yes/no) (during study) 12/7
Infiltrates on x-thorax (yes / no) 5/14
T a b le  7 .1 . C ha rac te ris tics  o f th e  s tudy  po p u la tio n , exp re ssed  as m ean (SEM) (N =  19 ).
N =  n u m b e r o f p a tie n ts , FEVi =  Forced E xp ira to ry  V o lum e in one  second , FVC =  Forced V ita l Capacity, MEF50 =  Mean E xp ira to ry  Flow a t 5 0 %  of 
exha la tion , TCO =  d iffu s in g  capacity, RV =  Residual vo lu m e , TLC =  To ta l Lung Capacity, %  o f p re d  =  in pe rce n ta g e  o f p re d ic te d  va lue
H ydrogen peroxide
The H 20 2 concentration did not change significantly during the study period, this was the same 
for the course o f the H 20 2 concentration in individual patients (figure 7.1).
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The mean H 20 2 concentration was 0.16 [0.03] ^mol/1 at visit 1 (day 1), 0.13 [0.02] ^mol/1 at visit 
2 (day 2), 0.15 [0.03] ^mol/1 at visit 3 (day 3) and 0.16 [0.02] ^mol/1 at visit 4 (day 7).
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F igure  7 .1 . Ind iv id ua l cou rses  o f th e  exha led  H ;0 ;  c o n c e n tra tio n  du rin g  th e  s tudy  (N =  19 )
Lung function and Borg scores
The FEVj  ^ did not change significantly during the study period. The mean FEVj  ^was 0.93 [0.07] 1 
at visit 1, 0.95 [0.07] 1 at visit 2, 0.94 [0.07] 1 at visit 3 and 0.96 [0.07] 1 at visit 4.
The course o f FEVj  ^ in four individual patients, however, did show an improvement during 
treatment (figure 7.2).
The FVC did not change significantly, nor did the individual courses. The mean FVC was 
2.08 [0.14] 1 at visit 1, 2.10 [0.14] 1 at visit 2, 2.18 [0.13] 1 at visit 3 and 2.15 [0.14] 1 at visit 4. The 
FEF50 did not change significantly during the study period, nor did the individual courses. The 
mean FEF50 was 0.34 [0.03] 1 at visit 1, 0.39 [0.03] 1 at visit 2, 0.37 [0.03] 1 at visit 3 and 0.40 [0.03]
1 at visit 4.
Exhaled hydrogen peroxide in COPD 119
Chapter 7 The course of biomarkers during COPD exacerbations
The Borg score did not change significantly. The mean score was 4.6 [0.6] at visit 1, 5 
[0.6] at visit 2, 4.4 [0.5] at visit 3 and 4.1 [0.5] at visit 4.
2.5
2.0 - 
©  1.5 -
>
UJ
1.0 
0.5 
0
visite 1 visite 2 visite 3 visite 4
F igure  7 .2 . Ind iv id ua l cou rses  o f th e  FEVi d u rin g  th e  s tu dy  (N =  19 )
Serum inflam m atory param eters
The CRP was decreased significantly at visit 3 and 4 (p = 0.001, p = 0,003), which was also true 
for the individual courses o f CRP (figure 7.3a). The mean CRP was 84.5 [21.5] mg/1 at visit 1,
53.5 [19.3] mg/1 at visit 2, 31.5 [11.7] mg/1 at visit 3 and 20.1 [6.7] mg/1 at visit 4. The mean CRP 
at visit 1 was higher in the patient group treated with antibiotics (p = 0.02).
The ESR was decreased significantly at visit 4 (p = 0.003). The mean ESR was 26.8 [5.9] 
mm at visit 1, 26.4 [5.8] mm at visit 2, 21.9 [4.9] mm at visit 3 and 11.4 [2.4] mm at visit 4. There 
was no significant difference in decrease between patients treated with or without antibiotics (p =
0.42) or between patients with and without infiltrates on the x-thorax. This is also shown in the 
individual courses o f the ESR (figure 7.3b)
There was a significant increase in number o f leukocytes at visit 4 (p = 0.003). The mean 
number o f leukocytes was 10.1 [0.7]/nl at visit 1, 11.5 [0.7]/nlat visit 2, 12.3 [0.8]/nlat visit 3 and 
14.2 [1.0]/n l at visit 4. The increase was also present in the individual courses (not shown).
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The number o f neutrophils did not change significantly, this was also true for the 
individual courses. The mean number o f neutrophils was 8.4 [0.6]/nl at visit 1, 9.7 [0.8]/nlat visit
2, 9.2 [0.8]/nlat visit 3 and 9.9 [1.2]/nlat visit 4.
The number o f eosinophils showed a decrease, but it was not significant. The mean 
number o f eosinophils was 0.13 [0.05]/nlat visit 1, 0.03 [0,01]/nlat visit 2, 0.04 [0.01]/nlat visit 3 
and 0.2 [0.05]/n l at visit 4.
The MPO concentration decreased significantly at visit 3 and 4 (p = 0.02, 0.04, 
respectively). The mean concentration o f MPO was 102.90 [14.81] M-g/1 at visit 1, 89.37 [14.58] 
^g/1 at visit 2, 74.00 [14.37] ^g/1 at visit 3 and 66.37 [10.98] l^.g/1 at visit 4. The reduction is also 
shown in the individual courses (figure 7.3c).
The ECP concentration did not change significantly. The mean concentration o f ECP 
was 8.1 [1.7] ^g/1 at visit 1, 9.15 [2.8] ^g/1 at visit 2, 10.9 [4.2] ^g/1 at visit 3 and 11.4 [3.8] l^.g/1 
at visit 4.
F igure  7 .3 a . Ind iv idua l co u rse s  o f th e  CRP du rin g  th e  s tudy  (N =  19)
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visit 1 visit 2 visit 3 visit 4
F igure  7 .3 b . Ind iv idua l cou rses  o f th e  ESR du rin g  th e  s tudy  (N =  19)
visit 1 visit 2 visit 3 visit 4
F igure  7 .3 c . Ind iv idua l cou rses  o f th e  MPO c o n c e n tra tio n  (N =  19 ).
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Correlations
There were no correlations between the concentration o f exhaled H 20 2 and lung function 
parameters nor with serum inflammatory parameters or symptom scores. No correlations were 
observed between lung function parameters and serum inflammatory parameters.
Within the group o f serum inflammatory parameters there were various correlations. Per 
visit the concentration o f MPO correlated strongly with ESR, CRP, total number o f leukocytes, 
and number o f neutrophils (respectively, p = 0.007, 0.003, 0.001, 0.001). The concentration of 
ECP correlated with the number o f leukocytes and neutrophils and with the concentration of 
MPO (respectively, p = 0.001, 0.003, 0.004).
D iscussion
This study showed no significant changes in H 20 2 concentration in EBC during treatment o f a 
COPD exacerbation. The lung function parameters only increased significantly during the first 
week o f treatment in a few patients. In contrast, ESR and CRP decreased significantly during 
treatment, as did the MPO concentration.
During hospital stay all patients attended the visits, but 11 did not show up at the last visit 
(day 30) which was an out-clinic visit. This problem could be explained by the fact that the 
patients included in this study were all patients with relatively severe COPD and serious 
impairments. Unfortunately it was not possible to examine the condition o f the patients at that 
the time o f the last visit.
In this study we did not find significant changes in H 20 2 concentration during 
exacerbation and subsequent treatment. In a previous study we measured the H20 2 concentration 
during stable disease in a comparable patient group and found a mean concentration in stable 
COPD patients (without inhaled or oral corticosteroids) o f 0.2 ^mol/1 (16). In the present study 
the mean H 20 2 concentration at day 1 (during exacerbation) was 0.16 ^mol/1. In contrast, 
Dekhuijzen et al. found a mean concentration o f 0.21 ^mol/1 during stable disease and 0.6 
^mol/1 during exacerbation (13).
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However, because o f a difference in technique used to measure the H 20 2 concentration, it is 
difficult to compare results between these studies.
The H 20 2 concentration at the beginning o f the study could have been influenced by the 
timing o f our measurements. The patients in our study were included the moment they arrived at 
the clinic. The exacerbation probably began some days before they came to the clinic; possibly 
the H 20 2 concentration reached its maximum earlier. Furthermore, treatment with 
corticosteroids and bronchodilators according to the study protocol began shortly after arriving 
at the clinic, while the measurements were taken the following day. It is possible that we missed 
an initial and fast decline in H 20 2 concentration. Most importantly, most patients were treated 
with inhaled steroids and /o r acetylcysteine before the start o f the study, and two patients already 
received a short course o f prednisone which could have influenced the H 20 2 concentration at the 
beginning o f this study.
Despite o f treatment with high dose intravenous steroids, the H 20 2 concentration was not 
reduced. It is possible that the period o f treatment was too short, unfortunately we could not 
analyze the data o f visit 5 (day 30) because o f a high dropout percentage.
The serum inflammatory parameters did show significant changes during exacerbation 
and treatment. The ESR and CRP decreased significantly during treatment. O f the 19 patients, 12 
patients received antibiotics next to the corticosteroids. There was no significant difference in 
decrease o f ESR between patients treated with or without antibiotics. The decrease shows that 
treatment with systemic corticosteroids affects the systemic inflammation during exacerbation. 
The CRP was significantly higher at the beginning o f the study in the patient group treated with 
antibiotics and decreased significantly during treatment. It is known that the CRP gives 
information about an acute inflammatory process, so it is to be expected that it is higher in 
patients with a bacterial infection. Exacerbations of COPD are often associated with viral and 
bacterial infections (4,6,17,18). We did not investigate if there were differences between with or 
without minor infiltrates on the chest x-ray.
The number o f neutrophils did not change significantly during the study. On the other 
hand, the MPO concentration decreased significantly during treatment. MPO is a cytokine that is 
associated with neutrophilic inflammation. We found a strong correlation between the number of 
neutrophils and the MPO concentration. Several studies have shown neutrophil activation in 
COPD and especially during exacerbations (10). It shows that corticosteroids do have an effect 
on the activity o f inflammatory cells, also on neutrophils.
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Aaron et al found no difference in neutrophilic activation during an acute COPD exacerbation 
associated with viral or bacterial infection (19).
The number o f eosinophils and the ECP concentration, which is a marker o f eosinophilic 
inflammation did not change significantly. Dahlen et al showed that patients who experienced an 
improvement in lung function during treatment o f an exacerbation had higher levels of 
eosinophilic markers (9). The patients in our study did not experience an improvement o f lung 
function, which may be associated with little eosinophilic inflammation.
The present study showed little effect o f treatment on the lung function parameters 
during the first week, there were no correlations between lung function and H 20 2 concentration. 
The FEVi did not improve significantly during treatment. After a month the FEVi increased 
more, but did not reach statistical significance. The patients in our study had severe lung function 
impairment, mean FEVj  ^ during stable disease was less than 11 with very low reversibility. O ther 
studies also showed little effect on lung function (20). It is thought that there is a discrepancy 
between lung function tests and subjective symptoms. For this reason a symptom score was also 
reported in this study. However, the symptoms o f our patients, measured through the Borg scale, 
did not decrease significantly during our study either. It is difficult to find a reliable tool for 
reporting subjective symptoms, since these serious COPD patients probably always experience 
some degree o f dyspnoea. Also, most symptoms could have already improved because o f the 
delay o f our measurements.
In conclusion, the H 20 2 concentration measured during a COPD exacerbation did not 
change during admission. This may be due to previous maintenance treatment and /o r due to 
treatment started before admission. This indicates that the concentration o f H 20 2 in EBC is not 
suitable as a therapeutic target during exacerbations. The lung function parameters measured in 
this study did not change either. In contrast, the serum inflammatory markers did decrease during 
hospitalization, thus providing a simple tool to monitor exacerbations.
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Abstract
The effects of inhaled corticosteroids (ICS) on markers of oxidative stress in patients with stable COPD are 
unclear. The aim of this study was to investigate the effect of ICS on exhaled H 2O2 in stable COPD 
patients and to compare ICS with different lung deposition.
Forty-one stable patients with moderate COPD (FEVi ~ 60% predicted) were randomized to 
sequence 1; first HFA-134a Beclomethasone Dipropionate (HFA-BDP, an ICS with more peripheral 
deposition) 400 bid, then Fluticasone Propionate (FP, an ICS with more central deposition) 375 p,g bid 
(N = 20) or sequence 2 ; first FP, then HFA-BDP (N = 21). Both 4-week treatment periods were preceded by 
a 4-week washout period. After each period the concentration of H 2O2 in exhaled breath condensate was 
measured.
The H 2O2 concentration decreased significantly after the first treatment period in both sequence 1 
and 2 (p < 0.05, p = 0.01, respectively). In neither sequence was there a return to baseline values after the 
second washout, indicating a carry-over effect. The concentrations remained low in both sequences during 
the second treatment period.
Both ICS appeared to reduce exhaled H 2O2 in stable COPD patients. However, this study showed 
no difference between ICS with different deposition patterns, which in part may be due to the carry-over 
effect.
Introduction
Oxidative stress and inflammation are involved in the pathogenesis o f Chronic Obstructive 
Pulmonary Disease (COPD). Oxidants are present in cigarette smoke and are produced 
endogenously by activated inflammatory cells (1). Oxidants may damage pro tease inhibitors, 
potentiate elastase activation and increase mucus secretion (1,2). Hydrogen peroxide (H20 2) is a 
marker o f oxidative stress, which can be measured in exhaled breath condensate (3). In stable 
COPD patients it has been shown that exhaled H 20 2 concentration is increased compared with 
healthy persons, with a further increase during exacerbations (4).
Whereas treatment with inhaled corticosteroids (ICS) is very efficacious in asthma in 
controlling the airway inflammation and symptoms, the role o f ICS in the treatment o f patients 
with COPD remains controversial. Recent studies have shown little or no benefit o f ICS on 
decline o f lung function (5-8), although some improvements in symptoms and frequency of 
exacerbations have been observed (6-9).
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This difference in effect o f ICS between asthma and COPD could be explained by a difference in 
the type o f inflammation. In asthma the most prominent cell is the eosinophil, while in COPD 
the neutrophil is the most important inflammatory cell. Steroids have a significant effect on 
eosinophilic markers, whereas the effect on neutrophilic markers is absent or small (10-13).
In addition, ICS might be less efficacious in COPD because airway inflammation in 
COPD is prominent in the peripheral airways and the deposition o f the traditional ICS is highest 
in more central airways (14). ICS are frequently administered by pressurized metered-dose 
inhalers (pMDI). Because o f their harmful effect on the ozone layer, new propellants like 
hydrofluoroalkane (HFA) are nowadays replacing the chlorofluorocarbon (CFC) propellants 
previously needed for pressurized inhalers.
The reformulated HFA-134a-containing beclomethasone (HFA-BDP) is a solution with a mean 
mass median aerodynamic diameter (MMAD) o f 1.1 (iM compared to 3.5 (iM with CFC-BDP. As 
a consequence, HFA-BDP is being delivered to both central and peripheral airways o f the lung 
(14-16).
The first aim o f this study was to investigate the effect o f ICS on oxidative stress. 
Furthermore, we hypothesized that, when lung deposition is important for the effect o f ICS, a 
difference in effect o f ICS with different lung deposition might be expected. To test this 
hypothesis we performed a single-blind randomized crossover study in which stable COPD 
patients were treated for four weeks with HFA-BDP (800 ^g) and for a period o f four weeks 
with fluticasone propionate (FP, 1000 ^g), an ICS with more central deposition (17,18).
Materials and m ethods
Patients
Patients were recruited from the outpatient clinic o f a large non-academic teaching hospital. 
Inclusion criteria were: age between 40 and 85 years, a diagnosis o f COPD (according to ATS 
criteria (19)) and stable disease (no increase o f symptoms over the previous three months). 
Patients had to show a postbronchodilator FEV! below 60% of predicted and /or FEVj/VC ratio 
below 60% on maintenance therapy with bronchodilators.
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Patients were not to have taken oral or inhaled steroids for at least two months prior to entry of 
the study to prevent any deterioration o f the disease during the study and they were not allowed 
to take oral or inhaled N-acetylcysteine or vitamin C and /o r E  during the study.
Patients were excluded if they suffered from asthma in the past or another pulmonary 
disease contributing to chronic airflow obstruction or from upper airway infections and when 
they showed bronchial hyperreactivity or an acute response in EEV^ to an inhaled bronchodilator 
o f more than 15% of predicted values. All patients were smokers or ex-smokers with at least ten 
packyears. All patients gave informed consent. The study was approved by the local ethics 
committee.
S tu d y  design
This was a single-blind, two-period randomized crossover study. After a two-months run-in 
period during which ICS, oral steroids and acetylcysteine were disallowed, the patients were 
randomized to one o f two treatment sequences. A four-week washout period preceded the 
second treatment period to wash-out the effects o f the preceded active treatment (figure 1).
The first treatment sequence (sequence 1) consisted o f 800 (jg HFA-BDP (4 puffs o f 100 
^g bid, by pMDI [QVAR™ 3M Pharmaceuticals]) for 4 weeks followed by a washout period o f 4 
weeks. Subsequently, patients were treated for 4 weeks with 750 |ag FP (3 puffs o f 125 ^g bid, by 
pMDI [Flixotide™ Glaxo Wellcome]). The second treatment sequence (sequence 2) consisted of 
750 FP (3 puffs o f 125 ^g bid, by pMDI) for 4 weeks, followed by a washout period and 
finally a 4-week treatment with HFA-BDP (4 puffs o f 100 ^g bid, by pMDI). Equivalent doses 
were used since FP is twice as potent as CFC-BDP and HFA-BDP is twice as potent as CFC- 
BDP (16,17).
Change o f H 20 2 concentration over the treatment periods was used as primary outcome 
measurement. Exhaled H 20 2 was measured each visit approximately one hour after inhalation of 
the patient’s own bronchodilator and the study medication, with each measurement at 
approximately the same time o f day. In a previous study we showed that exhaled H 20 2 
concentrations show a diurnal variation with the lowest values early in the morning, and did not 
change significantly during a period o f 1-3 weeks in stable COPD patients (20).
Exhaled hydrogen peroxide in COPD 132
Chapter 8 Effects of inhaled corticosteroids on exhaled hydrogen peroxide
M easurem en t o f  exha led  H 20 2 a n d  lu n g  function
The measurement o f exhaled H 2 0 2  was always performed before the spirometry at 
approximately the same time o f day. The smokers were asked to refrain from smoking starting at 
midnight before each visit day. Before the measurement the patients rinsed their mouth with 
water. The patients then breathed at a normal frequency and tidal volume for ten minutes 
through a mouthpiece into a breath condensate-collecting device, wearing a nose clip.
The collected breath condensate was immediately transported to the laboratory and 
frozen at —70°C, after adding p-hydroxyphenylacetic acid (modified after Hyslop and Sklar (21)). 
Every two weeks the products were measured fluorimetrically, with an excitation wave o f 295 nm 
and an emission wave o f 405 nm. The detection limit was 0.02 ^mol/1.
In a previous study we showed this procedure to be reproducible and the method o f analysis to 
be sensitive, with no changes in H 20 2 concentration after freezing the reaction product up to 40 
days; mean H 20 2 concentration at day 0 0.39 [0.17[ ^mol/1, at day 40 0.38 [0.17] ^mol/1 (22).
All pulmonary function tests were performed with the patient in sitting position. Forced 
vital capacity (FVC), FEV! and MEF 50/75 were measured using a spirometer (Master Screen 
Pneumotachograph, Jaeger, Germany) which recorded flow-volume or time-volume curves 
according to ATS criteria (18).
Statistical analysis
Data are presented as means [SD], The primary parameter o f interest in this study was the change 
from baseline in H 20 2 concentration in the breath condensates. To detect a mean difference of 
0.1 ^mol/1 between the two treatments at a significance level o f 0.05 with 80% power, 18 
patients per sequence were required for this trial. The primary analysis was based on all patients 
who completed all or part o f both treatment periods (per-protocol population).
The change from baseline in H 20 2 in condensates o f exhaled air and the change in lung 
function parameters were analyzed with an analysis o f variance model which included the terms 
for sequence, patient-within-sequence, smoking status, period and treatment. A comparison of 
the baseline levels o f H 20 2 was performed to determine if the patients returned to the same levels 
prior to starting each treatment period.
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Results
Patients
Over a period o f six months, 62 patients were screened and 41 patients were randomized. The 
reasons for exclusion were exacerbation during washout period, lung function different from the 
inclusion criteria or concomitant use o f medication that was not allowed (e.g. inhaled 
corticosteroids). Five patients were with drawn during the study, four because o f an exacerbation 
and one because o f another adverse event. One patient was excluded from the statistical analysis 
because o f protocol violation (use o f acetylcysteine throughout the study). The study was 
completed by 35 patients, who were subsequently included in the statistical analysis (per-protocol 
group) .Twenty patients were randomized to sequence 1 and 21 patients to sequence 2. Patient 
characteristics were comparable between the two groups, except for the duration o f COPD and 
FEV 1 % predicted. The patients in sequence 2 had a significantly longer history o f COPD (p = 
0.03) and a significantly lower FEV! % predicted (p = 0.04). The patient characteristics are 
shown in table 8.1.
Category Sequence 1
(n = 20)
Sequence 2
(n = 21)
Age (yr, mean + SEM) 65.6 ± 1.8 65.1 ± 2.0
Sex (male/female) 1 6 / 4 1 6 / 5
Cigarette smoking (smokers / ex-smokers) 7 / 1 3 8 / 1 3
Duration COPD (yr, mean + SEM) 7.8 ± 1.8 11.6 ± 1.6 *
FEV! (% predicted, mean ± SEM) 54 ± 0.48 45.9 ± 0.64 ++
Drug therapy for COPD (n) 
Acetylcysteine + 4 8
ICS + 13 18
Short-acting b-agonists 20 21
Long-acting b-agonists 13 15
T a b le  8 .1 . C ha rac te ris tics  o f s tudy  po p u la tio n . FEVi =  Forced E xp ira to ry  V o lum e in one  seco nd , ICS =  in ha la tion  co rtic o s te ro id s , n =  n u m b e r o f 
p a t ie n ts ,*  p =  0.03,** p =  0.04, + d isc o n tin u a tio n  a t least 3 m o n th s  p r io r  to  th e  s tudy
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E xh a led  H 20 2
At the start o f the first treatment period (week 0), the mean H 20 2 concentration was 0.32 ^mol/1 
[0.03 ^mol/1] for sequence one and 0.42 ^mol/1 [0.08 ^mol/1] for sequence 2 (p = 0.23). During 
the first treatment period (week 0-4) the mean H 20 2 concentration in sequence 1 decreased from 
0.32 ^mol/1 to 0.21 ^mol/1 (p = 0.04) (figure 2). The concentration in sequence 2 decreased 
from 0.42 ^mol/1 to 0.22 ^mol/1 (p = 0.01) (figure 3). The decrease o f H 20 2 concentration was 
not significantly different between sequence 1 and 2. When we combined the patients from 
sequence 1 and sequence 2 together in one group, the reduction in H 20 2 concentration was 
highly significant (p < 0.01).
At the beginning o f the second treatment period (week 8) the H 20 2 concentration was 
0.19 ^mol/1 [0.03 ^mol/1] for sequence 1 and 0.17 ^mol/1 [0.02 ^mol/1] for sequence 2 (p =
0.57). The difference between the H 20 2 concentration at week 0 and week 8 was significant for 
both sequences (p < 0.01 and p < 0.01, respectively), indicating a carry-over effect. During the 
second treatment period (week 8-12) the H 20 2 concentration in sequence 1 remained 0.19 
^mol/1. In sequence 2 the concentration increased from 0.17 ^mol/1 to 0.22 ^mol/1. Neither 
changes were significant (figure 2 and 3). There was no significant difference between the change 
in H 20 2 concentration in sequence 1 compared to sequence 2. The overall change in H20 2 
concentration was not significant for either treatment in the second treatment period.
There was no difference between patients who used ICS prior to the study (N = 24) and 
patients who did not (N = 11): 0.35 0.41 ^mol/1, respectively. The influence o f other
factors like sequence order and baseline value were also studied. The only factor that had a 
significant effect on the change o f H 20 2 concentration was the baseline value: the higher the 
baseline H 20 2 concentration, the greater the change after treatment (p < 0.05). There was no 
difference between smokers and ex-smokers (H20 2 concentration 0.40 0.35 ^mol/1,
respectively).
L u n g  func tion  param eters
At baseline mean FEV! % of predicted was 54.0% [2.2%] in sequence 1 and 48.5% [3.2%] in 
sequence 2 (per-protocol population, N=19 and N=16, respectively).
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Mean baseline FVC was 2.98 1 [0.11 1] in sequence 1 and 2.96 1 [0.21 1] in sequence 2. There were 
no significant or clinically relevant changes in lung function parameters during both treatment 
periods (data not shown).
D iscussion
The present study shows that ICS appear to reduce the concentration o f H 20 2 in exhaled breath 
condensate in patients with stable COPD. We did not find a difference in effect between ICS 
with more peripheral versus more central deposition. This may be due to the carry-over effect 
during the washout period.
The H 20 2 concentration decreased after the first treatment period with ICS. This 
decrease was significant for both sequences (initial treatment with HFA-BDP and initial 
treatment with FP). The magnitude o f effect o f HFA-BDP and FP on oxidative stress in COPD 
patients seemed to be similar during the first treatment period. The patients treated with HFA- 
BDP, however, had a significantly shorter duration o f disease and a higher FEV! predicted. 
Because o f this, no definitive conclusions can be drawn from these results with regard to the 
possible difference in potency o f these ICS.
Furthermore, the overall evaluation o f possible different effects o f HFA-BDP and FP on 
oxidative stress in COPD patients was made impossible by a serious carry-over effect. The results 
o f the second treatment period could not evaluated because o f this effect. Unexpectedly, a four 
week washout period was not long enough for the exhaled H20 2 levels to return to baseline 
levels. It might be speculated that an o n /o ff  phenomenon regulating oxidative stress might be 
responsible for this finding and that a four week off-treatment period was too short to turn the 
H 20 2 production back on.
W ien  combining both groups, there was a highly significant reduction in H 20 2 
concentration, indicating that ICS reduce this specific marker o f oxidative stress. We, however, 
cannot be entirely sure that this was the effect o f the treatment itself, because we did not include 
a placebo group, due to the initial design o f the study. Nevertheless, several theories support the 
hypothesis that oxidative stress might be lowered by ICS.
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Steroids inhibit the synthesis o f pro-inflammatory cytokines in inflammatory cells and may 
reduce the number o f activated cells that release pro-inflammatoy cytokines and thus reduce the 
production o f H 20 2. Although treatment with ICS or oral steroids does not change total and 
differential cell counts in induced sputum in COPD patients (10,13), in contrast to asthmatic 
patients (23), it significantly reduces the chemotactic activity o f neutrophils and increases the 
neutrophils elastase inhibitory capacity in induced sputum (11,12). In addition, evidence from in 
vitro studies suggest that among the anti-inflammatory actions o f steroids are a reduction in the 
generation o f reactive oxygen species by neutrophils (24) and stimulation o f the synthesis of 
glutathione in liver (25). A few in vivo studies showed antioxidant effects o f steroids. Two studies 
showed decreased production o f 0 2 by peripheral blood neutrophils after oral steroid treatment 
(26, 27). In another study inhaled steroids did not change neutrophil numbers in the peripheral 
blood but did decrease the number in the sputum of COPD patients (28).
In contrast to our findings Ferreira and coworkers recently found no effect on exhaled 
H 20 2 in COPD patients after a 2-week treatment with beclomethasone (500 ^g bid in a placebo­
controlled crossover study (29). This contradicting finding might be explained by several 
differences between our study and the study by Ferreira. The first difference is that in their study 
ICS were given for 2 weeks, which period might be too short to measure any effect. In our study 
the treatment period lasted for 4 weeks. Secondly, the patients in the study by Ferreira were all 
former smokers, while in our study most patients were current smokers. It is possible that ICS 
have more effect on current smokers, because the oxidative system is more triggered. Lastly, in 
the article by Ferreira the method o f analysis is described only shortly, without data on validation 
o f this method. Considering the difficulties o f setting up a reliable and reproducible method of 
analysis for measuring exhaled H 20 2, it is possible that the method used by Ferreira was not 
sensitive enough to detect possible differences. On the other hand we validated our method 
extensively (30).
In summary, ICS appear to reduce exhaled H 20 2. However, we did not find a difference 
in effect between a 4-week treatment with fluticasone (with more central deposition) versus 
HFA-beclomethasone (with more peripheral lung deposition) on exhaled H 20 2 levels in patients 
with stable COPD. This negative finding might be due to a significant carry-over effect, which 
may have obscured any difference due to differences in deposition patterns. The relevance of 
reducing markers o f oxidative stress by ICS in stable COPD needs to be explored in subsequent 
studies and they have to be correlated with other markers o f inflammation in order to gain more 
information on the pathophysiological processes in COPD.
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Summary
Chronic Obstructive Pulmonary Disease (COPD) is an important health problem. The incidence 
is increasing which leads to an increased use o f medical support and thus to an increase of 
medical costs. Up till now there is no cure for COPD. The pathophysiology o f COPD is not fully 
clear yet and has not been investigated as thoroughly as for example asthma.
The central feature o f COPD is progressive (irreversible airway obstruction which leads 
to complaints o f dyspnea, cough and sputum production. The airway obstruction is the result of 
the presence o f chronic bronchitis and /o r emphysema. Airway inflammation and oxidative stress 
play important roles in the development o f COPD. In order to investigate the pathophysiology 
o f COPD in large trials, it is important to that informative, reproducible and preferably non­
invasive techniques are available.
There is an increasing interest for biomarkers that can be measured (non-invasively) in 
exhaled air and exhaled breath condensate (EBC). They may reflect the nature and degree of 
airway inflammation and pulmonary oxidative stress. One marker that can be measured relatively 
simple in EBC is hydrogen peroxide (H20 2). Although this measurement has been used by 
several investigators, there are still quite a lot o f uncertainties regarding the reproducibility and 
clinical relevance o f this marker. The aim o f this thesis was to evaluate the accuracy o f the 
measurement o f exhaled H 20 2 and to establish its clinical significance.
In chapter 2 an overview o f markers that can be measured directly in exhaled air or in EBC is 
presented. The main goal o f this review was to discuss the origin o f exhaled biomarkers and their 
current role in the diagnosis, evaluation o f treatment and prognosis o f COPD. Data o f cross­
sectional, cohort and intervention studies on exhaled biomarkers were studied. These studies 
were identified by a Medline search on papers in the English language published from 1990 to 
November 2001. The following markers were discussed: exhaled nitric oxide (NO), exhaled 
carbon monoxide (CO), exhaled alkanes, exhaled hydrogen peroxide (H20 2), exhaled 
isoprostanes, exhaled N O  metabolites and exhaled thiobarbituric acid-reactive substances 
(TBARs). This review showed that exhaled biomarkers need to be studied further before using 
them in clinical practice.
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There is a need for standardization o f the measurements, for comparison o f COPD patients with 
healthy persons matched for age and smoking-status, for data on reproducibility and variability of 
all markers, for correlation o f exhaled markers with other parameters and for randomized, 
placebo-controlled intervention studies.
In chapter 3 the technical problems and possibilities o f the measurement o f H 20 2 in EBC were 
investigated. We adapted the fluorimetrical measurement o f exhaled H 20 2 by using an automated 
flow injection fluorimeter. The objective o f this study was to investigate the sensitivity and 
reproducibility o f the fluorimetrical method using an automated flow injection device with 
varying flow rates and measurements. 10 (jl p-hydroxyphenylacetic acid (1.0 mmol/1) and 10 (jl 
horseradish peroxidase (15 mU/1) were manually added to several H 20 2 containing solutions and 
EBC of COPD patients. The fluorescence o f the reaction product was measured with an 
automated sampler, flow injection and scanning fluorescence detector, excitation wave 295 nm, 
emission wave 405 nm at different flow rates. The degree o f fluorescence was expressed as either 
area under the curve (AUC) or peak value. A flow rate o f 1 m l/m in gave the best results. There 
were no significant differences in calibration curves or detection limits using AUC or peak value 
(resp. 0.007/0.005 ^mol/1). The mean H 20 2 concentration in the patient group was 0.2 ^mol/1 
and the standard deviation o f duplication 0.009 ^mol/1. In conclusion, the low detection limit 
may be explained by using flow injection, because it measures the fluorescence over a period of 
time. It is important to chose an appropriate flow rate. There is no difference in detection limit 
between measuring the fluorescence as AUC or as peak value.
Before investigating the clinical possibilities o f measuring exhaled H 20 2, a reliable and 
reproducible test procedure had to be developed. This process is described in chapter 4. The 
sensitivity and reproducibility o f the test procedure and the effect o f storage o f the condensate 
on the H 20 2 concentration were investigated. Twenty stable COPD patients breathed into our 
collecting device twice for a period o f ten minutes. The total exhaled air volume (EAV) and 
condensate volume were measured both times and the H 20 2 concentration o f the condensates 
was determined fluorimetrically in duplicate. The concentration was measured again after freezing 
the reaction product at —70°C for a period o f 10, 20 and 40 days. We collected 2-5 ml condensate 
in 10 minutes. The EAV and condensate volumes were strongly correlated. There was no 
significant difference between the mean H 20 2 concentration measured during the first and 
second test. A detection limit for the H 20 2 concentration o f 0.02 ^m ol/L  was obtained.
Exhaled hydrogen peroxide in COPD 143
Chapter 9 Summary and conclusions
The H20 2 concentration appeared to remain stable for a period up to 40 days of freezing. It was 
concluded that the collecting device was efficient, that the sensitivity of the method of analysis 
was good, that the test procedure was reproducible and that the condensate (after adding 
reagentia) could be stored for at least 40 days.
It is important to establish the (natural) variability of exhaled H20 2 in order to use this 
measurement in prospective trials. In chapter 5 the circadian variability of exhaled H20 2 in 
COPD patients and matched healthy controls is described. Twenty patients with stable mild 
COPD (FEVI ~ 70% of predicted) and twenty healthy subjects, matched for age, sex and pack- 
years were included, all smokers or ex-smokers. Breath condensate was collected and its H20 2 
concentration determined fluorimetrically three times on day 0 (9 and 12 a.m., 3 p.m.) and once 
on days 1, 2, 3, 8 and 21. The mean H20 2 concentration increased significantly during the day in 
both the patient and control group. Over a longer period up to 21 days, the mean concentration 
did not change in both groups. There was no significant difference in H20 2 concentration 
between patients and controls. The mean coefficient of variation (CV) over 21 days was 45% in 
the patient group and 43% in the control group. The conclusion was that there was a significant 
increase of exhaled H20 2 in both COPD patients and healthy persons over the day, there was no 
difference in H20 2 concentration between patients and controls. Over a longer period of time 
there were no significant changes in both groups. The cause of the increase over the day is not 
clear. Possibly there is a diurnal change in airway inflammation. Secondly, exhaled H20 2 might be 
influenced by intake of food and drinks and by exercise. It is therefore important to perform 
repeated exhaled H20 2 measurements at the same time of day, preferably early in the morning 
while the patients are still sober. In contrast to other investigators we found no difference in 
exhaled H20 2 between stable COPD patients and (for age and smoking status) matched healthy 
controls. This may indicate that the H20 2 concentration is influenced not only by chronic airway 
inflammation, but also by age and/ or smoking history.
The pathophysiology of COPD is complex. Increased oxidative burden is determined by an 
increase in the number of inflammatory cells like polymorphonuclear leukocytes (PMN), and by 
an increased production of oxidants per cell. PMN are activated by several stimuli, which leads to 
the release of oxidants, like superoxide anion (SA). The goal of the study in chapter 6 was to 
measure the spontaneous and stimulated release of SA by peripheral PMN in stable COPD 
patients compared with healthy controls.
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Seventeen patients with stable moderate COPD and 17 healthy age-matched controls were 
included. SA release from peripheral PMN was measured spectrophotometrically as the 
superoxide dismutase (SOD) inhibitable reduction o f cytochrome c. PMN were stimulated with 
phorbol myristate acetate (PMA, 1 and 10 ng/ml), diesel exhaust particles (DEP), carbon black 
(CB) and ultrafine CB (ufCB, 125, 250 and 500 |.ig/ml). The spontaneous SA release (PMA-0) 
between patients and control subjects was not significantly different. After stimulation with 
PMA, SA release increased in both patients and controls. The SA release did not increase after 
stimulation with D EP and CB in patients nor in controls. There was only an increase after 
stimulation with ufCB in the patient group. The increased SA release in COPD patients after 
stimulation with ufCB may suggest that PMN of COPD patients are more prone to stimulation 
and that the smaller particle size o f ufCB might be a crucial factor.
Thus far exhaled H 20 2 measurements were only performed in stable COPD patients. In chapter 
7 exhaled H 20 2 levels were measured in COPD patients who where admitted to hospital with an 
acute exacerbation. Twenty-five patients who were admitted to hospital with a COPD 
exacerbation were included. Within 24 hours after admittance, spirometry (FEVl5 FVC, MEF 50), 
measurement o f hydrogen peroxide (H20 2) in exhaled breath condensate (EBC), symptom scores 
and analyses o f ESR, CRP, ECP, and MPO in serum were performed. All patients were treated 
with intravenous dexamethasone, nebulised salbutamol/ipratropium and, if needed, antibiotics. 
The tests were repeated at day 2, 3, 7 and 30. Complete data o f the first four visits were collected 
in 19 patients. The H 20 2 concentration and spirometry parameters did not change significantly 
during the study period. CRP, ESR and MPO levels decreased significantly during treatment, 
while the other serum inflammatory parameters did not change. There were no significant 
correlations between H 20 2 concentration, spirometry and serum inflammatory parameters. In 
conclusion, this study showed no significant changes in H 20 2 concentration in EBC, or 
spirometry during treatment o f a COPD exacerbation. In contrast, several serum inflammatory 
markers did decrease during hospitalization, thus providing a simple tool to monitor 
exacerbations.
Finally, the effect o f therapy with inhaled corticosteroids (ICS) on exhaled H 20 2 levels in COPD 
patients was evaluated. In chapter 8 the difference in effect o f ICS with different lung deposition 
on exhaled H 20 2 in stable COPD patients is determined.
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Forty-one stable patients with moderate COPD (FEVj~ 60% predicted) were randomized to 
sequence 1; first HFA-134a Beclomethasone Dipropionate (HFA-BDP, an ICS with more 
peripheral deposition) 400 bid, then Fluticasone Propionate (FP, an ICS with more central 
deposition) 375 ^g bid (N= 20) or sequence 2 ; first FP, then HFA-BDP (N= 21).
Both 4-week treatment periods were preceded by a 4-week washout period. After each period the 
concentration o f H 20 2 in EBC was measured. The H 20 2 concentration decreased significantly 
after the first treatment period in both sequence 1 and 2. In neither sequence was there a return 
to baseline values after the second washout, indicating a carry-over effect. The concentrations 
remained low in both sequences during the second treatment period. The conclusion was that 
there seems to be an effect o f ICS on exhaled H 20 2 levels in stable COPD patients. Any 
difference in effect between ICS with different lung deposition could not be detected because of 
the carry-over effect.
Conclusions
There is an increasing interest in non-invasive biomarkers which can be used to investigate the 
pathophysiology, treatment and prognosis o f COPD. Several biomarkers have been studied so 
far, especially in exhaled air or EBC. However, for most markers there is no standardized 
procedure and few randomised studies have been performed with COPD patients.
We have developed an efficient, sensitive and reproducible procedure for measuring 
H 20 2 in EBC. We have shown that, since the mean H 20 2 concentration in EBC in stable COPD 
patients is low (0.2 ^mol/1), it is important to have a low detection limit.
W ien  we studied the variability o f exhaled H 20 2 over time, we found that the H 20 2 
concentration increased significantly over the day in both COPD patients and healthy controls. 
The cause o f this increase is still unclear, but it is possible that exhaled H 20 2 levels are influenced 
by the intake o f food and drinks or exercise. It is therefore very important to perform H 20 2 
measurements in follow-up studies at the same time o f day in the same conditions.
In contrast to other investigators, we did not find significant higher exhaled H 20 2 
concentrations in stable COPD patients compared with healthy controls.
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While in other studies the control group consisted of young non-smokers, our control group was 
matched with the patient group for age and smoking status. This means that exhaled H 20 2 levels 
can not be used to discover COPD patients.
Besides H 20 2 several other oxidants are produced by inflammatory cells in COPD 
patients. Compared with healthy persons, the number o f inflammatory cells and the activation of 
these cells seems to be increased in COPD patients. It was shown that peripheral PMN are more 
easily activated by certain stimuli like ufCB to release SA.
No changes were observed in exhaled H 20 2 levels during an COPD exacerbation and 
subsequent treatment. It is possible that we missed a fast and early reduction o f exhaled H 202, 
because most patients were tested the morning after admission and several patients were already 
treated with inhaled or oral corticosteroids before the admission. In contrast, serum 
inflammatory markers such as ESR, CRP and MPO concentration did show a reduction during 
treatment. This means that these parameters are more appropriate to evaluate the effect of 
treatment during exacerbation than exhaled H 20 2 levels.
Finally, we used exhaled H 20 2 levels to evaluate the effect o f two different ICS in stable 
COPD patients. The exhaled H 20 2 levels decreased in both treatment groups after four weeks 
and the effect lasted for several weeks after discontinuation. We found no difference in effect 
between both ICS. This study shows that ICS do influence the concentration o f exhaled H 20 2.
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Samenvatting
Chronisch Obstructief Longlijden (COPD) is een belangrijk gezondheidsprobleem. De incidentie 
van COPD neemt toe, waardoor het gebruik van medische ondersteuning toeneemt en dus ook 
de totale kosten van de gezondheidszorg. Tot nu toe is er geen echte genezing mogelijk van 
COPD. De pathofysiologie van COPD is nog niet helemaal bekend en ook minder goed 
onderzocht dan die van astma. H et centrale kenmerk van COPD is progressieve irreversibele 
luchtwegvernauwing, wat leidt to t klachten van kortademigheid, hoesten en opgeven van slijm. 
De luchtwegvernauwing is het gevolg van de aanwezigheid van chronische bronchitis e n /o f  
emfyseem. Luchtwegontsteking en oxidatieve stress spelen een belangrijke rol bij het ontstaan 
van COPD.
Om de pathofysiologie van COPD te kunnen onderzoeken in grote studies, is het nodig 
dat er informatieve, reproduceerbare en bij voorkeur niet-invasieve onderzoeksmethoden 
beschikbaar zijn. E r is groeiende belangstelling voor het meten van verschillende markers in 
ademcondensaat. Waterstofperoxide (H20 2) is een marker die relatief gemakkelijk in 
ademcondensaat gemeten kan worden. Hoewel deze marker door verschillende onderzoekers in 
studies in gebruikt, is er nog veel onduidelijkheid over de reproduceerbaarheid en klinische 
toepasbaarheid hiervan. H et doel van dit proefschrift is het evalueren van de betrouwbaarheid 
van de meting van uitgeademd H 20 2 en het bepalen van de relevantie in de kliniek.
In hoofdstuk 2 wordt een overzicht gegeven van markers die gemeten kunnen worden in 
uitgeademde lucht o f in ademcondensaat. H et doel van dit artikel was om een overzicht te geven 
van de oorsprong van deze markers, hun rol bij het stellen van de diagnose ‘CO PD ’, hun rol bij 
de evaluatie van therapie en bij het voorspellen van de prognose van COPD. Cross-sectionele, 
cohort en interventie studies werden bestudeerd. Deze studies werden verzameld met behulp van 
Medline, zoekend naar Engelstalige studies van 1990 to t en met november 2001. De volgende 
markers werden besproken: uitgeademd nitraat oxide (NO), uitgeademd koolstof monoxide 
(CO), uitgeademde alkanes, uitgeademd waterstof peroxide (H20 2), uitgeademde isoprostanen, 
uitgeademde N O  metabolieten en uitgeademde thiobarbiturisch zuur-reactieve stoffen (TBARs).
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Het overzicht liet zien dat uitgeademde markers verder bestudeerd moeten worden, voordat ze in 
de kliniek gebruikt kunnen worden. De metingen moeten gestandaardiseerd worden, er moeten 
vergelijkende studies worden verricht tussen COPD patiënten en gezonde personen met dezelfde 
leeftijd en rookstatus, er moet meer informatie komen over de reproduceerbaarheid en 
variabiliteit van alle markers, de correlaties van uitgeademde markers met andere parameters 
moeten onderzocht worden en er moeten gerandomiseerde, placebo gecontroleerde 
interventiestudies plaats vinden met verschillende medicaties.
In hoofdstuk 3 werden de technische problemen en mogelijkheden van het meten van H 20 2 in 
ademcondensaat onderzocht. We hebben de fluorimetrische methode om H 20 2 in 
ademcondensaat te meten aangepast door een geautomatiseerde injectiestroom fluorimeter te 
gebruiken. H et doel van de studie was het testen van de gevoeligheid en de reproduceerbaarheid 
van de fluorimetrische meetmethode met de geautomatiseerde fluorimeter bij verschillende 
stroomsnelheden. Tien ^1 p-hydroxyfenylacetylzuur (1.0 mmol/1) and 10 ^1 horsheradish 
peroxidase (15 mU/1) werden handmatig toegevoegd aan verschillende H 20 2 bevattende 
oplossingen en adem condensaat van COPD patiënten. De fluorescentie van het reactieproduct 
werd gemeten met een automatische, injectiestroom, scannende fluorescentie detector, excitatie 
golflengte 295 nm, emissie golflengte 405 nm, met verschillende stroomsnelheden. De mate van 
fluorescentie werd uitgedrukt als area under the curve (AUC) o f als piekwaarde. Een 
stroomsnelheid van 1 m l/m in gaf de beste resultaten. E r waren geen significante verschillen 
tussen de calibratiegrafieken o f detectielimieten gemeten met AUC of piekwaarde (resp. 
0.007/0.005 ^mol/1). De gemiddelde H 20 2 concentratie van de COPD patiënten was 0.2 ^mol/1 
en de standaard deviatie van duplicatie was 0.009 ^mol/1. Het is mogelijk dat de detectielimiet zo 
laag is, omdat deze fluorimeter de fluorescentie niet alleen op één tijdstip meet. Het is belangrijk 
om de juiste stroomsnelheid te kiezen, het maakt niet uit o f de fluorescentie wordt gemeten als 
AUC of als piekwaarde.
Het was belangrijk een betrouwbare en reproduceerbare test procedure te ontwikkelen, 
voorafgaand aan het onderzoeken van de klinische mogelijkheden van het meten van uitgeademd 
H 20 2. Dit is beschreven in hoofdstuk 4. De sensitiviteit en reproduceerbaarheid van onze test 
procedure en het effect van het invriezen van het adem condensaat op de H 20 2 concentratie 
werden onderzocht. Twintig stabiele COPD patiënten (geen gebruik van inhalatiesteroïden) 
ademden twee keer in ons adem condensaat-opvang-systeem gedurende tien minuten.
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Het totaal uitgeademde volume en het volume van het condensaat werden beide keren gemeten 
en de H 20 2 concentratie in het condensaat werd fluorimetrisch bepaald. De concentratie werd 
opnieuw gemeten nadat het condensaat (na toevoegen reagentia) werd ingevroren bij — 70 °C 
gedurende 10, 20 o f 40 dagen. Het gemiddelde condensaat volume was 2-5 ml na 10 minuten. Er 
was een sterke correlatie tussen het totaal uitgeademd volume en het volume van het condensaat. 
E r was geen significant verschil tussen de H 20 2 concentratie gemeten bij de eerste test en de 
tweede test. De detectie limiet was 0.02 ^mol/1. De H 20 2 concentratie bleef gelijk to t 40 dagen 
na invriezen. Concluderend was het opvangsysteem efficiënt, de sensitiviteit van de bepaling goed 
, de test procedure reproduceerbaar en het condensaat (na toevoegen reagentia) minstens 40 
dagen in te vriezen.
Het was belangrijk om de (natuurlijke) variabiliteit van uitgeademd H 20 2 vast te stellen voordat 
de meting gebruikt kon worden in prospectief onderzoek. In hoofdstuk 5 werd de circadiane 
variabiliteit van uitgeademd H 20 2 bij COPD patiënten en gematchte gezonde controle personen 
bepaald. Twintig stabiele COPD patiënten (FEV1 ~ 70%) en twintig gezonde personen, 
gematcht voor leeftijd, geslacht en packyears werden geïncludeerd (allemaal rokers o f ex-rokers). 
Adem condensaat werd 3 keer verzameld op dag 0 (9 en 12 uur ’s ochtends en 3 uur ’s middags) 
en 1 keer op dag 1, 2, 3, 8 en 21 (telkens zelfde tijdstip). De gemiddelde H 20 2 concentratie nam 
significant toe gedurende de dag bij de patiënten groep en de controle groep. Over een langere 
periode tot 21 dagen veranderde de gemiddelde concentratie niet. E r was geen significant verschil 
in H 20 2 concentratie tussen de patiënten groep en de controle groep. De gemiddelde variatie 
coëfficiënt over 21 dagen was 45% in de patiënten groep en 43% in de controle groep. De 
conclusie was dat de uitgeademde H 20 2 concentratie significant toeneemt gedurende de dag bij 
patiënten en gezonden, deze toename was gelijk voor beide groepen. Over een langere periode 
zijn er geen veranderingen. De oorzaak van de toename over de dag is niet duidelijk. Mogelijk 
vertoont de luchtwegontsteking een circadiaan ritme. Verder zou de H 20 2 concentratie beïnvloed 
kunnen worden door eten en drinken o f inspanning. H et is daarom belangrijk om herhaalde 
H 20 2 metingen op hetzelfde tijdstip uit te voeren, bij voorkeur in de ochtend. In tegenstelling tot 
andere onderzoekers vonden we geen verschil in H20 2 concentratie tussen COPD patiënten en 
(voor leeftijd en rookgewoonten) vergelijkbare gezonde personen. Dit kan betekenen dat de 
concentratie van uitgeademd H 20 2 niet alleen wordt bepaald door de mate van luchtweg 
ontsteking, maar ook door leeftijd en rookgeschiedenis.
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Het is ook van belang om de pathofysiologie van oxidatieve stress bij COPD te bestuderen. 
Toegenomen oxidatieve stress wordt veroorzaakt door een toename van het aantal 
ontstekingscellen zoals polymorfonucleaire neutrofielen (PMN), en door verhoogde productie 
van oxidanten per cel. PMN worden geactiveerd door verschillende stimuli, wat leidt tot 
productie van oxidanten, onder andere Superoxide. H et doel van de studie in hoofdstuk 6 was 
het meten van de spontane en gestimuleerde Superoxide productie door perifere PMN in stabiele 
COPD patiënten vergeleken met gezonde controle personen. Zeventien patiënten met matig 
COPD en 17 vergelijkbare vrijwilligers werden geïncludeerd. De Superoxide productie door PMN 
werd spectrofotometrisch gemeten als de Superoxide dismutase rembare reductie van cytochrome 
c. PMN werden gestimuleerd met phorbol myristate acetate (PMA, 1 en 10 ng/ml), diesel exhaust 
particles (DEP), carbon black (CB) en ultrafine CB (ufCB, 125, 250 en 500 ^g/m l). De spontane 
Superoxide productie was niet significant verschillende tussen de patiënten en de gezonden. Na 
stimulatie met PMA nam de Superoxide productie bij beide groepen toe. De Superoxide productie 
nam niet toe na stimulatie met D EP en CB. Alleen bij de patiënten nam de productie toe na 
stimulatie met ufCB. Dit zou kunnen betekenen dat PMN van COPD patiënten gevoeliger zijn 
voor stimulatie en dat de vooral de kleinere deeltjes van ufCB een belangrijke factor zou kunnen
De voorgaande onderzoeken vonden plaats bij stabiele COPD patiënten. In hoofdstuk 7 werd 
de uitgeademde H 20 2 concentratie bij patiënten met een exacerbatie gemeten. Vijfentwintig 
COPD patiënten die werden opgenomen in het ziekenhuis met een exacerbatie werden vervolgd 
tijdens de opname. Binnen 24 uur na opname werd de H 20 2 concentratie in het adem condensaat 
gemeten, longfunctie onderzoek werd verricht (FEVl5 FVC, M EF50), symptoom scores werden 
genoteerd en bloed werd afgenomen voor bepaling van bezinking (ESR), aantal en differentiatie 
leukocyten, CRP, MPO en ECP. Alle patiënten werden behandeld met dexamethason 
intraveneus, vernevelingen met ipatropium en salbutamol en zo nodig antibiotica. De metingen 
werden herhaald op dag 2,3,7 en 30. Gegevens van de eerste vier visites waren compleet in 19 
patiënten. De H 20 2 concentratie en longfunctie parameters veranderden niet significant tijdens de 
studieduur. De bezinking, CRP en MPO concentratie namen significant af, terwijl andere 
bepalingen in het bloed niet veranderden. E r waren geen significant correlaties tussen 
uitgeademde H 20 2, longfunctie parameters en parameters in perifeer bloed. De conclusie was dat 
deze studie geen veranderingen liet zien tijdens een COPD exacerbatie en de behandeling 
daarvan wat betreft uitgeademd H 20 2 o f longfunctie.
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Daarentegen namen bepaalde parameters in het perifere bloed wel duidelijk af, waardoor deze 
gebruikt kunnen worden om exacerbaties te vervolgen.
Uiteindelijk hebben we het effect van medicamenteuze therapie op uitgeademd H 20 2 gemeten. In 
hoofdstuk 8 wordt het verschil in effect van inhalatiesteroïden met verschillende longdepositie 
bij stabiele COPD patiënten beschreven. Eenenveertig patiënten met matig COPD (FEV1 ~ 
60%) werden gerandomiseerd voor sequentie 1; eerst HFA-134a Beclomethason Dipropionate 
(HFA-BDP, een steroïd met meer perifere depositie) 400 ^g bid, daarna Fluticason Propionate 
(FP, een steroïd met meer centrale depositie) 375 ^g bid (n = 20), o f sequentie 2; eerst FP, daarna 
HFA-BDP (n = 21). Allebei de vier weken durende behandelperioden werden voorafgegaan door 
een vier weken durende washout periode. Na elke periode werd de H 20 2 concentratie gemeten. 
De H 20 2 concentratie nam significant af tijdens de eerste behandelperiode bij beide sequenties In 
geen van beide groepen keerde de H 20 2 concentratie terug naar de uitgangswaarde na de washout 
periode, wat kan duiden op een carry-over effect. De concentratie bleef laag in beide groepen 
tijdens de tweede behandelperiode. De conclusie was dat inhalatiesteroïden zeker effect lijken te 
hebben op de uitgeademde H 20 2 concentratie bij stabiele COPD patiënten. Een verschil in effect 
kon worden gevonden als gevolg van het carry-over effect.
Conclusies
De belangstelling voor niet-invasieve biomarkers die gebruikt kunnen worden om de 
pathofysiologie, behandeling en prognose van COPD te onderzoeken, neemt nog steeds toe. Tot 
nu toe zijn er al verschillende biomarkers bestudeerd, vooral in uitgeademde lucht en 
ademcondensaat. Echter, voor de meeste markers bestaat geen gestandaardiseerde procedure en 
er zijn maar weinig gerandomiseerde studies gedaan met COPD patiënten.
Wij hebben een efficiënte, gevoelige en reproduceerbare procedure ontwikkeld voor het 
meten van H 20 2 in adem condensaat. We hebben laten zien dat het belangrijk is om een lage 
detectielimiet te hebben, omdat de H20 2 concentratie in adem condensaat van stabiele COPD 
patiënten laag is (0.2 ^mol/1).
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Toen we de variatie van uitgeademd H 20 2 over de tijd bestudeerden, zagen we dat de 
H 20 2 concentratie significant toenam gedurende de dag bij zowel COPD patiënten als gezonde 
proefpersonen. De oorzaak hiervan is nog niet duidelijk, maar het is mogelijk dat de H 20 2 
concentratie wordt beïnvloed door eten en drinken o f door inspanning. Het is daarom erg 
belangrijk om bij vervolgstudies de H 20 2 metingen te verrichten op hetzelfde tijdstip onder 
gelijke omstandigheden.
In tegenstelling to t andere onderzoekers, vonden we geen verschil in uitgeademd H 20 2 
tussen stabiele COPD patiënten en gezonde proefpersonen. Terwijl de controlegroep bij andere 
studies bestond uit gezonde, niet-rokende personen, was onze controlegroep vergelijkbaar wat 
betreft leeftijd en rookgewoonten. Deze bevinding betekent dat uitgeademd H 20 2 niet gebruikt 
kan worden om COPD patiënten te ontdekken.
Naast H 20 2 worden ook andere oxidanten geproduceerd door ontstekingscellen in 
COPD patiënten. Vergeleken met gezonde personen lijkt het aantal ontstekingscellen, maar ook 
de activiteit van de cellen verhoogd bij COPD patiënten. We hebben aangetoond dat perifere 
PMN sneller aangezet worden tot Superoxide productie door bepaalde (kleine deeltjes).
Wij vonden geen veranderingen in uitgeademd H 20 2 tijdens een COPD exacerbatie en de 
behandeling hiervan. H et is mogelijk dat we een eerste en snelle afname in uitgeademd H 20 2 
hebben gemist, doordat de meeste patiënten voor het eerst werden gemeten op de ochtend na 
opname en doordat een aantal patiënten al voorbehandeld was met inhalatie en orale 
corticosteroïden. Daarentegen was er wel een duidelijk afname in bepaalde parameters in het 
perifere bloed zoals de bezinking, CRP en MPO concentratie. Dit betekent dat deze parameters 
meer geschikt zijn het effect van behandeling van een exacerbatie te evalueren.
Tenslotte gebruikten we H 20 2 concentraties om het effect van twee verschillende ICS te 
evalueren. De H 20 2 concentratie nam af bij beide behandelingsgroepen na vier weken en dit 
effect duurde nog enige tijd voort na het beëindigen van de therapie. We vonden geen verschil in 
effect tussen de twee ICS. Deze studie laat zien dat ICS wel effect hebben op de H 20 2 
concentratie in stabiele COPD patiënten.
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Van jongs af aan wilde ik Geneeskunde studeren, dus die keus was niet moeilijk na de middelbare 
school. Ik ging studeren in Maastricht en heb daar een plezierige studententijd gehad. Aan het 
einde van de co-schappen kwam echter de vraag: wat nu? E r waren een aantal specialismen 
waarvan ik zeker wist dat ik dat niet wilde doen en ik wist ook zeker dat ik geen promotie­
onderzoek wilde doen.
Uiteindelijk werd mijn eerste keus Keel- Neus- en Oorheelkunde. Dat leek mij een 
interessant en praktisch vak. Ik kon beginnen als AG N IO  bij de KNO in Maastricht gedurende 
drie maanden. Die maanden waren echter snel om en toen ging ik op zoek naar een (tijdelijk) 
alternatief. Ik had mijn co-schap Longziekten in het Catharina ziekenhuis gelopen en dat was ook 
erg goed bevallen. Gelukkig was er op dat moment een plaats vrij en kon ik aan de slag.
Ik moest wel erg wennen aan zo’n grote en bedrijvige afdeling. Maar ik vond het steeds 
leuker worden. Uiteindelijk heb ik toch gekozen voor de Longziekten en daar heb ik geen spijt 
van gehad. Toen kwam er een interessant onderzoek, o f ik daar belangstelling voor had? Ik had 
daar eigenlijk nooit serieus over nagedacht, onderzoek was toch niets voor mij?! Maar daar was de 
kans en de gelegenheid, dus heb ik toch de stap genomen.
Ik kan niet zeggen dat ik nooit twijfels heb gehad over deze keuze, maar nu ik het 
eindresultaat zie, is het toch zeker de moeite waard geweest. Er zijn een aantal mensen zonder 
wie dit nooit gelukt zou zijn, die wil ik hierbij graag bedanken.
Professor Dekhuijzen. Beste Richard, je had al vele assistenten begeleid bij het promoveren. Ik 
was de eerste promovendus op afstand. Daar moesten we allebei even aan wennen. Maar gelukkig 
is er e-mail (wat een geweldige uitvinding). Je was altijd heel snel met het reageren op vragen en 
problemen en je was altijd bereid om iets af te spreken zodat we persoonlijk konden overleggen. 
Zonder jou zou het niet gelukt zijn.
D r Smeenk. Beste Frank, je wist heel goed wat er allemaal komt kijken bij promotie-onderzoek, 
aangezien je zelf ook nog niet zolang geleden gepromoveerd was. Je las mijn artikelen steeds 
nauwkeurig en gaf gedetailleerd commentaar. Ik kon altijd bij jou aankloppen met vragen. Ik wil 
je ook bedanken omdat je mij hebt aangenomen voor de opleiding.
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Maatschap Longziekten. Beste Jacques, Rob, Pascal, (Harm), jullie hebben mij de ruimte gegeven 
om me fulltime met mijn onderzoek bezig te houden. Bedankt voor het doorsturen van patiënten 
voor mijn studies. Voor en tijdens deze periode heb ik veel geleerd van jullie als groep en van 
jullie individuele kwaliteiten.
Arts-assistenten Longziekten. Beste collega’s, bedankt voor het luisteren naar mijn geklaag als er 
weer eens iets niet goed ging en voor het aanleveren van patiënten voor mijn onderzoek.
Ik denk dat jullie mij wel eens benijdden om het feit dat ik minder diensten deed, maar daar heb 
ik nooit commentaar over gehoord.
Research-afdeling. Beste Jeannette, Robert, Birgit (Hester, Marit, Maria), jullie hebben me altijd 
gesteund bij mijn onderzoek. Ijs in de bak doen, even een patiënt blazen, dat deden jullie zonder 
morren. Ik kon ook regelmatig wat frustraties van me af praten. Ik wil in het bijzonder Robert 
bedanken voor zijn hulp met de computer (met name in het begin) en zijn eindeloze geduld.
Sandra van de Poel en Philip Salden, 3M Pharma Nederland. Beste Sandra en Philip, de eerste 
studie van mijn promotie-onderzoek werd met jullie ondersteuning uitgevoerd. Bedankt voor 
jullie hulp en vertrouwen.
D olf Harff, Maria van den Bosch. Beste Dolf, het heeft wel enige tijd geduurd voor ik een 
“wetenschappelijke” denkwijze heb verkregen (zover als mogelijk). Bedankt voor je geduldige 
uitleg. Je hebt steeds interesse getoond, ook tijdens de periode waarin je het zelf moeilijk had. 
Beste Maria, jou mag ik zeker niet vergeten, jij hebt uiteindelijk het overgrote deel van het 
praktisch werk uitgevoerd. Je was altijd enthousiast bezig met “ons” onderzoek. Ik heb met 
plezier met je samen gewerkt.
Mijn ouders. Lieve Pap en Mam, eindelijk is het dan zover! Pap, je kunt nu toch je nette pak aan. 
Jullie werden vaak gebruikt als klaagpaal, zo gaat dat met ouders. Maar als ik belde dat er weer 
een artikel geaccepteerd was, dan leefden jullie ook mee. Bedankt voor jullie liefde en steun.
Lieve Pascal, ik ben blij dat je zo’n geduldig type bent. Ik weet dat het af en toe moeilijk is om 
met mij samen te leven, maar ik ben altijd weer gelukkig als ik ’s avonds bij jou thuis kom.
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Curriculum Vitae
De schrijver van dit proefschrift werd geboren op 17 april 1973 in Hilvarenbeek. In 1991 werd 
het VWO diploma behaald aan het St. Odulphus Lyceum te Tilburg. Vervolgens ging zij de 
studie Geneeskunde volgen aan de Universiteit Maastricht. Het doctoraal examen werd behaald 
in 1995 en het basisarts examen in 1997. De verplichte wetenschappelijke stage werd gelopen aan 
de Keel- Neus- en Oorheelkunde afdeling in het Academisch Ziekenhuis Maastricht en beëindigd 
met de publicatie “De Stem Interval Test, luidroepend maar weinigzeggend?”. Vervolgens werkte 
zij drie maanden als A GN IO  bij de bovengenoemde afdeling. Van mei 1998 to t mei 2002 was de 
auteur werkzaam als A G N IO  Longziekten in het Catharina ziekenhuis te Eindhoven. Van juni 
1999 to t mei 2002 was zij fulltime bezig met dit promotie onderzoek., daarna is zij begonnen met 
de opleiding to t longarts in het Catharina ziekenhuis Eindhoven. De auteur is nu werkzaam in het 
St. Elisabeth ziekenhuis te Tilburg bij de Interne Geneeskunde in het kader van de vooropleiding. 
Zij is gehuwd met Pascal Moeskops.
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